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ABSTRACT
It is over 15 years since HIV was identified as the causal agent of AIDS, and
the global epidemic continues to expand at an alarming pace. A cumulative number
of 27.9 million people have been infected with HIV since the beginning of the
pandemic. Of these, 68% have lived in sub-Saharan Africa. Of the 3 million infants
born in the world with HIV, over 90% have been born in Africa. It is in Africa that
there are still many problems about the diagnosis ofHIV infection and management of
infants born to seropositive women. In addition, the molecular features ofHIV-1 and their
relevance to the transmission from mother-to-child remain poorly understood. The research
described in this thesis deals with these two important issues:
1. Early diagnosis of HIV-1 infection in children born to HIV-1 infected women: The
diagnosis of HIV infection in children born to HIV-1 infected mothers is hampered by
the passive transfer of maternal IgG across the placenta which is detectable up to 12 or
even 15 months of age. In the first months of life, it is not possible to discriminate the
mother's IgG from the child's by using commercially available ELISA techniques. This
delays the diagnosis ofHIV-1 in children until 18 months of age. Alternatively, several
techniques can achieve the diagnosis ofHIV-1 infection during the first few months of
life. These include the Polymerase Chain Reaction (PCR), measurement of in vitro
antibody production and co-cultivation of the lymphocytes with stimulated donor cells.
All these techniques are expensive and technically unsuitable for small laboratories in
Developing Countries. Therefore simple, cheap, sensitive and specific tests, the
Antibody class A specific capture enzyme immuno assay (AAC-EIA) and class M
specific capture enzyme immunoassay (MAC-EIA) were employed for the detection of
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IgA and IgM anti HIV-1 in children born to seropositive mothers. Contrary to the
currently held dogma, it was demonstrated in the present study that IgA and IgM DO
CROSS the placental barrier. The maternally derived IgA and IgM class anti-HIV-1
decline and are undetectable by 3 months of age, but after this time, detection of these
antibodies (IgA and IgM) in infant samples is a strong indicator ofHTV infection.
2. The genotype, the serotype and the level of antibodies against the vertically-
transmitted virus: The relative role of different subtypes of HIV-1, the nature of the
antibodies and indeed their amounts in mothers who do and do not transmit infection to
their children is largely unknown. All previously described methods on serotyping of
HIV-1 are subject to a high level of cross-reactivity. In this study, a de novo method for
serotyping HIV-1 was developed and applied. It was demonstrated that
immunodominant antibodies to the principal neutralising domain ofHIV-1, the V3 loop,
are not subtype specific and correlate poorly with HIV-1 genotype. Significant cross-
reactivity of V3 loop based peptides to react with heterologous peptides may increase the
sensitivity of serological assays. In addition, it was shown that there was a lack of
correlation between the level of antibodies to V3 loop in maternal samples and the
outcome ofHIV-1 infection in children. At the molecular level, there was no evidence of
preferential mother-to-child transmission of one subtype ofHIV-1 over the others.
However, a remarkable molecular heterogeneity was observed in a small number of
patients examined in this study, with at least 7 subtypes (A, C, D, F, G, H and J) and
another possible new subtype ofHIV-1 present in the population examined.
ABBREVIATION
AACELISA Antibody class-A capture Enzyme linked immunosorbent assay
AIDS Acquired Immunodeficiency Syndrome
ARV AIDS-related virus
AZT 3'-azido-3' deoxythymidine
BIV Bovine immunodeficiency virus
bp base pair(s)
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BSA Bovine serum albumine
BW Buffered water
°C Degree centigrade
CD4 Cluster determinant 4
CDC Centers for Disease Control and prevention, Atlanta, USA.
cDNA Complementary deoxyribonucleic acid
CIZA (CILU) Cimenterie du Zaire (change recently to CILU, Lukala)
CO (CUT) Cut off
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CMV Cytomegalovirus
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EIA Enzyme immuno assay
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INTRODUCTION: THE HUMAN IMMUNODEFICIENCY
VIRUS TYPE 1 (HIV-1)
1
1.1. CLINICAL ASPECTS OF HIV-1 INFECTION
1.1.1. HISTORIC OVERVIEW: THE DISCOVERY OF HIV-1
The first few cases of a novel disease, which soon was called the 'acquired
immunodeficiency syndrome' (AIDS), were reported in June, 1981 by the Centers for
Disease Control (CDC) (Gottlieb et al., 1981.a; Gottlieb et al., 1981 .b). The patients
concerned in the early reports were mainly homosexual men presenting with
Pneumocystis carinii pneumonia and mucosal candidiasis (Gottlieb et al., 1981a;
Gottlieb et al., 1981b; Colon et al., 1996), hence AIDS was known for some time as
a homosexual or 'gay' disease. Coincident with the epidemic in the homosexual
community were reports of cases ofAIDS among Haitians immigrants to the United
States of America (USA), with no history of homosexuality (Vieira et al., 1983). In
1982, the first cases ofAIDS in very young children (Centers for Disease Control,
1982; Rubinstein et al., 1983) provided the first clues as to the possibility of an
infectious agent being the cause ofAIDS. Other cases were also reported among
haemophiliacs, transfusion recipients and the sexual partners of high-risk individuals
(intravenous drug users and homosexuals). At that time, viruses such as
cytomegalovirus (CMV), hepatitis B virus (HBV) and human T-cell lymphotrophic
virus type 1 (HTLV-1) were thought to be possible causative agents ofAIDS since
enlarged lymph nodes were common features among AIDS patients (Gottlieb et al.,
1981.b). However, it seemed unlikely that HTLV-1 (or HTLV-2) could be the cause
of AIDS as it is unable to kill lymphocytes, but tends to immortalise them (Miyoshi
et al., 1981). Conversely, the depletion of CD4 lymphocytes is a characteristic of
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advanced HIV-1 infection (Barre Sinoussi et al., 1983; Dalgleish et al., 1984;
Rubinstein et al., 1983).
In early 1983, a team led by Montagnier of the Institut Pasteur in Paris
isolated a virus from a patient with persistent generalised lymphadenopathy (PGL)
and this new virus was given the name of Lymphadenopathy Associated Virus (LAV)
(Barre Sinoussi et al., 1983). Subsequently, the same virus was isolated by a
different group led by Gallo in the United States of America (USA) (Gallo et al.,
1984). They called this 'novel' agent the Human T-cell Lymphotropic Virus type III
(HTLV-III) (Gallo et al., 1984). In addition, other names, including AIDS related
virus (ARV), immunodeficiency associated virus (IDAV) were also used by other
research groups.
The International Committee on the Taxonomy ofViruses (ICTV) agreed on
one name, the Human Immunodeficiency Virus (HIV). In 1986, another human
retrovirus distinct from HIV, yet with similar biological and morphological
properties, was isolated from West African patients and subsequently in Europe and
North America (Clavel et al., 1986a; Clavel et al., 1986b; Guyader et al., 1987). The
original virus was specified as HIV-1 and the newly identified one as HIV-2.
HIV-2 is transmitted through the same routes and causes a similar spectrum
of disease as HIV-1. Whereas HIV-1 is more prevalent and widely distributed
throughout the globe, HIV-2 strains have been more limited to patients in several
parts ofWest Africa. There are small numbers ofHIV-2 cases in Europe, United
States and South America often in individuals with a West African connection (Levy,
1994). Furthermore, HIV-2 appears to be less pathogenic and less transmissible than
HIV-1 (Traverser/., 1995; Marlink et al., 1994). The average incubation period
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from infection with HIV-2 to the development ofAIDS appears to be longer than is
is the case for HIV-1. However, data about HIV-1 and HIV-2 infected individuals
followed up from infection to the development ofAIDS are scarce.
1.1.2. EPIDEMIOLOGY OF HIV-1 INFECTION
1.1.2.1. PREVALENCE AND TRENDS OF HIV/AIDS
Enormous progress has been made in the elucidation of the epidemiology of
HIV-1. It is now over 15 years since HIV was identified as the causal agent ofAIDS.
Although the risk factors for the transmission ofHIV-1 are known, the global
epidemic continues to expand at an alarming pace. As of July 1996, nearly 1.4
million AIDS cases - in adults and children - had been reported to the World Health
Organization (WHO) (UNAIDS, 1997). This represents approximately a 19%
increase from the 1,169,811 cases reported by June 1995. Allowing for under¬
diagnose, incomplete reporting, and reporting delay, the United Nations Programme
on HIV / AIDS (UNAIDS) estimated that over 7.7 million AIDS cases have occurred
worldwide since the pandemic began. Due to the average 10 year incubation period,
the overall number of AIDS case may merely reflect the trend ofHIV infection of a
decade ago (UNAIDS, 1997). The UNAIDS estimates the global trends for HIV
infection to be 3.1 million new cases during 1996. This figure suggests that there
were over 8,500 new infections occurring daily - 7,500 adults and 1,000 children
(UNAIDS, 1997). As ofNovember 1997, UNAIDS estimated that about 21 million
adults, and more than 800 thousand children were living with HIV / AIDS . Of adult
cases, 90% were living in developing countries. Among children, HIV / AIDS
prevalence was estimated to be 35 times greater in the developing world than
4
industrialized nations (UNAIDS, 1997). In addition, over 9 million children under
age 15 have lost their mothers to AIDS, and one in three children orphaned by HIV /
AIDS is younger than 5 years old. However, in some areas in the developing
countries, the epidemic has shown signs of stability (Green et al., 1994) and even a
decrease (Nelson et al., 1996).
1.1.2.2. TRANSMISSION ROUTES OF HIV-1
The routes of transmission ofAIDS were known well before the identification
of the aetiology. It is generally admitted that HIV is transmitted (i) through sexual
contact, (ii) by parenteral routes and (iii) from an infected mother to her offspring.
1.1.2.2.1. SEXUAL AND PARENTERAL ROUTES OF HIV-1
TRANSMISSION
The transmission through anal intercourse was suggested in early 1981
following an unusual outbreak ofPneumocystis carinii among homosexual men as a
result of an unknown infectious agent responsible for inducing immunodeficiency
(Gottlieb et al., 1981.b; Masur et al., 1981). Anal intercourse between men has been
the common mode of transmission ofHIV in the United States, whereas heterosexual
transmission is the predominant mode of transmission in Africa, in Asia and in
Central and South America. Heterosexual transmission ofHIV has direct
consequences in that women at child-bearing age also become infected with the virus
may also transmit the virus to their offspring (see section 1.1.2.2.2.). Social and
economic changes currently observed in many African countries may have adverse
effects on the HIV epidemic. Mulder et al. (1994) measured the excess death
attributable to the HIV epidemic in rural Uganda. In this study the mortality rate among
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seronegative adults was 7.7 per 1000 compared with mortality rate as high as 115.9 per
1000 seropositive adults of the same population. Also, 50-80% of all deaths in this
population were associated with HIV-1 infection. Similar findings by Ryder et al.
(1994a) showed higher rates (5-10 fold) among seropositive women, their partners and
children than among HIV-1 seronegative control women. These high mortality rates
have direct effects upon economic growth, demographic and social stability in many
countries. For example, Ryder et al. (1994b) in another study assessing the
socioeconomic consequences ofHIV, note that children born to seropositive mothers
are at greater risk of becoming orphans than children born to seronegative mothers.
Once again the burden lies within developing nations, with 90% of maternal orphans
living in sub-Saharan Africa (UNAIDS, 1997).
Parenteral transmission through the transfusion of contaminated blood or
blood products is another important route of transmission. The importance of this
route in the United States and Western industrialised countries was substantially
reduced when HIV-1 antibody testing was introduced (Selik et al., 1993). However,
in developing countries, many transfusions are still being carried out without prior
screening for HIV-1 antibodies in donated blood units. In addition, transmission by
the parenteral route can occur through the use of contaminated and shared needles
among drug users (review in Kaplan, 1989; Hoelscher et al., 1994). The risk of
needle-stick injuries with infected blood among health care workers appears to be
low. In one study, only 0.36% of cases (n=l103) seroconverted following accidental
injury with HIV contaminated needles (Tokars et al., 1993). However, people who
accidently prick themselves with contaminated needles need better standards of care.
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1.1.2.2.2. MOTHER-TO-CHILD TRANSMISSION OF HIV-1
Another important route of transmission ofHIV-1 is from an infected mother
to her child: mother-to-child transmission (MCT). Of the estimated cumulative
number of 3 million infants born in the world with HIV since the beginning of the
epidemic, over 90% have been born in Africa (World Health Organisation, 1996;
UNAIDS, 1997). Among children, MCT represents the main source of infection
though transmission attributable to parenteral routes is also possible.
It is difficult to determine the time when MCT ofHIV occurs. Transmission can
occur in utero, and/or at the time of delivery, and/or intrapartum, and/or postnatally
through breast-feeding. However, the relative contribution of these periods is not
precisely known. Generally, the timing ofHIV transmission from mothers to their
children is very variable and at present no method can determine with accuracy the time
and mechanism of transmission. In most cases occurring in the developing countries a
large proportion of all vertical transmission ofHIV occurs before delivery. Krivine el
al. (1992) using highly sensitive tests were unable to detect HIV-1 infection at birth in
almost 70% of babies who subsequently were found to be infected. These findings
suggested an active replication ofHIV during the first weeks of life and support the
hypothesis that transmission ofHIV-1 takes place either at the end of pregnancy or at
delivery. A number of in utero infections occur at an early gestational period. This
was confirmed by the detection of virus antigens by immunohistochemistry and in situ
hybridization in abortus material as early as 8 weeks (Lewis et al., 1990) and from a 15
week old fetus (Schafer et al., 1986). However, these findings still need to be
confirmed by independent investigators. Nevertheless, studies in Africa have shown
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that early transmission ofHIV may adversely affect pregnancy outcome: fetal wastage,
prematurity, stillbirth and neonatal death (Braddick et al., 1990; Temmerman et al.,
1990; Ryder and Temmerman, 1991). Other studies (Gloeb et al., 1988; Selwyn et al.,
1989), however, failed to show any of these outcomes to be attributable to HIV in
pregnant women.
In studying a cohort of children bom to HIV-1-infected mothers in Kinshasa,
former Zaire, Bertolli et al., (1996) estimated 23% of infected children might have had
intrauterine and 65% intrapartum/early postpartum transmission. In this study, labour
and delivery played a significant role in MCT ofHIV-1. Some gynecological
conditions like placentapreviawhen a large amount of blood may enter the fetal
circulation, may be a major source of infection with HIV at the end of pregnancy.
During labour, uterine contraction may drive maternal blood into the fetal circulation,
particularly if the labour is intense, difficult or prolonged. Tissue damage may occur as
the result of labour or obstetric intervention, e.g. forceps delivery which increases the
risk of blood-to-blood contact between the mother and the fetus. It is likely that
children are susceptible to HIV infection when they pass through the birth canal, where
they may ingest viral particles present in maternal blood and other fluids.
In addition to MCT ofHIV-1 in utero or during deliveiy, there is an additional
risk of postnatal infection through breast-feeding. HIV-1 was detected by culture in
breast milk of 3 asymptomatic women (Thiry et al., 1985) and raised the concern about
postnatal transmission through breast feeding. Confirming this theory, Ziegler et al.,
(1985) reported a case ofHIV infection in a breast-fed child whose mother had
1
a placenta which develops in the lower uterine segment, in the zone of dilatation
accompanied with painless haemorrhage in the last trimester, particularly during the eighth
month.
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acquired the virus by blood transfusion after caesarian section. Others (Behets et al.,
1991) found no significant role of breast-feeding but have shown that breast milk
confers protection against gastrointestinal and upper respiratory illness in children bom
to infected mothers. Another study by Van de Perre et al. (1993) showed that detection
of integrated viral DNA in the mother's cells (in breast milk) is a risk factor for
infectivity but the presence of anti-HIV-1 specific IgA and IgM conferred protection
against postnatal transmission ofHIV-1. Because 1 in 7 breast-fed children ofHIV
positive mothers acquire post-natal HIV, this protective effect is often insufficient.
Computer models have been developed to assess the impact of breast-feeding, HIV
infection and socioeconomic factors on under-five mortality and to assist in evaluating
implications of breast-feeding policy. In the model proposed by Del Fante et al.
(1993), analysing data from a hypothetical West African country, it was shown that in
urban areas, under-5 mortality would increase by 27% and 108% among children bom
to seropositive and children bom to seronegative mothers, respectively, if breast¬
feeding ceased. In general, not breast-feeding would increase the mortality rate in that
hypothetical setting by 82%. Dunn et al. (1992) estimated the total risk of infection
through breast-feeding by seropositive mothers: when mothers have been infected
prenatally, the additional risk of postnatal transmission ofHIV-1 through breast¬
feeding, above transmission in utero and intrapartum is estimated at 14%. When
mothers become infected postnatally, the risk of transmission is 29% (Dunn et al.,
1992). A possible explanation of the increased risk of transmission through breast milk
when maternal infection has occurred post-natally, may be the viraemia associated with
the primary infection period.
The protective properties of breast milk in the presence ofHIV-1 infection have
been previously documented (Victoria et al., 1987; Howie et al., 1990). In general, the
protection provided by breast-feeding against a variety of illnesses is independent of
associated personal and social factors (Cunningham (1979). In addition to psychosocial
and child-spacing benefits, breast milk contains protective elements including
immunological components (IgA, IgM, IgG, cells) and biochemical factors (lysozyme,
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lactoferrin, lactoperoxidase, bile salt stimulated lipase). It also contains factors like
complement, Lactobacillus bifidus growth factor and nutrients that make breast milk
the best food for the new born especially in developing countries (Cunningham, 1979).
The rate of vertical transmission ofHIV varies widely from study to study
(Dabis et al., 1993). It is higher in developing countries than in the industrialised
World. In Africa for example, the rates of vertical transmission ofHIV may range
between 25% and 48% whereas in Europe and North America figures between 13%
and 32% have been reported (Dabis et al., 1993). No direct comparison could be made
between these studies because the methods of calculation ofmother-to-child
transmission rates were different. Therefore a standardized method has been proposed
by the Ghent Working Group ofMother-to-Child Transmission ofHIV to allow all
studies to report rates of transmission in a comparable fashion (Dabis et al., 1993).
1.1.2.2.3. MATERNAL FACTORS INFLUENCING MCT OF HIV-1
Not all children born to HIV-seropositive women are infected. About 60-80%
of such children remain uninfected and it is difficult to predict accurately the outcome
of children bom to HIV-infected mothers. Maternal factors have been suggested to
play an important role in MCT ofHIV. These include p24 antigenemia (StLouis et al.,
1993), high viral RNA load (Dickover et al., 1996), impaired immune system
determined by low CD4 count (<700/mm3), or CD4-to-CD8 ratio (<0.6) or the stage of
clinical AIDS (Newell et al., 1992; Ryder et al., 1989; StLouis et al., 1993). However,
asymptomatic seropositive pregnant women, with no indicators that maternal infection
is advanced, may also transmit HIV to their offspring. This has been shown in a study
carried out in Congo (then Zaire) that HIV-1 infected women with normal CD4 counts
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but higher CD8 counts (>1800) were at increased risk of transmitting HIV, although
some of them were at the early stage of infection (StLouis et al., 1993). Becoming
pregnant during the year of seroconversion is another risk factor for MCT ofHIV
(Hague et al., 1993). This may be explained by the fact that this particular period is
characterised by intense replication ofHIV as indicated by p24 antigenemia (Newell et
al., 1992; Krivine et al., 1992).
The structure of the placental barrier if damaged by chorioamnionitis may
facilitate infection of the fetus. This inflammation of the placental membrane may be
due to intercurrent infections including sexually transmitted diseases (STD) during
pregnancy. In our own study (Green et al., 1991) as in others (St Louis et al., 1993),
placental membrane inflammation was associated with perinatal transmission. In
addition, the synergistic effect of pregnancy and HIV may cause reactivation of several
infectious agents including herpes simplex virus (HSV) and cytomegalovirus (CMV).
HSV and other STDs such as syphilis (Treponemapallidum) and chancroid
(Hemophilus ducreyi) cause cervicitis and genital ulcers and these agents may enhance
the risk of both intrauterine and intrapartum transmission ofHIV. In a population of
high prevalence ofHIV-1, unprotected sexual intercourse with multiple partners before
and during pregnancy was shown to increase the likelihood ofMCT ofHIV-1 (Bulterys
etal., 1993).
Several studies have been conducted to determine the role ofmaternal
antibodies in the reduction ofMCT ofHIV. Results on this topic remain conflicting.
Whereas some studies (Scarlatti et al., 1993a; Scarlatti et al., 1993d; Rossi et al., 1989;
Devash et al., 1990) reported that maternal antibodies to the principal neutralising
domain (PND) of the envelope glycoprotein gpl20 and gp41, protect the fetus from
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infection, others (Parekh etal., 1991; Halsey etal., 1992; Robertson etal., 1992) failed
to confirm the findings. This discrepancy may be due to lack of sufficient information
about the neutralising activity of the antibodies or the choice of strains or peptides to
make up assays. In the present thesis, the role ofmaternal antibodies to PND using a
cocktail ofpeptides from different subtypes ofHIV-1 was also investigated (for more
information see chapter 6).
1.1.2.2.4. PREVENTION AND INTERVENTION TO REDUCE MCT OF HIV-1
The development of strategies to prevent vertical transmission ofHIV is an
important objective to reduce and even eliminate the possibility ofMCT ofHIV. The
first priority in preventing MCT ofHIV is to prevent women in childbearing age
becoming infected with HIV. This can be achieved by education programmes for
AIDS awareness in juvenile populations before they become sexually active. Routine
antenatal screening ofpregnant women and early diagnosis ofHIV infection in the
newborn are important for appropriate counselling. Named (rather than unnamed and
unlinked) testing ofpregnant women as shown in a study from Sweden (Lindgren et al.,
1993) can provide valuable data on the importance of spread of the epidemic and
opportunities for counselling to reduce vertical transmission ofHIV in later
pregnancies.
A number of studies of intervention strategies to reduce vertical transmission of
HIV are currently underway. An option for preventing perinatal transmission ofHIV,
consists of the treatment ofpregnant women at the end of pregnancy or intrapartum
with antiretroviral drugs. The AIDS Clinical Trial Group using the protocol 076
(ACTG076) have shown some benefit in the use of zidovudine (AZT) in order to
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reduce the rate ofmother-to-child transmission ofHIV-1. A reduction (by 60%) of
MCT was observed as a result of of intervention using AZT (Wiznia et al., 1996;
Connor et al., 1994). Long term harmful effects of AZT on the fetus or on the
pregnancy remain unclear. A particular concern is AZT's teratogenicity1. In a study by
Toltzis et al. (1994) a direct effect on developing mouse embryos was reported, when
AZT was administered in early pregnancy.
With the existing evidence that HIV immune plasma can neutralise circulating
infectious HIV-1 (Karpas et al., 1990 and 1994), passive immunisation ofpregnant
women was suggested as another option for prevention ofMCT ofHIV-1. This
involves administration of anti-HIV immunoglobulins (HIVIG) to HIV-1 positive
pregnant women. However, there are conflicting reports about the value ofmaternal
immunoglobulins in the prevention ofMCT ofHIV.
Active immunisation ofpregnant women during pregnancy is another type of
intervention. In a previous study by Vanrompay et al. (1996), active immunisation of
pregnant rhesus macaques successfully prevented infection with simian
immunodeficiency virus (SIV). It was suggested that strategies such as active
immunization of HIV-infected pregnant women may decrease the rate of perinatal
HIV infection. However, the lack of understanding of the immune responses
necessary to prevent and contain HIV-1 constitutes the most basic problem in the
development of an HIV vaccine (Ada, 1992). It is not clear whether or not there is a
protective immune response to HIV due to intracellular transmission. A number of
candidate vaccines have been developed and their clinical trials have been initiated
' Fetal hematologic toxicity
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(table 1.1). It will take several years before the value of these vaccines is established
and they become readily available for use worldwide.
There is increasing evidence that most MCT ofHIV occurs close to delivery or
when the baby passes through the birth canal (Newell et al., 1992; Goedert et al., 1991;
Krivine et al., 1992). Elective caesarean section has been suggested as a possible
intervention procedure to reduce MCT rate ofHIV-1 (Newell et al., 1992; Newell et
al., 1994). The European Collaborative Study found that the likelihood ofMCT of
HIV-1 was higher in vaginal delivery than when babies were delivered by elective
caesarean section. In this study, there was no statistical difference between the two
modes of delivery, possibly due to confounding factors (Newell et al., 1992). In
another study, when confounding factors such as maternal clinical stage were taken into
account, it was clear that caesarean section could halve the rate ofMCT ofHIV-1
(Newell et al., 1994).
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Table 1.1. HIV vaccines relevant to MCTs
Trial Vaccine HIV-1 strain Target population
AVEG 102 rgpl60 LAI HIV infected pregnant women
AVEG 104 rgpl20 MN HIV infected pregnant women
ACTG 185 Hyper HIV IgG Pooled HIV+ plasma HIV infected pregnant women
AVEG 007B rgpl20 SF-2 HIV uninfected individuals
AVEG 003 rgpl60 LAI HIV uninfected individuals
AVEG 009 rgpl20 MN HIV uninfected individuals
Army rgpl60 LAI HIV uninfected individuals
AVEG 103 rgpl20 SF-2 HIV infected individuals
s modified from McElrath and Corey, 1994.
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Other preventive measures such as cleansing of the birth canal before
membrane rupture have been suggested as a way to reduce the risk of transmission for
infants born to HIV-1 infected women (Goedert et al.t 1991). The efficacy of such a
procedure in reducing perinatal transmission was examined by Biggar et al. (1996) in
Malawi. In that study, the intervention had no significant impact on HIV transmission
rates, except when membranes were ruptured more than 4 hours before delivery
(transmission 25% in the intervention group vs. 39% in the control group).
The only effective way to prevent postnatal transmission ofHIV-1 occurring
through breast-feeding is by providing alternative methods of feeding to new bom
babies. However, this recommendation is not universal. It depends on circumstances,
and varies with the environmental and domestic circumstances of the mother (World
Health Organisation, 1992).
I.1.3. NATURAL HISTORY OF HIV-1 INFECTION
Without intervention, infection with HIV-1 is a slow, progressive and
irreversible process, from the initial infection to what has been designated as 'full¬
blown AIDS'. The clinical manifestations ofHIV-1 infection have been grouped by
the Centers for Disease Control and Prevention (CDC) into four clinical stages: group I,
II, III and IV (Table 1.2; Centers for Disease Control, 1987). This classification was
modified in 1992, to include CD4+ cell count and other immunological and clinical
conditions (Centers for Disease Control, 1992). However, at present few laboratories
in the developing countries can afford the cost for CD4 estimation which makes it
difficult to compare data from different studies.
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The early phase ofHIV-1 infection (group I) starts from the time the
individual comes in contact with the virus until the production of antibodies or
illness. This period may vary between 1 to 4 weeks for the 'flu-like' illness and up to
6 weeks after which some neurological conditions can be observed (Ho et al., 1985).
A wide variety of symptoms and signs can be observed during the early stage ofHIV-
1 infection, the commonest ofwhich are fever, malaise, diarrhoea, myalgia, sore
throat, headaches and maculo-papular rash (Ho et al., 1985; Kinlochdeloes et al.,
1995). During this phase, the plasma HIV-1 titre (as measured by p24 Ag, plasma
RNA) can show a substantial increase (Clark et al., 1991; Daar et al., 1991). The
fact that the observed plasma viremia is only transient suggests that the immune
system, and more precisely, the cellular cytotoxic T lymphocytes (CTL) may play an
important role in containing the replication ofHIV-1 (Autran et al., 1996).
Occasionally, the CD4 counts in some patients can show a decrease (Fahey et al.,
1990; Bofill et al., 1996). The appearance ofCTL activity coincides with a decrease
in viral load as monitored by plasma viremia (D'Souza and Mathieson, 1996).
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TABLE 1.2: Centers for Disease Control case classification ofHIV infection
CDC Stage Clinical manifestation
Group I Acute infection: flu-like illness
Group II Asymptomatic infection
Group III Persistent generalised lymphadenopathy (PGL)
Group IV
Subgroup A Constitutional disease: weight loss (>10% of the normal body
weight), fever (>38°C), diarrhoea (>2weeks).
Subgroup B Neurological disease: HIV encephalopathy, myelopathy, peripheral
neuropathy.
Subgroup C Secondary infectious diseases:
CI: AIDS defining secondary infectious disease (.Pneumocystis
carinii pneumonia, cerebral toxoplasmosis, cytomegalovirus
retinitis)
C2: Other specified secondary infectious diseases (oral candidiasis,
pulmonary tuberculosis, multidermatomal varicella zoster).
Subgroup D Secondary cancers: Kaposi's sarcoma, non-Hodgkin's lymphoma.
Subgroup E Other conditions (lymphoid interstial pneumonitis).
(Centers for Disease Control, 1987)
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Early high virus load with sustained viremia is often accompanied, in both adults and
infants, by the inability to mount an effective immune response, resulting in rapid
disease progression (D'Souza and Mathieson, 1996). Seroconversion with the
production of detectable antibodies, takes place approximately 4 weeks after infection.
Antibodies to the envelope glycoprotein gpl20 are the first to be detected followed by
antibodies to p24 (gag), p53 and p64 (pol) proteins. The role of these antibodies in the
neutralisation of the virus has been reported by several investigators (Poignard et al.,
1996; McElrath etal., 1996; Sattentau, 1996; Mascola et al., 1996; Halsey et al., 1992).
However, the time at which neutralising antibody appears is variable and unpredictable
(D'Souza and Mathieson, 1996). It appears that the main target for the neutralising
antibodies is the gpl20 glycoprotein, particularly the principal neutralising determinant
(PND), the V3 loop, situated at the tip of the envelope hypervariable region (Kuiken et
al, 1993; Zwart et al., 1991; Wolfs etal., 1991; Javaherian et al., 1990). Another
hypervariable region, V2 (Warrier et al., 1994; Gorny et al., 1994; Moore et al., 1993),
and the glycoprotein gp41 (Purtscher et al., 1994; Muster et al., 1994; Back et al.,
1993) have also been reported to elicit the production of neutralising antibodies.
However, the mechanism of neutralisation still remains unclear.
Patients in group II present no clinical symptoms or signs (hence asymptomatic
HIV infection). From a virological point of view, this period is characterised by a high
viral turnover of infected cells (Wei et al., 1995; Ho et al., 1989). The asymptomatic
period can last from a few months to several years until the development of painless
systemic, enlarged lymph nodes- a state called persistent generalised lymphadenopathy
(PGL). PGL is the main characteristic of the CDC stage III. Occasionally, night sweats
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and weight loss can be observed in addition to the markedly asymmetrical and enlarged
lymph nodes.
During the CDC IV stage, a wide range of clinical illnesses can be noted, and
have been subdivided into subgroups A to E (Table 1.2). Individuals classified within
the CDC group IV-A present with one or more of the following symptoms: fever (>1
month), diarrhoea (>1 month) and/or involuntary weight loss (>10% of the individual
normal weight) as a direct consequence of HIV infection. The subgroup B includes
individuals presenting with neurological conditions including dementia, myelopathy
and peripheral neuropathy, which are a direct consequence ofHIV-1 invading the
cerebro-spinal system. The group C includes patients presenting with secondary
infectious diseases and this subgroup is divided into two categories: CI and C2.
Patients classified in the CI category present one or more AIDS defining secondary
infectious diseases {Pneumocystis carinii pneumonia, cerebral toxoplasmosis,
cytomegalovirus retinitis). C2 includes individuals with other specified secondary
infectious diseases such as oral candidiasis, pulmonary tuberculosis and/or varicella
zoster. Subgroups D and E are associated with the secondary cancers (Kaposi's
sarcoma, non-Hodgkin's lymphoma) and other clinical conditions (such as lymphoid
interstitial pneumonitis) (Table 1.2).
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The natural history ofHIV infection in children born to seropositive mothers
requires additional consideration and needs to be interpreted from a paediatric point of
view (table 1.3). In general, HIV-infected children appear well for the first few months
although some immune abnormality can be noticed. Some infected children can
remain well for more than 5 years. The CDC classification for children born to
seropositive mothers is summarised in Figure 1.1 (details see appendix 2). The clinical
features in children are classified by categories or classes: class P-0, class P-l, and class
P-2. The class P-0 includes children (<15 months old), in whom the HIV status cannot
be established, by lack of definitive evidence ofHIV infection or AIDS. The P-0 is
followed by the asymptomatic infection stage (class P-l), including children with
normal immune function (P-l, subclass A) or those with apparent immune disfunction
(P-l, subclass B) including hypergammaglobulinemia, CD4 lymphopenia, decreased
CD4-to-CD8 ratio or absolute lymphopenia. The asymptomatic P-l class is followed
by the class P-2, symptomatic infection phase and is subdivided into 6 (A-F)
subclasses.
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P2-B: Progressive neurologic disease
P2-C: Lymphoid interstitial pneumonitis
P2-D: Secondary infectious diseases
P2-D1: Opportunistic infections
P2-D2: Unexplained, recurrent, bacterial infections
P2-D3: Other infectious diseases
P2-E: Secondary cancers
P2-E1 Kaposi's sarcoma, B cell non-Hodgkin's lymphoma,
or primary lymphoma of brain
P2-E2: Other malignancies possibly associated with HIV
P2-F: Other conditions possibly caused by HIV:
including hepatitis, cardiopathy, nephropathy,
hematologic disorders, dermatologic diseases.
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1.1.4. LABORATORY DIAGNOSIS OF HIV INFECTION
The wide variability of the time when MCT occurs makes the diagnosis ofHIV
infection, the management of children and counselling ofmothers very complicated.
Most proposed clinical criteria for paediatric classification ofHIV infection, including
those proposed by the CDC classification have low sensitivity, specificity and positive
predictive value especially in very young children, in developing country settings. The
diagnosis ofHIV infection in children bom to seropositive mothers is more accurate if
based on laboratory findings. In adults, serological diagnosis ofHIV is based on the
detection of IgG antibodies in plasma or serum or other body fluids of infected
individuals. Unfortunately, the early diagnosis ofHIV infection in children is
hampered by the passive transfer ofmaternal antibodies into childrens' circulation.
These maternal antibodies persist in the child's circulation for a mean time of 10
months (Mok et al., 1987) and in some cases they can be detected at up to 2 years
(Newell and Peckham, 1993). Generally, 15 months is the cut-off time after which, if a
baby is found to have HIV specific IgG, he or she may be considered as infected.
To overcome the difficulty associated with this delay, alternative serological
methods for early diagnosis have been sought. These are based on 2 principles: a)
detection of antibodies that have a short half-life and b) detection of antibodies that 'do
not cross placenta'. Based on the hypothesis that maternal IgA and IgM do not cross
the placenta, their detection has been used to establish a diagnosis ofHIV-1 infection of
children (reviewed in Sison and Campos, 1992). Evaluation of the sensitivity and
specificity of this method is hampered by various factors including the variation of time
of infection of the baby and the level of B cell impairment that might result in
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hypogammaglobulinemia. Early diagnosis ofHIV by detection of IgA and IgM in the
baby was studied in this thesis and the results are presented in chapter 4.
Detection of p24 antigen with or without preliminary acid dissociation
treatment is another possible means of diagnosis ofHIV in children (Quinn et al.,
1993). However, it is essential that p24 is dissociated from the antibody so that it can
be identified and is not masked in the complex. By prior treatment of the sample with
acid (acid dissociation), the sensitivity of the test can be increased from 18 % to 90%
(Quinn et al., 1993).
The in vitro antibody production (IVAP) technique is another research tool for
HIV antibody detection in the new-born (De Rossi et al., 1988; Sison and Campos,
1992). It relies on the principle that during HIV infection, B cell lymphocytes are
activated to produce antibodies. In vitro, peripheral blood lymphocytes from a patient
suspected ofHIV infection are isolated and cultured. Antibody production from
sensitised cells is activated by mitogen such as pokeweed or a virus such as Epstein-
Barr virus (EBV) which induces polyclonal B cell activation. The presence ofHIV-1 is
confirmed by testing the culture supemate for the presence ofHIV-1 antibodies. IVAP
has been used by DeRossi et al (1988) for the diagnosis ofHIV infection in children.
They identified 92.5% of27 infected children but there is not much information on the
evaluation of this technique on a larger sample and its use may be limited to
well-equipped laboratories.
Viral culture can also be used for the diagnosis of vertically acquired HIV
infection in infants. The sensitivity and specificity of the HIV culture by 6 months has
approached 100%, but varied with reports of 38-50% at birth and increasing thereafter
(Hutto et al., 1991; Rogers et al., 1991; Sison and Compos, 1992). This variation may
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be related to the time of infection and the amount of virus in the baby at the time of
culture. Culture can be of limited value in small laboratories in developing countries as
it needs to be performed in well equipped laboratories with adequate safety measures.
However, HIV culture is not a rapid diagnostic test, as it can take up to 28 days to
complete (Sison and Compos, 1992).
The most successful method for early diagnosis of vertically acquired HIV in
children is probably the polymerase chain reaction (PCR) (Paul et al., 1996; Newell el
al., 1995; Roques et al., 1995; Newell et al., 1996; Bertolli et al., 1996; Sison and
Campos, 1992; Krivine et al., 1992). The PCR technique allows the amplification of
the viral nucleic acid by amillion - to a billion fold. The method is dealt with at length
in the present study (see Materials and Methods) and the results are presented in
chapter 5.
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1.2. VIROLOGICAL ASPECTS OF HIV-1
1.2.1 OVERVIEW OF THE RETROVIRIDAE
A unique feature of the retroviruses is that they contain an enzyme called
reverse transcriptase (RT), which enables them to replicate "backwards" (hence
retro), from RNA to DNA. The cryptogram code of the retroviruses is:
[R/l: 7-10/2: Se/* : V/C, I, O, R].
This code summarises the general features of the members the retrovirus family: virus
contains a single strand ofRNA of 7-10 million molecular weight (about 2% of the
infective particle). The virus particle is essentially of spherical symmetry and is
enveloped. The systematic classification of Retroviridae is shown in Table 1.3.
Based on the viral structure, the utilisation of particular cell receptors, the presence or
absence of oncogenes and other pathogenetic properties, the ICTV subdivides
retroviruses into 3 subfamilies. These are the oncoviruses, the spumaviruses and the
lentiviruses.
The oncoviruses include a variety of viruses (types A-D) associated with
the activation of certain cell genes leading to tumour development. They cause
disease in both animals and humans. The spumaviruses are readily isolated from
humans and animals (particularly primates) but have not been associated with any
specific disease. The lentivirus genus includes viruses responsible for a range of
slow progressive (hence lend- which means slow) neurological and immunological
diseases; the viruses are not directly implicated in malignancy. The prototype
member of the Lentivirinae is the visna virus of sheep which can cause slow but
progressive pathological conditions in the brains of infected animals. Other members
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of the subfamily of lentiviruses include the equine infectious anaemia virus, the
caprine arthritis-encephalitis virus, the feline and bovine immunodeficiency viruses
(FIV and BIV) and the human and simian immunodeficiency viruses (HIV and SIV)
(Clements et al., 1988; Levy, 1994).
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TABLE 1.3. The family ofRetroviridae
Subfamily Example
Oncoviruses: associatedwith immortalisation ofhost cells
Type A Mouse intracisternal type A
Type B Mouse mammary tumour virus
Type C Murine leukaemia virus
Human T cell lymphotropic virus type I and II
Feline leukaemia virus
Bovine leukaemia virus
Type D Mason-Pfizer virus
Spuntuvirus: Isolated in primates and human. Not associated with any specific disease
Simian foamy virus
Human foamy virus
Lentivirus: Produce slow andprogressive destruction of the immune system
Feline immunodeficiency virus





Group M: subtype A, B, C, D, E*, F, G, H, I**, J**.
Group O
HIV-2: subtype A, B, C, D and E.
(Table modified from Fields Virology, 1996. * isolates classified as subtype E have
been classified as such based on the analysis of the env gene ofHIV-1 and were
shown to be subtype A when the gag genes were analysised. **Subtypes I and J are




A schematic diagram of the structure of the HIV-1 virion is represented in
figure 1.2. HIV-1 has several characteristics in common with HTLVs and other
retroviruses. These include morphological and structural features, biochemical and
biological properties (Gallo et al., 1984). The viral particle is about 1 lOnm in
diameter. When viewed by electron microscopy, it shows a cone-shaped core which
is the viral capsid (or nucleoid) composed of the viral p24 gag protein (CA)
(Gelderblom et al., 1989; Gelderblom et al., 1987). On its surface, the virus is
studded with 70-80 protrusions that project radially. These knobs derive from a
structural protein (gpl60) consisting of two protein sub-units (gp41 and gpl20)
encoded by the envelope (env) gene (McCune et al., 1988). Each knob has a
diameter of about 15nm, a height of 9nm and plays an important role in viral
infectivity (Gelderblom et al., 1989; Gelderblom et al., 1987). In addition, the
envelope contains other proteins which derive from the host (such as human
leukocyte antigens, HLA) which the virus may have acquired when budding through
the cell membrane (Cantin et al., 1996; Desantis et al., 1996). These host
components may affect virus-host immune system interaction.
The nucleocapsid, or core, is roughly spherical to conical shape measuring
about lOOnm in length. The viral matrix protein, gag pi7 (MA), is attached to the
inner surface of the lipid bilayer. The conical capsid protein surrounds two other
nucleocapsid proteins (p7 and p9), enzymes (integrase, pi 1; reverse transcriptase,
p66 and p51; and protease, pi 5) and the two identical copies of the HIV RNA
genome (Gelderblom et al., 1987).
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FIGURE 1.2: Structure of the HIV-1 virion shown in cross section
















In brackets are abbreviations of viral proteins: NC, nucleocapsid; PR, protease;
RT, reverse transcriptase; IN, integrase; Vpr, regulatory ofmature virus
particle; SU, surface glycoprotein; TM, transmembrane glycoprotein; MA,
matrix; CA, capsid.
30
1.2.3. GENOME STRUCTURE AND ORGANISATION
Figure 1.3 shows the schematic representation of the structure of the
genome and proteins encoded by various HIV-1 genes. The genome is relatively
small, about 9.2 kilobases (kb) long, yet its function is very complex. The genes
encode for three major structural proteins (gag, pol and env) and at least 6 additional
proteins involved in the regulation of the viral gene expression. There are also two
non-coding regions, known as long terminal repeats (LTRs), at each end of the
genome which have identical nucleotide sequences (Wain Hobson et al., 1985;
Ratner et al., 1985).
1.2.3.1. THE NON-CODING REGIONS: LONG TERMINAL REPEAT
REGIONS (LTR)
The non-coding LTR regions are located in terminal regions (figure 1.3),
which contain important recognition signals for the synthesis ofDNA or RNA. The
LTR has a redundant (R) section, which is the same in both the 3' and 5' ends of the
genome. The R sequence plays an important role during reverse transcription by
transferring the nascent DNA from one end ofRNA to the other. The unique
information region (U5) is the first to be translated into DNA and becomes U3 at the
3' end of LTR. There is a simple variable untranslated region separating the env and
the beginning of the U3, which may play the role of the rev gene (Bray et al., 1994).
It is thought that some U5 sequences are essential for initiation of RT. Other regions
of the LTR include the primer binding site (PB) and the leader site (L) (Rosen et al.,
1985; Sodroski et al., 1985a; Sodroski et al., 1985b).
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1.2.3.2. HIV STRUCTURAL, ENZYMATIC AND REGULATORY GENES
The structural and regulatory genes ofHIV-1, their approximate size and
the function they play in the viral life cycle are summarised in table 1.4.
A. STRUCTURAL AND ENZYMATIC GENES
The envelope ienv) gene encodes a protein (p85), which is glycosylated to
form the envelope precursor protein gpl60. It is a monospliced message from the
viral mRNA. The cleavage of this gpl60 yields the surface envelope gpl20 and the
transmembrane gp41 glycoproteins (Stein and Engleman, 1990). The attachment of
the virus to the cellular receptor (CD4) is mediated by the gpl20. In addition,
gp41 contains amino acids which play an important role in syncytium formation
(Wang et al., 1996; Hart et al., 1996). Other spliced mRNA genes of the env region
encode regulatory and accessory proteins, which play, at various levels, a role during
the viral replication (Figure 1.3; Table 1.4.).
The pol gene encodes a precursor protein, which is cleaved into the reverse
transcriptase (RT), integrase and protease. The RT also has an RNase H activity
which degrades the RNA template during the synthesis ofDNA (Varmus, 1988a;
Varmus, 1988b).
The group specific antigen, gag, encodes a 55kd protein precursor that is
cleaved by the viral protease into three proteins, the myristoylated matrix protein
(pi7), the phosphorylated capsid protein (p24) and the nucleocapsid binding protein
(p6/7 and p9) (Veronese et al., 1988). The p7 interacts with the viral RNA through
its 'zinc finger' (Veronese et al., 1988), and supports the structure of the membrane
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(Veronese et al., 1988; Green and Chen, 1990). The pi 7 region has been the focus of
the molecular analysis ofHIV-1 isolates described in this thesis.
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TABLE 1.4. Structural and regulatory genes ofHIV-1




Env (envelope) gpl60 Precursor of gp 120/41
gpl20 Outer env glycoprotein
gp41 Transmembrane glycoprotein
Gag (core) p55 Precursor of gag proteins
p24 Capsid structural protein
p!7 Matrix structural protein
pl5,p9, p7 Other gag proteins






Tat pl4 Transactivator ofRNA synthesis
Rev pi 9/20 Regulation of viral mRNA expression
Nef p27 Negative factor (pleiotropic)
Vif p23 Infectivity factor
Vpu pi 6 Virus release
Vpr pi 8 Virus replication
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B. REGULATORY GENES
The genome ofHIV contains at least 6 additional genes that encode genetic
information for the synthesis of regulatory proteins. These proteins are synthesised
via translation from multiply spliced genes, which play an important role in virus
gene expression (Table 1.2). For example, the transactivator protein, tat, is a major
protein involved in up-regulation ofHIV replication. It interacts with the loop formed
at the 3' LTR ofRNA called the tat responsive element (TAR) (Herrmann and Rice,
1993). Another gene involved in the regulation of viral protein expression, rev,
interacts with the cis-acting RNA loop structure called rev responsive element (RRE)
(Malim et al., 1989). This interaction helps the viral mRNA to migrate from the cell
nucleus to enter the cytoplasm where synthesis of viral protein takes place (Sodroski
et al., 1986a). The nefgene or 'negative factor' gene is so-called for its negative
influence on viral expression (Ahmad and Venkatesan, 1988; Niederman et al.,
1989). This was shown experimentally by Luciw et al. (1987) by deleting the nef
gene from a wild virus SF2 which resulted in a variant that replicated to higher titre
and produced a more pronounced cytopathic effect than the original SF2 isolate.
However, these findings need to be confirmed.
In addition HIV-1 has a 23kd vifprotein which has been found to be essential
for the spread ofHIV-1 in peripheral blood lymphocytes and in primary cultures of
macrophages, as well as in some established T-cell lines. It is required at the stage of
viral particle formation, for cell-to-cell as well as for cell-free transmission ofHIV-1
(Vonschwedler et al., 1993). The role of the accessory gene product of vpr during
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HIV-1 infection remains unclear. As for vif the product encoded by the vpr gene
possibly plays a role during the late phase of the production of infectious viruses. The
vpr protein is incorporated into the virion at the C- terminal end of the gag protein
precursor Pr55 (gag) (Li et al., 1996). Sato et al. (1996) demonstrated a direct
association between vpr and the C-terminal region ofmatrix protein pi 7 within the
mature virion. The interaction plays a direct role in the nuclear transport of the viral
pre-integration complex in non-dividing cells such as macrophages. Far from being
merely called 'non-essential' or 'accessory genes', Balliet et al. (1994) showed that
vpr, vpu (and nef) may be related to each other in facilitating productive infection in
macrophages. In fact, the loss of vpr or vpu genes reduced viral antigen production
in macrophages by up to 1000- fold, while replication in lymphocytes was only
marginally affected. However, the loss of nefhad little or no effect on infection of
lymphocytes, but decreased the viral replication in macrophages to a small extent.
1.2.4. VIRAL REPLICATION CYCLE
The life cycle ofHIV-1 is illustrated in figure 1.4. Like all viruses, the
replication ofHIV-1 is critically dependent on a host cell, which provides essential
conditions for the virus to reproduce itself.
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FIGURE 1.4. Life cycle ofHIV-1 (modifiedfrom Peterlin, 1988)
During the life cycle, HIV attaches to cells by specific interactions between gpl20
and CD4 (a). After penetration and uncoating (b), virion associated reverse
transcriptase (c) converts genomic viral RNA into double-stranded linear DNA,
which is translocated (d) from the cytoplasm to the nucleus and (e) converted to
supercoiled molecules containing one or two copies of the long terminal repeat
(LTR). Efficient retroviral growth requires integration (f) of a DNA copy of the viral
RNA genome into a chromosome of the host. It is not known whether in some
circumstances HIV replicates without integration of the viral genome into a host
chromosome. In the nucleus, HIV gene expression (g) involves synthesis of viral
transcripts by host-RNA polymerase II and other cellular and viral factors. Primary
transcripts are differentially spliced (h) and transported to the cytoplasm. Full-length
transcripts are messenger RNAs for gag and gag-pol precursors and genomes for
assembly of virion. Spliced transcripts are translated into viral proteins (i).
Morphogenesis involves formation of two molecules ofHIV genomic RNA
complexed with gag and pol gene products. This core buds through the cellular
membrane and acquires a coat containing env glycoproteins.
38
FIGURE 1.4. Life cycle of HIV-1 (modified from Peterlin, 1988)
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1.2.4.1. ATTACHMENT AND ENTRY
The main cellular receptor for HIV-1 is a determinant cluster 4 (CD4)
glycoprotein (Isobe et al., 1986; Maddon et al., 1986; Dalgleish etal., 1984). The
CD4 is a 54kd transmembrane glycoprotein expressed on various cells including
helper T lymphocytes, on B cells and cells of monocyte-macrophage lineage and
some cells of the central nervous system (Maddon et al., 1986). The first step of
HIV-1 infection is the binding of the virion gpl20 to the CD4 receptor, although the
mechanisms of fusion and entry remains poorly understood (Dalgleish et al., 1984;
Klatzmann et al., 1984). However, specific sites within the V3 loop domain of
gpl20 and the transmembrane gp41 protein have been shown to be critical for virus
fusion and infectivity (Freed et al., 1991; Page et al., 1992). The introduction of the
nucleocapsid into the host cell cytoplasm was initially thought to occur by
endocytosis of the receptor-virus complex (Pauza and Price, 1988). Another line of
evidence suggests that HIV-1 entry to the host cytoplasm occurs by direct fusion and
this pathway appears to be acidic pH-independent (Stein et al., 1987).
The hypothesis, that 'CD4 positive cells are the host ofHIV' was supported
by the finding that a substantial decline of CD4 positive cells was observed in
individuals following infection with HIV. In addition, pre-incubation ofCD4+
lymphocytes with CD4-specific monoclonal antibodies prevents the binding and
entry of the virus into these cells (Klatzmann et al., 1984). Several co-receptor
molecules, however, have been suspected. For example, HIV-1 can only bind to, but
not enter some murine cells which naturally express the CD4 molecule (Maddon et
al., 1986). Nevertheless, if fused with human cells, murine cells become infectable
40
with HIV-1, which provides more evidence of the existence of co-receptors ofHIV-1
entry (Alkhatib et al., 1996). More compelling pieces of evidence were reported by
Feng et al. (1996) who identified the existence of fusin, a protein which is a putative
G-protein-coupled chemokine receptor. In fact, the infection of lymphocytes by T-
cell-line-tropic isolates is successfully blocked by antibodies against fusin (Feng et
al., 1996). In addition, Cocchi et al. (1995) identified molecules called (i) RANTES
(regulated upon activation, normal T expressed and secreted), and (ii) macrophage
inflammatory proteins (MlP)-la and MIP-ip, which are chemokines released by
CD8 positive T-cells. They found that these chemokines suppressed infection of
CD4+ cells by HIV-1. Another important discovery is the identification ofCCKR5,
a protein that belongs to the same family as fusin, and serves as receptor for the p-
chemokines RANTES, MlP-la and MIP-1 p. The last three molecules block HIV-1
infection by interfering with the binding ofCC-CKR5 to gpl20 or by sending signals
which down regulate their own production (Deng et al., 1996; Dragic et al., 1996;
Alkhatib et al., 1996; Choe et al., 1996; Doranz et al., 1996). Several cells, other
than CD4+ human T lymphocytes, including CD8+ T-cells, macrophages, and
dendritic cells have also been shown to be susceptible to HIV but the mechanism of
infection remains unclear (Schnittman et al., 1989; Dalgleish et al., 1984; Klatzmann
et al., 1984; Livingstone et al., 1996). It also is possible that an HIV-antibody
complex binds to macrophages through the constant fragment (Fc) during the natural
killing process (Homsy et al., 1989; Jouault et al., 1989).
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1.2.4.2. REVERSE TRANSCRIPTION AND INTEGRATION OF PROVIRAL
DNA
After fusion of the viral and cellular membranes, the viral core is delivered
into the cell cytoplasmic matrix (Bukrinsky et al., 1993). Initiated by various tRNA
molecules as primers, the reverse transcription is mediated by the pol gene product,
the reverse transcriptase (RT) (Lund et al., 1993). The RT has two major functions:
the DNA polymerase and the ribonuclease H (RNase H). DNA polymerase activity
enables the RT to use the RNA and DNA as templates to synthesise the proviral
DNA. Then through RNase H activity, the viral RNA from an RNA-DNA hybrid
molecule is selectively degraded allowing the synthesis of the second strand ofDNA
(Varmus, 1988a; Varmus, 1988b). As a result ofRT activity, there are three forms of
DNA in the cell cytoplasm. The linear molecule appears to have all HIV-1 genes in
the order they are found in the genome and flanked by two LTRs. There are in
addition two circular forms and it remains unclear whether these forms play a role in
the life cycle (Bukrinsky et al., 1993).
Efficient retroviral growth requires integration of a DNA copy of the viral
RNA genome into a chromosome of the host. It is not known whether in some
circumstances HIV replicates without integration of the viral genome into a host
chromosome. In one study, although integration was found to be necessary for viral
replication, a limited amount of virus replication seemed to occur without integration
(Sakai et al., 1993). Following its translocation to the nucleus, the linear double-
stranded viral DNA is inserted into the cellular DNA using the virus pol gene
encoded integrase (Bushman et al., 1990). Several other viral components, including
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the protease, and more importantly the integrase also enter the nucleus. Prior to
integration, the integrase cleaves the colinear double-stranded proviral DNA at the 3'
end of both strands which results in the loss of 2 bases (Varmus, 1988a; Varmus,
1988b). At the repeat bases located at the end of the LTR region is an important
recognition site for the integration. Mutations within this region have a negative
effect on proviral DNA integration.
1.2.4.3. TRANSCRIPTION AND TRANSLATION
After integration, transcription of the full-length viral RNA, initiated by
cellular proteins (transcription factors), occurs as the proviral DNA takes over the
cellular transcription process. The viral RNAs evolve into two pathways. One group
ofRNA molecules becomes the mRNA for production of various viral proteins; the
other group of full-length RNA molecules plays the role of viral genome. At an early
phase of the viral expression, the multiply spliced mRNA, which encodes regulatory
proteins (tat, rev and nef) is transported into the cytoplasm (Kim el al., 1989). The
nefprotein is not required for the replication of the virus in vitro. However, tat, the
transactivating protein, enhances the transcription activity of the HIV-1 and rev plays
a significant role in the cytoplasmic transport of transcript of the viral structural
proteins (Malim et al., 1989; Malim et al., 1988; Sodroski et al., 1985a; Sodroski et
al., 1986b). In addition to tat, various cell factors bind to tat or co-operate with it in
order to process the RNA polymerase II, initiate the viral transcription, increase the
level of initiation and enhance RNA elongation (Cullen, 1986).
The late expression of viral genes is also mediated by the rev protein. At this
stage, the gag-pol mRNA and the singly spliced env mRNA are translated into
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precursors of viral structural and enzymatic proteins. These precursors are subject to
proteolytic cleavage, glycosylation, phosphorylation and myristoylation. Other
regulatory proteins, vif vpu and vpr intervene during the late phase of the viral gene
expression. Their late expression suggests that they may be involved in the
processing or the assembly of the various viral and structural proteins. Particularly,
the vpu protein, only found in HIV-1 and not in HIV-2 (where it is replaced by vpx),
is required for maturation and increases the release of virions from infected cells
(Klimkait et al., 1990). Once the late expression of viral genes is completed, mature
virus particles are packaged and released by budding through the cell membrane
(Popovic et al., 1984). During the budding process, the virus particles acquire the
outer lipid bilayer, which contains the external and transmembrane envelope
glycoproteins (figure 1.4).
1.2.4.4. ASSEMBLY AND RELEASE
The packaging of the newly replicated HIV virions is the most poorly
understood aspect of the replication cycle. During assembly, RNA genomes are
assembled by highly specific interaction with p55 and pi60 gag-pol polyprotein
precursor molecules. Prior to packaging, the precursors of viral proteins undergo
various modifications. The p55 and pi60 gag-pol are modified after their translation
by the attachment of a myristoyl group onto their N-termini, which may anchor the
constituent of the nascent virus to the cytoplasmic side of the cell membrane. In
addition, the cleavage and glycosylation of the glycoprotein gpl60 takes place in the
endoplasmic reticulum and the golgi complex to produce the gpl20 and the gp41
glycoproteins (Stein and Engleman, 1990); their incorporation is not well understood.
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Naturally, the budding of the viral component from the cellular membrane will result
in the death of the host cell.
1.2.5. GENETIC HETEROGENEITY OF HIV-1
Retroviral replication is a highly error-prone process with varying estimates
of about 7x10"6 to 1.4xl0~4 base-pair substitutions per nucleotide per replication cycle
(Dougherty and Temin, 1988; Leider et al., 1988; Pathak and Temin, 1990a). The
observed mutation rates are the result of an error-prone reverse transcriptase, which
in the case ofHIV-1 has a misincorporation error rate of approximately 10~4 per base
per replication cycle (Roberts et al., 1988; Preston et al., 1988). Additional factors
contributing to viral heterogeneity are the frequent occurrence of insertion and
deletion (Dougherty and Temin, 1988; Pathak and Temin, 1990a; Pathak and Temin,
1990b) and the commonly observed hypermutation expressed by frequent G-to-A
transitions (Fitzgibbon et al., 1993; Pathak and Temin, 1990a; Vartanian et al.,
1991). Furthermore, recombination constitutes another factor contributing to the
high genetic heterogeneity observed in HIV-1 strains (Srinivasan et al., 1989).
Recombination has been observed to occur in vivo in a baby dually infected with two
different strains (Diaz et al., 1995). With a viral half life of about 2 days in infected
individuals (Ho et al., 1995), the combined effect of hypermutation, base
substitution, recombination and intergenomic recombination can produce a large
number of variants within the same individual. These are called viral 'quasispecies'
(Goodenow et al., 1989; Simmonds et al., 1991; Holmes et al., 1992; Balfe et al.,
1990).
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Phylogenetic analysis ofHIV strains from different parts of the world resulted
in the division ofHIV in two super-groups, namely HIV-1 and HIV-2. Genetically,
HIV-1 is subdivided into 2 distinct groups, the main (M) group and the outlier (O)
group (Myers et al., 1995). Group M viruses appear to be the most prevalent and
have a worldwide distribution. At least 8 group M subtypes (A- H) have been
identified based on the analysis of the gag region. Usually, HIV-1 strains grouped
together in clades (subtypes) when analysed on the basis of the gag and env region
sequences (Myers et al., 1995). However, all currently published env subtypes E do
not group as a distinct clade, but cluster within subtype A on the basis of the gag
gene (Sharp et al., 1994; Myers et al., 1995). It is not yet known whether the two new
subtypes provisionally assigned the letters I and J based on the env phylogeny
(Kostrikis et al., 1995; Leitner et al., 1995) will constitute distinct clusters if they are
analysed in the gag region. In addition to group M clades, it is believed that HIV-2
may also be divided into five subtypes (A-E) (Chen et al., 1996; Albert et al., 1996).
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AIMS OF THE STUDY
The present study was originally designed to provide basic information on the
natural history ofHIV-1 infection among mothers and children in a rural community
in Kimpese, Congo. In the course of the recruitment process, it was shown that the
seroprevalence ofHIV-1 among child-bearing mothers was both low and remained
stable over a 5 year period (Green et al., 1994). In addition, the vertical transmission
rate was observed to be one of the lowest ever reported in Africa (Dr AG Davies,
personal communication). Reasons for both situations remain poorly understood.
Part of the explanation could be the social behaviour within the population and it
required a social scientist to carry out such an investigation1. The nature of the virus
was also suggested as a possible avenue for study. It was therefore important to
define as early as possible the study group (HIV-1 infected patients) and matched
controls (HIV-1 uninfected patients). For adults, there were commercial tests for
detection of IgG anti-HIV-1. However, in children, the diagnosis ofHIV-1 is
hampered by the presence ofmaternally derived IgG anti-HIV-1, which can persist
beyond 12 months of age (Newell et al., 1995). In developing countries, highly
sensitive techniques for diagnosis ofHIV-1 in children such as the polymerase chain
reaction (PCR) and virus culture are not always available. The few laboratories where
these methods are used cannot cope with the rising numbers ofHIV-1 infections in
children.
1 Dr Louise de la Gorgendiere, of the Department of Sociology, University of Edinburgh, visited Kimpese to
carry out a pilot study on social behaviour which could explain the low and stable seroprevalence ofHIV-1 in
the region. No specific marker was found to be associated with the stability in the region.
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The aims of this project were:
• Diagnosis: to develop a simple and inexpensive method for early diagnosis of
HIV-1 infection in children (Mokili et al., 1996).
• Subtype: to investigate the distribution ofHIV-1 subtypes in Kimpese, and to
establish their biological significance in mother-to-child transmission. Detailed
analyses of the nucleic and amino acid sequences of the pi 7 gag region were planned
to determine the specific characteristics ofHIV-1 variants of transmitting and non-
transmitting mothers.
• Serotype: Because of the large number of cases studied in this project, the
determination ofHIV-1 subtypes by sequencing was too expensive and time
consuming. It was planned to develop a serological method to subtype a large
number of samples containing antibodies to the principal neutralising domain of
HIV-1. The same system would also measure the level of antibodies to V3 loop in
transmitting and non-transmitting mothers.
This study would therefore lay foundations for future research, including the





2.1. SITES OF INVESTIGATIONS
2.1.1. KIMPESE
The samples analysed in the present study were collected from mothers and
children in Kimpese, a rural town in the Democratic Republic ofCongo (DRC),
formerly Zaire (Figure: 2.1). Kimpese is a town of 30,000 people, situated on the
main road between the capital Kinshasa (220 kilometre, km), and the port city of
Matadi (140 km). The economy of Kimpese is based upon subsistence agriculture
with local trading and a few industries. Kimpese is for many local people a
commercial centre. Immediately surrounding the hospital where the study was based
is a cattle farm, 'Les Grands Elevages de Kimpese'. Farmers bring their crops to sell
them at Kimpese's weekly Sunday market and to buy necessary provisions to take
back to their villages. The hospital, Institut Medical Evangelique (IME), is a joint
enterprise between American, British, Canadian, Swedish and Congolese
missionaries. It was founded in 1950 as a small rural health centre but now the
hospital has expanded to be the reference hospital of a health region, which covers a
population of over 120,000 people. With 400 beds, the hospital recorded over 9,000
admissions in 1985. The number of admissions dropped to 4,800 in 1993, probably
due to growing socio-economic difficulties, which make it difficult for poor villagers
to get to hospitals or afford the cost of treatment. However, those who cannot afford
to pay for hospital treatment are subsidised by charitable funds available as part of
the hospital mission. Specialities include internal medicine, surgery and
orthopaedics (with three operating theatres), obstetrics, gynaecology and paediatrics.
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There are four antenatal clinics where all the patients involved in this study have
been recruited (IME, Lamba, Cite and CIZA-Lukala1). In addition, specialities like
ophthalmology, a dental unit, a tuberculosis sanatorium and a leprosy unit make IME
probably the biggest rural hospital complex in the Democratic Republic of Congo.
2.1.2. UNITED KINGDOM
The construction of branched peptides (discussed below) was carried out at the
Medical Research Council (MRC), Institute ofVirology, University ofGlasgow, under
the supervision ofDr Eloward Marsden. The serological testing was performed at
various sites in UK, including the Regional Virus Laboratory, City Hospital,
Edinburgh, the Public Health Laboratory Service, Colindale (by coutesy ofDr John V
Parry) and at the AIDS Clinical Trials laboratory, St. Mary's Hospital, London (by
courtesy ofDr Rachanee Cheingsong-Popov). The molecular work was carried out at
the Molecular Virology laboratory, Department ofMedical Microbiology, University of
Edinburgh by courtesy ofDr Peter Simmonds.
1 CIZA-Lukala: cimenterie zai'roise de Lukala, recently changed to CILU, cimenterie de Lukala.
/
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2.2. RECRUITMENTAND ASSESSMENT OF PATIENTS
The protocol for this study was approved by the hospital, the (former) Zairian
Ministry of Health and, in the UK, by the regional paediatric ethical committee in
Edinburgh (Appendix 1). The recruitment of patients was carried out in two phases.
During phase I of the study, which spanned August 1988 and December 1991,
pregnant women attending antenatal care were screened for HIV-1 antibodies at four
maternity clinics (IME, Lamba, Cite and CIZA-Lukala) in Kimpese. The screening
continued at these four antenatal clinics until December 1990. In June 1991, the
screening was discontinued at Cite and CIZA-Lukala clinics due to workload created
by the follow up of mothers and children recruited for the HIV-1 mother-child
transmission study. At the end of phase I, 9129 mothers had been screened in the
Kimpese laboratory for antibody to HIV-1 using the Abbott recombinant HIV-1/HIV-
2 enzyme linked immunosorbent assay (ELISA) (Abbott Diagnostic Division,
Minehead, Berckshire, UK). Samples reactive at this stage were re-tested using the
same ELISA test and a competitive ELISA (Wellcozyme, manufactured by Murex,
formerly Wellcome Diagnostics, Dartford, Kent, UK) for HIV-1 only.
All HIV-positive mothers were invited to enrol in the project and gave signed
consent before entry (Appendix 2). A control group ofHIV negative pregnant
women was recruited at the same time. Infected and control mothers were group
matched for age, parity, social background and residence (village, town, or city). It
was explained that the project was a study of childhood illness including HIV
infection. All necessary medical care of the children was provided free of charge.
Phase II: February 1993-February 1994. In order to increase the number of
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children in this study, the screening of antenatal mothers was resumed at IME and
Lamba. During this period 2,183 antenatal mothers were tested for antibody to HIV-
1. It is possible that during phase I, some women undergoing seroconversion were
missed by the Abbott HIV-l/HIV-2 ELISA as this test only detects IgG antibodies.
A test that could detect both IgG and IgM anti-HIV was therefore needed to address
this problem. The first line screening tests, Murex Base Pack GEO 1/02/03 and
Detection Pack GE11/12/13 for detection of IgG and IgM anti HIV-1 and HIV-2,
were kindly provided by Dr Urszula Beckford ofMurex Biotech (Murex Biotech
limited, Central Road, Temple Hill, Dartford, Kent England).
Mothers were asked to bring their children to the study clinic at ages 3, 6, 9,
12, 15, 18 and 24 months for full assessment by a paediatrician and for blood tests.
The children were also seen by a study nurse at each of the intervening months and
by a nurse or doctor when brought to the clinic because of illness. Clinicians were
blind to the HIV status ofmother and child unless this became evident from clinical
manifestations. The HIV staging of infected mothers and children was based on the
medical history and physical examination during the puerperium (CDC, 1987). In
total there were 292 live births in the study including six pairs of twins, and six
stillbirths, five of them to infected women. Fourteen babies were lost to follow up
from birth. The remaining 278 (91%) were followed to death or at least 12 months of
age, 81% to at least 15 months, and 62% to 24 months.
PLACENTAL HISTOLOGY
In order to study placental histology, portions of placenta, from 43 HIV
infected and from 54 uninfected women, were fixed in formalin, embedded in
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paraffin wax, sectioned, and stained with haematoxylin and eosin. The same
pathologist (Dr Ann Nelson, University of Kinshasa), blind to the HIV status of the
mothers and children, examined sections from all placentae for malaria parasites and
pigment, chorioamnionitis and funisitis. Each feature was graded in two categories:
absent or slightly abnormal, and moderately or markedly abnormal.
ESTIMATION OF VERTICAL TRANSMISSION RATE
The rate of vertical transmission was estimated by the direct and indirect
methods recommended by the Working Group on Mother-to-Child Transmission of
HIV (Dabis et al., 1993). These methods were described in order to facilitate
comparisons between different studies. The direct method uses the HIV antibody
status of the child at or after 15 months, by which age maternal antibody has
disappeared from the blood of virtually all children of HIV-infected mothers.
Clinical assessment ofHIV status is used in children for whom the presence of
antibody at age 15 months cannot be ascertained. When clinical assessment is also
not possible, the child's status is classified as indeterminate. For the direct method,
three rates of the transmission rate are made: a minimum rate which assumes that the
indeterminates are not infected, a maximum rate which considers all indeterminate as
infected, and an intermediates rate which disregards the indeterminates. The indirect
method relies on antibody status at 15 months together with an estimate of the
excess mortality amongst the children ofHIV positive women in comparison with a
control group of children born to uninfected women. The excess is computed by life
table analysis. The advantage of this method is that it obviates clinical assessment of
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whether children under 15 months are infected and whether early deaths are HIV
related.
2.3. SEPARATION AND STORAGE OF BLOOD SAMPLES
At the antenatal and pediatric clinics, 5ml of blood drawn by venepuncture
was collected in a tube containing EDTA-K and four drops were dried on card and
sealed (Guthrie cards, kindly provided by Dr Anthony Girdwood, Scottish Neonatal
Screening Laboratory, Stobhill Hospital, Glasgow). Whole blood samples were
transported to the Kimpese laboratory and prepared for storage within 4 hours of
venepuncture. After centrifugation at 1,200 revolution per minute (RPM) for 15
minutes, plasma samples were separated from cells and were first stored at 4-8°C
until they were tested by ELISA (2-3 days), then at -20°C until they were transported
to the Regional Virus Laboratory in Edinburgh, United Kingdom (UK).
Official permission for 'export of biological research materials' was obtained
from the national committee for AIDS research in Congo (then Zaire). Samples were
shipped to UK frozen and thawing time was kept minimal. The confirmatory testing
was performed by Mr Tom Shaw of the Regional Virus Laboratory, City Hospital,
UK. This included measurement of p24 core antigen (Abbott, without acid
dissociation technique) and anti-p24 antibodies (Abbott) and western blot (Organon
Teknika).
Buffy-coat containing peripheral blood mononuclear cells (PBMC) was
either stored immediately at -20°C or the lymphocytes were separated using ficoll
gradients. The Lymphoprep™ (Nycomed Pharma As, Diagnostic Division, Norway)
was used for cell separation. The technique is based on the aggregation of
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erythrocytes and granulocytes in sodium metrizoate and polysaccharide, thereby
increasing their sedimentation rate (Ting and Morris, 1997). The isolation of the
peripheral blood mononuclear cells was carried out as follows: 1.5ml of huffy coat
was mixed with 1.5 ml distilled water containing 0.9% of sodium chloride (NaCl).
Lymphoprep (1.5ml) was measured in a 5ml sterile tube. Three ml of blood was
carefully layered on top of the lymphoprep avoiding mixing the blood with the
separation fluid. The tube was capped and centrifuged at 800 x g for 20 minutes at
room temperature, in a swing-out rotor. PBMCs were harvested from the interface
between plasma above and aggregated cells below, using a pasteur pipette. The
harvested cells were washed in 0.9% NaCl solution and pelletted at 250 x g for 10
minutes. Samples were then stored at -20°C in Kimpese. Samples stored this way
were adequate for PCR and sequencing performed later in the UK.
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MOLECULAR METHODS
2.4. EXTRACTION OF DNA FROM PBMC
REAGENTS
- DNA lysis buffer (EDTA, 0.05M; Tris-Cl, 0.1M, pH 7.5; NaCl, 0.05M) (, Sigma:
Poole, UK).
- Proteinase K (lOmg/ml) (Sigma: Poole, UK).
- N-lauroylsarkosyl (10%, w/v in sterile distilled water) (Sigma: Poole, UK).
- Chloroform-isoamylalcohol (50:1) (Merck Ltd, Merk House, Poole, Dorset, UK)
- Phenol (Merck Ltd, Merck House, Poole, Dorset, UK)
- Ethanol, 100% (Rathburn Chemicals Ltd, Walkburn, Scotland)
- Sodium acetate (Sigma-Aldrich Company Ltd, Fancy Road, Poole, Dorset, UK).
PROCEDURE
Stored PBMCs (400pl) were resuspended in 400pl ofDNA lysis buffer
containing 4pl of proteinase K, 44pl N-lauroylsarkosyl (10%, w/v in sterile distilled
water) and incubated at 65°C for 2 hours. The suspended cells were mixed with an
equal volume of phenol (Rathburn Chemicals Ltd, Walkburn, Scotland) and
vigorously shaken for 10 minutes then spun at 15,000 RPM for 10 minutes. After
centrifugation, the supernate was vigorously mixed with chloroform-isoamylalcohol
(50:1) (both supplied by Merck Ltd, Merk House, Poole, Dorset, UK). The mixture
was centrifuged for 10 minutes, at 15,000 RPM. The nucleic acid present in the
supernate was precipitated in 840pl solution containing 800p.l of 100% ethanol
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(Rathburn Chemicals Ltd, Walkburn, Scotland) and 40|_il sodium acetate (Sigma-
Aldrich Company Ltd, Fancy Road, Poole, Dorset, UK). After incubation at -40°C
for 2 hours (or overnight at -20°C), the precipitated DNA was collected by
centrifugation at 15,000 RPM (0°C) for 10 minutes. The nucleic acid was then
resuspended in 100-200 pi of distilled water. An aliquot (5pi) of the DNA was
analysed to determine the yield and the purity ofDNA using a spectrophotometer set
at 260 and 280nm (ultra violet spectrophotometer Cecil 2000).
2.5. EXTRACTION OF RNA FROM PLASMA
REAGENTS
- TNE buffer: 0.11M NaCl, 55mM Tris, pH 8.0; 1.1 mM EDTA, pH 8.0; 0.55%SDS
- Proteinase K (10%, w/v in sterile water)
- Poly A RNA carrier (Sigma-Aldrich Company Ltd, Fancy Road, Poole, Dorset,
UK).
- Chloroform-isoamylalcohol (50:1) (Merck Ltd, Merk House, Poole, UK)
- Phenol (Merck Ltd, Merk House, Poole, Dorset, UK)
- Ethanol, 100% (Rathburn Chemicals Ltd, Walkburn, Scotland)
- Sodium acetate (Sigma-Aldrich Company Ltd, Fancy Road, Poole, Dorset, UK).
PROCEDURE
A protocol modified by Mr Neil Adams (Molecular Virology Unit, Med.
Microbiology, University ofEdinburgh) for the extraction ofRNA was used
successfully in the extraction ofRNA from plasma samples. Briefly, lOOpl of plasma
was mixed with pre-heated (37°C) 400pl of extraction buffer containing 350pl TNE,
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42 pi proteinase K (10%), and 8pi poly A RNA carrier. The mixture was incubated
for 10 minutes at 37°C, then phenol-chloroform extraction and precipitation of the
nucleic acid was carried out as described under 2.2.4 (Extraction ofDNA from
PBMC).




50mM Tris-Cl, pH 8.0 (Sigma-Aldrich Company Ltd, Poole, Dorset, UK).
5mM MgCl2 (Sigma-Aldrich Company Ltd, Poole, Dorset, UK).
5mM DTT
50mM KC1 (Rathburn Chemicals Ltd, Walkburn, Scotland)
0.05pg/pl BSA
600pl of each dNTP; 20% DMSO; 150 ng of outer antisense primer;
10 units RNAsin (Promega, Southampton, UK)
10 units AMV reverse transcriptase
Water-bath or thermocycler (set at 42°C).
PROCEDURE
Prior to the polymerase chain reaction, it is essential to reverse transcribe
the RNA extracted from patient's plasma or serum to a complementary DNA
(cDNA). To promote the reaction, a specific viral primer, an antisense primer used
during the primary PCR, is needed. The extracted RNA (5pi) was added to 15 pi of
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RT buffer and incubated in a water bath or a thermocycler set at 42°C for 30
minutes. The resulting cDNA product was allowed to reach room temperature for 20
minutes before use or stored at -20°C.
2.7. PRIMER DESIGN
The design of the primers was based on the consensus sequence of the most
conserved regions of the gag gene of 72 aligned sequences from various parts of the
world compiled in the Los Alamos database (Myers et al., 1995). The primers were
synthesised by OSWEL DNA service of the University of Southampton
(Boldrewood, Southampton, SO 16 7PX, UK). To ensure that primers can target only
HIV proviral DNA, a search of identical or similar sequences (to the primers)
contained in the Genbank was performed using the programme Blast (Miyoshi et al.,
1981). Care was taken to (i) avoid primers being complementary with each other and
(ii) minimise the mismatch of the primer and template by not having a T at the
terminal base at the 3' end. The annealing temperature was determined using the
equation,
T=4(G+C)+2(A+T)
where A,T, G and C are the number of those bases in the oligonucleotide. The




IDSequence SetO: a:531GCGAGAGCGTCAGTATTAAGCGG b:532GGGATTCTTA GCC c:533CTTCTACTACTTTTACCCATGC d:534TCTGAAACGGG
Position gag 795-817 835-857 1248-1269 1296-1318
IDSequence Set3:
i:S3P1CARATRAGRGARARCCAAGGGGAAG j:S3P2GAYATGCGCT k:S3P3CCTTCYYTGCCACARTTGAARCA 1:S3P4GAYCAGGRGCCYTCA
Position
gag 1467-1489 1491-1512 1962-1984 2000-2016
Set1:gag a:S1P1ATGGGTGC AGAGCGTC789-808 b:S1P2CATNTAGTRTGGGCAAGCAG885-904 c:S1P3CYTCTAYYACYTTYACCCATGC1248-1269 d:S1P4TCTGRTATGCWRAAC1298-1318 Set2:gag e:S2P1GACCCRGAGCYT1074-1093 f:S2P2AGYAAATTAYCCYATAGTRCA1173-1195 g:S2P3ATCYCTTT TA1596-1619 h:S2P4GGYCCTTGTYTTATRTCCARAATGC1630-1654
Set4: m.S4P1TCCAAYGCRAGT n.S4P2TAGAGATGCGTYC o.S4P3GCCARTKYTCCTAAAAAATTAGC p.S4P4TGGCCTYCCCTTGYKGGAAGG Set5: El E2 E3 E4TACATGGTT TGGCA TCTAG ATTCGCATGGGAGT GGAGGGGCATCTT
gag 1757-1781 1817-1841 2080-2104 2104-2123 env 6957-6976 7009-7028 7465-7482 7520-7537
Outerprimers:s t0:a,d;12eh t3:1,1;4 ,;s5:E1,E4 Innerprime s:s t0:b,c;1 t2fg3jks4 ,o;5E2,3. Codef rambiguities:R:AG;YrTKW:ot.
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2.8. NESTED POLYMERASE CHAIN REACTION (PCR)
MATERIALS:
- Reaction mixture (primary PCR: 45pl, secondary PCR: 20pl)
50mM KC1, (Promega, Southampton, UK)
lOmMTris-HCl (pH 8.0) (Promega, Southampton, UK)
0.1% Triton X-100 (Promega, Southampton, UK)
3.3pM of each dNTP (Boehringer Mannheim UK Ltd, BN7 1LG, UK)
0.5pM of each of the primers (outer primers, Primary PCR, inner primers:
secondary PCR) synthesised by OSWEL DNA service of the University of
Southampton (Boldrewood, Southampton, SO 16 7PX, UK)
20 units/ml of Taq polymerase (Promega, Southampton, UK)
- DNA or cDNA (lpg)
PROCEDURE
Approximately 1 pg DNA per reaction was subjected to nested PCR
amplification as previously described (Simmonds et al., 1990). The amplification of the
selected section of the gag or the env (V3-V4) gene was performed in two steps: the
primary PCR and the secondary PCR. During the primary PCR, two outer primers, (e.g.
set 0: a, sense and d, antisense; table 2.1) are needed to screen the desired region of the
genomic DNA in which the proviral DNA has been inserted. The secondary PCR
requires primers of the same set (table 2.1) (e.g. set 0: b, sense and c, antisense) specific
to the inner section of the region amplified during the primary PCR. The PCR
amplification cycles consist of denaturation of double stranded DNA, annealing of
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primers, synthesis of cDNA; the reactions were carried out at 95°C for 0.6 min., 45°C
for 1.5 min and 68°C for 3 min respectively. The reaction mixture for the first round
PCR (50pl) contained 50mM KC1, lOmMTris-HCl (pH 8.0), 1.5mM MgCh, 0.1%
Triton X-100; and 3.3pM of each dNTP; 0.5pM of each of the outer primers; 20
units/ml of Taq polymerase and approximately 1 pg ofDNA or cDNA. One drop of
liquid paraffin was added before subjecting the tubes to 30 cycles of amplification
reactions. At the end of 30 cycles, as high as 10,000 fold amplification of the template
can be achieved (Simmonds et al., 1990). One pi of primary PCR was subjected to
another amplification, the secondary PCR. This second amplification step was
performed with 2 inner primers (e.g. primers b and c in table 2.1) and with the same
ingredients and cycling conditions as for the primary PCR but in 20pl volume, for 40
cycles. The set 0 and set 1 of primers (Table 2.1) were used to screen the presence of
HIV proviral DNA in the sample. If the amplification failed using these primers,
alternative primers (Table 2.1: sets 2, 3 and 4; figure 2.2) specific to the gag gene were
used. PCR was also performed to amplify the region encompassing the hypervariable
domain of the envelope gene (env) using the set 5 primers (Table 2.1). Prior to PCR
amplification of the V3-V4 region, the template was serially diluted in order to perform
the sequencing on approximately one single copy of the virus.
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cd s1p34 1248-129 - 126831
gh s2p34 1596-630 161954
k1 s3p34 1301-20 13222018





- 13pl PCR buffer: 50mM KC1, lOmM Tris-HCl (pH8.0), 1.5mM MgCl2 0.1% Triton
X-100 and 3.3pM of each dNTP (Boehringer Mannheim Ltd, BN7 1LG, UK)
- 0.05pM of each of the outer primers, one of which is biotinylated (Figure 2.2)
- 2 units/ml of Taq polymerase (Promega, Southampton, UK)
- 1 pg of primary PCR product
- Diethylpyrocarbonate (DEPC) treated-water
PROCEDURE
The biotinylated PCR was a modification of the PCR described under 2.2.8.
The secondary PCR was carried out in lOOpl (instead of 20pl) ofPCR mix
containing 13pl of PCR buffer, O.OSpM of each of the outer primers, 2 units/ml of
Taq polymerase (Promega, Southampton, UK) and approximately 1 pg of the
primary PCR product. Only one biotinylated primer at a time was needed in each
biotinylated PCR. If the desired sequencing product is a sense fragment, the antisense
primer used during the secondary PCR was biotinylated. The total reaction mix
(lOOpl) was subjected to an amplification reaction for 40 cycles.
2.10. VISUALISATION OF AMPLIFIED PCR PRODUCT
REAGENTS
- 2% (w/v) Agarose (SIGMA, Poole, Dorset, UK).
- TBE: 0.089M Tris-borate and 0.089M boric acid, 0.01M EDTA;
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pH 8.2-8.9) (SIGMA, Poole, Dorset, UK).
- Ethidium bromide (lOmg/ml) (SIGMA, Poole, Dorset, UK).
PROCEDURE
A 2% agarose solution was prepared by dissolving 6g of agarose in 300ml of
lx TBE (0.089M Tris-borate and 0.089M boric acid, 0.01M EDTA; pH 8.2-8.9).
The gel solution was heated at 100°C for 5 minutes, then cooled down to about 42-
46°C. 25pi of ethidium bromide (lOmg/ml) was added and mixed (final
concentration of 0.8pg/ml). The mixture was poured onto a pre-levelled 20 x 20 cm
electrophoresis gel plate with mounted combs and left to polymerise at room
temperature. Once the gel was set, the PCR product was put in holes occupied by the
comb during the polymerisation. The electrophoresis was carried out at 150 volts
(90.5mA) for 5 minutes without immersing the gel in TBE. The gel was then flooded
with TBE and electrophoresis carried out for a further 10 minutes. The
electrophoresis system included a gel tank and a power supply (TriPak 400/200,
Bioscience services, UK or BioRad model 200/2.0). A transluminator was used to
view the amplified PCR product and a Polaroid camera (MP-4 land camera) was used
to photograph the gel.
2.11. SOLID PHASE EXTRACTION OF SINGLE STRANDED
DNA FROM PCR PRODUCT
MATERIALS
o
- Dynabeads (6.7 x 10 beads/ml; Dynal) coated with streptavidin
- Bovine serum albumin [BSA, 0.1% (w/v) in phosphate buffered saline, pH 7.2]
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- Buffered water (BW) (10 mM Tris-HCl, pH 7.5; ImM EDTA and 2M, NaCl)
- Sodium hydroxide (NaOH, 0.15M)
- Tris-EDTA solution (TE: 10 mM Tris-HCl, pH 7.5 and ImM EDTA)
- Biotinylated PCR product (double stranded DNA)
PROCEDURE
The PCR product of the biotinylated PCR containing double-stranded DNA
was subjected to treatment to remove the non-biotinylated single stranded DNA
using a modified Dynal DNA separation protocol (Dynabead, M280, Dynal). A
suspension of beads (20pl at 6.8 x 108 beads/ml) was washed with 40pl bovine
serum albumin (BSA, 0.1% in phosphate buffered saline, pH 7.2) and 40pl buffered
water (BW) (10 mM Tris-HCl, pH 7.5; ImM EDTA and 2 M NaCl) using a magnetic
stand. Beads were then resuspended in 40pl BW at a concentration of approximately
5pg beads per pi BW. Forty pi of the biotinylated PCR product containing double-
stranded DNA was mixed with washed beads and incubated at room temperature for
15-20 minutes with occasional resuspension. The supernate was removed, and the
double stranded DNA (now immobilised on beads by biotin-streptavidin affinity) was
washed with 40pl BW. The DNA was then denatured with 40pl sodium hydroxide
(NaOH, 0.15M) and the non-biotinylated single-stranded DNA discarded. The
biotinylated single stranded DNA was washed with 50pl BW, then with 50 pi TE (10
mM Tris-HCl, pH 7.5 and ImM EDTA). The washed biotinylated single stranded
DNA was resuspended in 30 pi of TE and stored at 4°C until sequenced.
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2.72. DIRECT SEQUENCING OF PCR PRODUCT
MATERIALS
- Biotinylated single stranded DNA immobilised on beads
- Annealing mix (10% DMSO, 200mM Tris-HCl pH 7.5; lOOmM MgC^; 250mM
NaCl; lOng primer) (United States Biomedical, USA)








- Termination mix: (United States Biomedical, USA)
- 80pM dNTP (dGTP, dATP, dCTP, dTTP)
- 50mM NaCl





0.1% Xylene Cyanol FF
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PROCEDURE
Biotinylated PCR product was sequenced directly from single strand DNA
immobilised on streptavidin-coated beads using the dideoxy-chain termination
method according to the Sequenase protocol (Sequenase, United States Biochemical).
After the annealing of a primer to the template, the DNA polymerase synthesises the
complementary strand ofDNA using deoxyribonucleotide triphosphates (dGTP,
dATP, dCTP and dTTP) the same way as during an ordinary PCR reaction. The
elongation reactions take place in 4 wells of a microtitre plate. In addition, modified
dNTPs, called dideoxynucleotide (ddNTP) are also incorporated in each reaction
well, one at time. Dideoxynucleotides have a hydrogen (H+) instead of the hydroxyl
group (OH-) at the 3' position on their sugar component. This causes the elongation
of the DNA molecule to stop (termination) after ddNTPs have been incorporated by
the DNA polymerase. In practice, 5pl ofDNA was mixed with the annealing mix
and incubated for 2 minutes at 67°C. The mixture was left to cool down slowly to
reach the room temperature. A labelling and extension mix was added to the tube
containing the annealed template. For each sample, the labelling extension mix
contained 1 pi dithiothreitol (DTT, 0.1 M), 2 pi of labelling nucleotide mix (1:20),
0.5 pi of [a- S] or [a- PJdATP (5pCi) and 2 pi diluted sequenase polymerase (1:8,
approximately 3.25 units). For each sample, 2.5 pi of dideoxy termination mixture
was put in each of four V bottomed wells labelled 'G', 'A', 'T' and 'C' of a
microtitre plate. Each termination mix contained 80pM dNTP (dGTP, dATP, dCTP,
dTTP) 50mM NaCl and 8pM of one of the 4 ddNTP (ddGTP or ddATP or ddTTP or
ddCTP). After a 5 minute incubation at 37°C, the extension and termination
71
reactions were stopped by adding the stop solution (95% Formamide, 0.02 M EDTA,
0.1% Bromophenol Blue and 0.1% Xylene Cyanol FF).
2.13. POLYACRYLAMIDE GEL ELECTROPHORESIS
MATERIALS
Gel
- 20ml acrylamide/bisacrylamide solution (30%; 1.034%, respectively), Easygel,
Scotlab, UK.
- 50g urea (BDH laboratory supplies, Poole, UK)
- 32ml distilled water
- 0.1 g ammonium persulphate (Sigma, Poole, Dorset, UK)
- 10ml lOx TBE (Sigma, Poole, Dorset, UK)
- TEMED (N, N, N'N'-Tetramethylethylenediamine, Sigma, Poole UK)
Fixative
-7% acetic acid (Rathburn Chemical Ltd, Scotland)
-7% methanol (Rathburn Chemical Ltd, Scotland)
-Tap water
PROCEDURE
The product of the sequencing reaction is a mixture of different sizes of single
stranded DNA. During the sequencing reaction, the synthesis of the complementary
DNA is made possible by incorporation of dNTPs. This reaction was terminated
every time ddNTPs are incorporated during sequenase activity. Because DNA is
negatively charged, it was possible to separate different fragments ofDNA by
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running the sequencing reaction product electrophoretically through a 5.3%
polyacrylamide gel (containing 0.18% bisacrylamide). Throughout this study,
wedged gels (thickness: 0.4mm at the top and 1,2mm at the base of the gel) were
used. For 112ml of 5.3% gel, 50g urea, 20 ml of acrylamide/bisacrylamide solution
[(30% and 1.034% w/v, respectively), Easygel, Scotlab, UK], 0.1 g ammonium
persulphate and 10ml lOx TBE (pH 8.8) and 32ml distilled water were mixed under
hot tap water. The mix was allowed to cool to room temperature, then 25pi of
TEMED was added to the gel mix before pouring the gel between two cleaned glass
plates separated by two wedged spacers and levelled horizontally. The even
distribution of the gel between the glass plates was achieved by capillary motion.
The gel was allowed to set for between 20 minutes and up to 24 hours. Prior to
loading, the sequencing products were heated at 95°C for 2 minutes to denature any
double stranded DNA in the sequencing product, then loaded between spaces left by
inserting a comb on top of the gel. The electrophoresis was set to run at 75 watts in a
tank containing TBE, until bromophenol dye reached the bottom of the gel. The gel
was fixed in tap water containing 7% acetic acid and 7% methanol for 10-15 minutes.
The gel was then dried in a gel dryer (Bio-Rad, model 583) for 3 hours at 80°C, and
then exposed to X ray film (Kodak) in a dark chamber for about 24 hours.
2.14. AUTORADIOGRAPHY
The films were developed using an automatic X-ray processor. Figure 2.3.
shows an autoradiograph exposed overnight. From each patient, there were 4
sequencing reactions. The bands at the bottom of the figure represent shorter DNA
fragments, with less nucleotide incorporated than those at the top of the gel. The
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ddNTPs were incorporated after only a few dNTPs were joined together to form the
complementary DNA. To read an autoradiograph, it is necessary to record the
position of each band from the fastest moving to the heavy and slow migrating DNA
molecules in four lanes, size in the four columns labelled. Each band in the column
represents fragments of a DNA (same size) terminated by the incorporation of a
dideoxynucleotide (ddNTP). There is one band for each level of the four columns.
The sequences are read from the bottom (shorter DNA framents) to the top (longer
DNA fragments) and noting for each level one band at a time.
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FIGURE 2.3: Autoradiograph showing nucleotide sequences
The sequencing was carried out on single stranded biotinylated PCR products. The
proviral DNAs were primarily amplified using the S3P1 and S3P4 during the primary
reaction and S3P2 and S3P3 in secondary reaction (Figure 2.2 and Table 2.1). The
numbers on top represents the patients from whom the samples were obtained (1:
Sq61M; 2: Sq62M-l; 3: Sq62M-2; 4: Pedl2; 5: Sql3M; 6: Sq63M). For each
sample, there are four columns labelled G, A, T and C (2'-deoxyguanosine, 2'-
deoxyadenosine, 2'deoxythymidine and 2'-deoxycytidine). Each band in the column
represents a fragment of a DNA terminated by the incorporation of a
dideoxynucleotide (ddNTP). There is one band for each level of the four columns.
The sequences are read from the bottom (shorter DNA framents) to the top (longer






















































Sequences from this study were entered in a computer using Word Perfect
computer software (Wordperfect Corporation, Orem, Utah, USA). The on-screen
view applications were modified such that each letter representing a different
nucleotide was shown in different colours (G: yellow, A: green, T: white and C: red).
This allowed easy manual alignment during the reading of the nucleotide sequences.
The alignment was carried out relative to sequences available in the Los Alamos
database (Myers et al., 1995). The Genetic Data Environment (GDE) package was
also used to check the alignment (Smith et al., 1994). Preliminary analyses were
performed using Molecular Evolutionary Genetics (MEGA) software (Kumar et al.,
1993) using the Jukes-Cantor distance estimation method. Final phylogenetic
analysis was carried out using the programmes available in the Phylogenetic
Inference Package (PHYLIP) provided by Dr J. Felsenstein (Felsenstein, 1993).
Phylogenetic trees were constructed using the neighbour-joining (Saitou and Nei,
1987) (program NEIGHBOR) and Fitch-Margoliash (Program Fitch) (Fitch and
Margoliash, 1967) distance method, with nucleotide sequence distances calculated
for all pairwise sequence comparisons using the generalised two-parameter
(maximum likelihood) model (program DNADIST) or the Kimura two-parameter
method using the MEGA software (Kumar et al., 1993). The Kimura method
estimates the distance between two sequences as if one has evolved from another. To
calculate the divergence of two sequences (pairwise distance), the Kimura model
takes into account two forms of substitution of nucleotides which can happen by
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transition (purine replaced by purine or pyrimidine replaced by pyrimidine) or by
transversion (purine replaced by pyrimidine, and vis versa). Assuming that one
sequence has evolved from another, the estimated number of nucleotide substitution
(K) was calculated by the expression:
K = -l/2 ln[(l-2P-0 V(l-20]
where P is the number of sites at which the sequences differ by transition and Q the
fraction ofwhich they differ by transversion. The comparison was performed for
each pair of sequences (interhost nucleotide distance) contained in the dataset and
was generated as a matrix table (see appendix 5). The analysis of the distance matrix
between and within subtypes was performed using the Systat computer programme
(Systat for Windows, version 5.03, Evanston Illinois, USA). Bootstrap resampling
(Felsenstein, 1985) (programs SEQBOOT and CONSENSE) was employed to assign
support to the neighbour-joining tree. One hundred to 2,000 bootstrap replications
were performed. The presentation of the phylogenetic trees was carried out using the
Treeview computer programme kindly provided by Dr Roderic D.M. Page of the the
Institute of Biomedical and Life Sciences (Glasgow, UK).
SEROLOGICAL METHODS
2.16. MUREX IgM-IgG ANTI-HIV-1+2 ELISA
(Base Pack GEO 1/02/03 and Detection Pack GE11/12/13)
The Murex assay used microwells coated with a mixture of rabbit anti-
human-IgG and -IgM. Serum or plasma samples were incubated in the wells and a
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proportion of human IgG and IgM is captured. Unbound antibody was removed by
thorough washing. A conjugate made ofHIV-1 recombinant antigens was added
which bound to anti-HIV-l/HIV-2 IgM and IgG captured on the well. Unbound
conjugate was washed away and a substrate containing 3, 3', 5, 5'-tetra
methylbenzidine (TMB) and hydrogen peroxide was added. Wells with bound
conjugate developed a purple colour, which turned into an orange colour when the
reaction was stopped with sulphuric acid. The amount of the colour was determined
spectophotometrically and was proportional to the amount of IgG and IgM present in
the sample. Reactive samples were tested again with the same Murex test and
confirmed with a second generation Abbott ELISA for antibody (IgG) to HIV-1 and
HIV-2. All assays were performed according to manufacturers' instructions.
2.17. DETECTION OF ANTI-V3 LOOP ANTIBODIES
2.17.1. MONOMERIC PEPTIDES
The monomeric peptides, representing the principal neutralising domain of 5
HIV-1 subtypes (A, B, C, D, E), were kindly provided by Dr H.C. Holmes of the
National Institute for Biological Standards and Control and by Dr R. Cheingsong-
Popov of St Mary's Hospital, London. These peptides have previously been used for
serotyping HIV-1 in relation to HIV-1 genotype (Cheingsong-Popov et al., 1994).
The amino acid sequences are shown in table 2.2.
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2.17.2. BRANCHED PEPTIDES
The synthesis of the branched peptides was carried out under the supervision
ofMs Karen MacEachran and Dr Howard Marsden at the Institute ofVirology,
University of Glasgow, UK. The branched peptides correspond to consensus
sequences of deduced amino acid sequences encompassing the V3 loop region of
subtype A-F sequences available in the Los Alamos database (Myers et al., 1995). In
addition, another peptide called Zr was derived from the amino acid sequence of the
V3 loop of a highly divergent strain identified in the present study. The branched
peptides (A-F, and Zr) were synthesised by continuous-flow Fmoc (9-
fluorenylmethoxycarbonyl) chemistry. Each peptide was synthesised in a four-
branched molecular structure with four glycine spacers between each V3 branch
(monomeric peptide) and the lysine linker complex attached to the solid phase resin
core (4BTGA) (Table 2.2). Peptides constructed in this way (branched structure with
4 glycine spacers) have an advantage over monomeric peptides, in that smaller
amounts of peptides are necessary to detect traces of antibodies in serum or plasma
(Marsden et al., 1992).
The synthesiser used was a PSSM-8 model, which was designed to be able to
perform simultaneously multiple solid-phase peptide synthesis. The amino acids
were prepared and put at the right sequence order for the PSSM-8 to use in peptide
synthesis. The synthesising scale was graduated in micromole (5-50 pmol for each
of the eight reaction vessels) and synthesis performed using information entered in a
computer software. The necessary amino acids needed were weighed and dissolved
in dimethylformamide (DMF, cat. number: PST6020; Rathburn Chemical Ltd,
Scotland).
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TABLE 2.2. Monomeric and branchedpeptides













Amino acid sequences ofV3 loop monomeric and branched peptides. Peptides A-F
peptides correspond to consensus sequences of deduced amino acid sequences of
subtype A-F sequences available in the Los Alamos database (Myers et al., 1995).
Each branched peptide was synthesised by continuous flow Fmoc chemistry based on
the corresponding monomeric peptide representing the same subtype.
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To synthesise simultaneously 5 branched peptides (A-F), 54.8 ml of
piperidine were dissolved in 127.8 ml DMF then the solution was added to
appropriate tube in which the synthesis reaction took place. Amino acids were put in
tubes and aligned in the order in which they are incorporated into the peptide. This
process was carried out for 16 hours.
The cleavage of the resin residue from the peptide was carried out as follows.
Each peptide-resin complex was washed with 2-3 ml ofDMF. The peptide-resin
complex was dried up by removing the DMF using nitrogen gas to flush it through
the syringe containing the complex. The same procedure was repeated with tert-amyl
alcohol (2-methyl-2 butanol, cat number: PST6005; Rathburn Chemical Ltd). A
series of washes was carried out, using acetic acid, tert-amyl alcohol and di-ethyl
ether. A mixture of reagents (81.5% Trifluoroacetic acid; 5% Thioanisol; 5%
Phenol; 2.5% EDTA and 1% Triisopropylsilane and water) designated reagent K was
prepared for the cleavage reaction of the complex. The reagent K (2 ml) was added
to the washed resin-branched peptide complex and the mixture was left to cleave for
6 hours. The peptide solution was collected in a 15 ml falcon tube ready for
precipitation of the peptide. The precipitation of the branched peptide was carried
out by adding diethyl ether to the solution, mixing and centrifuging for 5 minutes at
2,500 revolutions per minute (rpm). At the end of the centrifugation, the supernate
was poured off (without disturbing the pellet, peptide). The process was repeated
twice.
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Each peptide was dissolved in 40 ml of distilled water and transferred to a
200 ml round bottom flask. Prior to dry-freezing, the flask containing the peptide
solution was shell frozen by rotating it on a bowl of dry ice and ethanol. The flask
was then attached to a freeze-dryer and left overnight.
Dried peptide was collected from the flask and weighed. A small amount of
peptide (0.5 mg diluted in water, lmg/ml) was analysed for purity by high-
performance liquid chromatography (HPLC). The evaluation of the purity of peptide
by HPLC is based on the separation principle in that peptide and impurities in the
synthesis product will separate as a result of their interaction with the insoluble
support, or stationary phase. In addition, there was a cylindrical column that
contained the derivatised support upon which separation occurred and a mobile phase
(liquid) by which the separation is developed. The binding of the component in
solution (peptides and debris) to the solid phase occurred through hydrophobic
interactions with the column support of a two-system reverse-phase HPLC. The
column was equilibrated in 0.05% trifluoroacetic acid (TFA) for sample loading and
elution was produced by an increasing gradient of acetonitrile as a water miscible
organic modifier.
2.17.3. OPTIMISATION OF ELISA CONDITIONS
To optimise the conditions of the ELISA, plasma samples from 23 HIV-1
infected individuals and 16 HIV-1 negative controls were tested under different
conditions:










Buffer: with or without Tween20.
2.17.4. INDIRECT BRANCHED PEPTIDE-BASED ELISA
MATERIALS
- Branched peptides (A-F and Zr)
- Flat bottomed plates: Nunc-F, cat. No. 67466.
- Carbonate coating buffer: 20mM sodium carbonate, pH 9.8
- Phosphate buffer saline (PBS), pH 7.4: NaCl 8g/l, KC1 0.2g/l, Na2HP04 anhydrous
1.15g/l KH2PO4 0.2g/l. Alternatively, commercially available tablets were used
(Dulbecco PBS, cat. 2810305, Sigma, UK)
- Blocking buffer or sample diluent (PBS, pH 7.4 containing 0.01% chloracetamide,
5% dried skimmed milk and 10% heat inactivated new born calf serum)
- Dried skimmed milk (Tesco, UK)
- Heat inactivated newborn calf serum (Life Technologies, cat 023-0610)
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- Tween 20 (Polyethylene sorbitan monolaurate)
- Conjugate: Anti-human IgG F(ab)2 (Sigma A2290) conjugated with peroxidase.
- 0.1M citrate phosphate buffer, pH 5.
Citric acid 6.7g/l
Disodium monohydrogen phosphate, 9.46g/l
- 30% Hydrogen peroxide
- 1-2-phenylenediamine dichloride (OPD, Dakopatts, Denmark, cat. no. S2000).
- goat antihuman IgG peroxidase conjugate (cat. A2290, Sigma, UK)
- Stop solution: 1M H2SO4
PROCEDURE
Each peptide was diluted in carbonate coating buffer (lpg/ml) and lOOpl of
the mix was added to each well (lng/well) of an ELISA plate (Nunc-F
immunomodule, cat. No. 67466). The plates were allowed to coat for 24 hours at
room temperature, and were then washed with PBS and blocked with the blocking
solution for 2 hours at room temperature. The plates were washed again and were
ready for use. If plates had to be stored, 200pl of PBS containing 0.01% sodium
azide was added to each well and plates were kept at 4°C until use. Plates prepared
this was could be stored for up to 3 months.
Each sample was tested against a panel ofV3 loop branched peptides (A-F)
coated in each of 6 wells of the same plate (Nunc-F, cat. No. 67466) and a cocktail-
well containing all 6 peptides. Plasma (0.5pi), diluted 1:200 in sample diluent
(phosphate-buffered saline, PBS) pH 7.4 containing 5% dried skimmed milk, and
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10% heat-inactivated new born calf serum), was added to each well and incubated at
37°C for 60 min. The plates were then washed with phosphate buffer saline (PBS).
Anti-human IgG F(ab)2 (Sigma A2290), conjugated with peroxidase was diluted
1:10,000 in sample diluent. This conjugate (lOOpl) was added to each well and
incubated at 37°C for 1 hour. After washing, the colour was developed for 20
minutes using ortho-phenylenediamine dihydrochloride substrate (OPD, Dakopatts,
Denmark, cat. no. S2000). The reaction was stopped by the addition of lOOpl
sulphuric acid (1M), and the optical density (OD) measured spectrophotometrically at
492nm. Twelve HIV-1 negative samples were included in each plate. The cut-off
(CO) value was determined as (mean of negative samples + 3 SD) x 2. The average
cut-off lay between 0.15 to 0.3 OD units. The ratio of specific antibody bound to the
peptide to the cut-off value was determined (OD/CO). The highest ratio of antibody
binding to a particular peptide among the panel ofA-F was determined, and the
serotype was ascribed to that peptide.
2.17.5. V3 LOOP COMPETITIVE ELISA
The ELISA consisted of two phases (Table 2.3). The solid phase consisted of
a panel of 6 peptides (A-F) and two peptide cocktails of all A-F peptides immobilised
in wells of an ELISA plate (Nunc-F, cat. No. 67466) at a concentration of lpg/ml in
carbonate buffer. The liquid or competitive phase, contained a cocktail of branched
peptides (lOpg/ml) excluding the peptide found on the solid phase. The sample
(0.5pi) was mixed with peptides in the competitive phase, then incubated with the
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peptide on the solid phase for 1 hour (at 37°C). Any cross-reactive antibodies in the
samples are blocked by the high concentration of peptides in the liquid phase.
Each sample was controlled by two cocktail-control wells, the negative and
the positive control wells. The negative control well was coated with a cocktail of all
peptides (A-F) (1 pg/ml carbonate buffer) and the sample tested in this well was pre-
incubated with a cocktail of peptides at lOpg/ml (lOx the concentration of peptides
on the solid phase). In the positive control well, the sample was tested without the
inhibition of the cross-reactive antibodies to V3 peptides. In addition, there were 4
negative controls which were tested in the same way as the patient samples and were
used to determine the cut-off (mean OD of 32 negative wells plus 2 standard
deviations).
The sample with highest OD/CO after inhibition of cross-reactive antibodies
was recorded and the serotype assigned to the subtype corresponding to the peptide
on the solid phase. The highest OD/CO had to be greater than the reading of the well
with complete inhibition of antibodies (Table2.3, reading in well 8). If the reading in
well 8 was over 1 (positive), the values of the individual A-F wells had to be
subtracted prior to assignment of the subtype.
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TABLE 2.3: Template showing the panel ofpeptidesfound on the solidphase (SP) and the
liquidphase (LP) of the competitive ELISA.
MICROTITRE WELLS
1 2 3 4 5 6 7 8
Peptide on SP A B c D E F A-F A-F
Peptide on LP B-F A, C-F A-B, D-F A-C, E-F A-D,F A-E ~ A-F
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2.17.6. MONOMERIC PEPTIDE-BASED ELISA
Antibody binding to a panel ofV3 loop monomeric peptides representing the
consensus sequences of subtypes A-E was tested as previously described
(Cheingsong-Popov et al., 1994). Briefly, flat bottomed microtitre plates (Nunc-F,
cat. No. 67466) were coated with monomeric peptides at a concentration of 10pg/ml
in 20mM carbonate buffer, pH 9.6, and stored at room temperature (RT) for 48
hours. The plates were washed, blocked with blocking buffer [phosphate-buffered
saline (PBS) pH 7.4 containing 5% dried skimmed milk, and 10% heat-inactivated
new born calf serum] for 2 hours at RT then washed twice. As for branched
peptides, if plates were to be stored, 200pl of PBS containing 0.01% sodium aside
was put in each well and kept at 4-8°C until use. The ELISA procedure was the same
as previously described (Cheingsong-Popov et al., 1994) except that the conjugate
was diluted 1:10,000 instead of 1:100.
2.18. ANTI-HIV-1/HIV-2 IgG, IgM AND IgA CAPTURE ELISAs
The immunoglobulin G class-specific capture ELISA (GACELISA)
previously described by Connell et al (1993) was designed for detection of low levels
of antibody (less than 0.1 pg/ml) in samples such as saliva and urine. The test was
adapted for the detection of anti-HIV-1 and HIV-2 IgA and IgM for early diagnosis
ofHIV-1 infection in children (Mokili et al., 1996). The principle ofGACELISA is
illustrated in figure 2.4. Briefly, each well in U-bottomed plates (Nunc
Immunomodule Maxisorb, cat.no. 4-77631) was coated with 100 pi of high affinity
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anti-human IgG (DAKO, cat. no. A424) at a concentration of 5.3 mg/L of freshly
prepared carbonate/bicarbonate buffer (1.6g Na2CC>3, 2.94g NaHC03 in 1 litre of
distilled water, pH 9.6). The plates were then left for antibody to adsorb at room
temperature overnight in a moist chamber. Two hundred pi of 5% Sol-u-pro
(Dynagel Inc, Illinois) was added and left at room temperature for 2 hours. The
plates were washed and dried at 37°C overnight. Plates prepared in this way could be
stored, sealed in plastic bags for up to 3 months. Quality control of every new batch
of plates was performed against previously prepared plates.
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FIGURE2.4.Schematicr presentationoftprincipleclass-specificantib dyELISA Y
a)Solidphaseco tedwi hnti-humanIgG capturinghumanIgGinplasmaorseru
b)Detectionofanti-HlVantibodiesyproteins conjugatedtalkalinephosph tase(AP)
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c)Detectionofcapturedonjugatebyamplifyingsubs rate(NADP) dephosphorylatingtNAD.Thereactionsultsincolourvel pm nt.
Colour development
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The test consists of capturing IgG in the patient's plasma or serum with anti-
human antibodies coated on the solid phase. Captured HIV antibodies are detected
by adding recombinant core and envelope proteins conjugated to alkaline
phosphatase. After removal of unbound materials by washing, the conjugate bound
to the solid phase is detected by an amplifying substrate, nicotinamide adenine
dinucleotide phosphate (NADP), which is dephosphorylated to nicotinamide adenine
dinucleotide (NAD).
The immunoglobulin M class-specific capture ELISA (MACELISA) and the
immunoglobulin A class-specific capture ELISA (AACELISA) were designed in the
same format except that, for the detection of IgM and IgA, the solid phase was coated
with anti-human IgM and anti-human IgA, respectively.
Five pi of sample was diluted in 95pl of sample diluent and put in a
microtitre plate well containing anti-human antibodies bound on the solid phase.
Three negative and two positive controls (serum containing HIV-1 and HIV-2
antibodies) were also added to the wells at a volume of 50 pi. Samples and controls
were incubated for 1 hour at 37°C (Fig. 2.3.a). After plates were washed three times
and dry blotted, a 50pl conjugate was added into each well and incubated at 37°C.
The conjugate contained immunodominant gp41 and p24 antigen molecules linked to
alkaline phosphatase (Figure 2.4.b.). A substrate was added (50pl) to each well and
incubated for 20 minutes at 37°C. The reaction enzyme-substrate was enhanced by
adding lOOpl of amplifier reagent in each well and left in a dark chamber at room
temperature (Figure 2.4.c). The colour develops in wells corresponding to samples
of patients infected with HIV. The intensity of the colour in each well was measured
by spectrophotometry at a wavelength of 492nm.
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CHAPTER 3
DETERMINANTS OF VERTICAL TRANSMISSION OF HIV-1 IN
KIMPESE, RURAL DEMOCRATIC REPUBLIC OF CONGO,
FORMERLY ZAIRE
3.1. INTRODUCTION
By the end of 1995, more than 6 million women had been infected with HIV in
sub-Saharan Africa, out of a world total of nearly 9 million women (World Health
Organisation, 1996). This total is expected to increase to 14 million by the year
2000. Aproximately one third of the babies born to HIV-infected women are also
infected. The likelihood of transmission is higher in developing countries where
reported rates vary between 20 and 48%, compared with 13 to 25% for industrialised
countries (Dabis et al., 1993).
Vertical transmission is increased when there is a heavy maternal viral load, as
is found in advanced HIV disease and when the CD4 count (<700/mm ), or CD4-to-
CD8 ratio (<0.6) are low (Newell et al., 1992; European Collaborative Study, 1992;
Ryder et al., 1989; Stlouis et al., 1993; Peckham & Gibb, 1995). Breast-feeding is an
important potential mode of transmission (European Collaborative Study, 1992).
Placental inflammation and placental malaria may also increase the risk of
transmission (Zachar et al., 1994; Bloland et al., 1995). Some studies suggested that
high levels ofmaternal antibody to peptides in the V3 loop ofHIV RNA protect
against vertical infection (Rossi et al., 1989; Scarlatti et al., 1993a; Scarlatti et al.,
1993d), while others have not (Halsey et al., 1992; Parekh et al., 1991; Robertson et
al., 1992).
In the present study the rate ofmother-to-child transmission was estimated in a
population served by medical facilities in a small town in Bas-Congo (former Zaire),
where the maternal seroprevalence has remained stable at 4% between 1988 and
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1993 (Green et al., 1994). Evidence has been sought of a relationship between
vertical transmission and breast-feeding, stage of the mother's infection, placental
pathology, and maternal antibody response to V3 loop peptides.
3.2. RESULTS
3.2.1. MATERNAL FACTORS FOR MCT OF HIV-1
3.2.1.1. AGE AND PARITY
Two hundred and eighty seven mothers enrolled, ofwhom 208 were infected
with HIV. Seven infected women and one uninfected woman enrolled in two
pregnancies. The mean age of transmitting mothers did not differ significantly from
that of infected women who did not transmit (24.6 vs. 26.2 years, Kruskal-Wallace, p
= 0.06), neither did the mean number of previous pregnancies differ significantly (2.5
vs. 3.1, Kruskal-Wallace, p = 0.1).
3.2.1.2. MORBIDITY AND MORTALITY
Because of small numbers at different clinical stages, mothers were grouped
according to whether they were symptomatic or not. Similar proportions of
transmitting and of non-transmitting mothers had symptoms ofHIV infection (27%
vs. 29%, x2 = 0.02, P = 0.9). During the period of study, eleven of the 196 infected
mothers and one of the 80 uninfected mothers died (Fisher exact test, p = 0.09).
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3.2.1.3. PLACENTAL CHANGES
Moderate or large numbers ofmalaria parasites and moderate or large
amounts ofmalarial pigment were seen in higher proportions of placentae from HIV
positive women than from negative women, but chorioamnionitis and funisitis were
not significantly associated with maternal HIV infection (Table 3.1). There was no
significant association between vertical transmission and any of these histological
conditions.
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TABLE 3.1. Proportions ofplacentae showing malariaparasites andpigment,
chorioamnionitis andfunisitis
Mother n Parasites Pigment Chorioamionitis Funisitis
HIV positive 43 30%a 26%b 26% 17%
• Transmitting 14 36% 21% 29% 8%
• Non-transmitting 29 28% 28% 24% 21%
HIV negative 54 7% 6% 29% 15%
Comparison was made between 1) HIV positive and negative mothers and 2) mothers who
transmitted and those who did not. a: x2 ~ 8.6, P = 0.003 for HIV positive vs. HIV negative; b:
X2= 7.8, p = 0.005 for HIV positive vs. HIV negative.
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3.2.2. DETERMINANTS OF VERTICAL TRANSMISSION OF HIV-1 IN
CHILDREN
3.2.2.1. LENGTH OF GESTATION AND BIRTH WEIGHT
The mean length of gestation did not differ significantly in uninfected babies
according to the HIV status of their mothers, but was slightly less in infected babies
compared with all uninfected (39.3 vs. 39.7 weeks, P = 0.01). Babies born before 40
weeks were 2.3 times as likely to be infected (95% CL 1.2, 4.6). Birth weight did not
differ significantly with the status of either the mother or the baby (mean for infected
babies: 2,740g, uninfected: 2,860g, P = 0.5).
3.2.2.2. MORTALITY
In the 24 months from birth, there were 35 (16.5%) known deaths in the 211
children born to HIV positive mothers and 6 (7.4%) deaths in the 81 children of
negative mothers. Comparison of the two groups by Kaplan-Meier life table analysis
indicated a significantly increased mortality in the HIV-infected group in the first two
years of life (Lee-Desu statistic = 4.4, p=0.04). The causes of death are given in
Table 3.2.
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TABLE 3. 2. Causes ofchild deaths
HIV STATUS No. of Principal condition
MOTHER CHILD Deaths (age of death in months)
Infected Infected
n=34
12 AIDS (4, 11, 12, 22, 22)
















chronic lower respiratory infection (2)
malaria (8, 9, 12)
gastro-intestinal malformation (2)
anaemia (1)




6 prematurity (0, 0)




3.2.2.3. COGNITIVE AND MOTOR DEVELOPMENT
Eleven children born to HIV-1 positive mothers and who were vertically
infected (PP) were compared with 15 seroreverters (children who lost maternal
antibodies) (PN) matched for age, gender, educational level of the mother and
general economic status of the home environment as assessed from a home
evaluation. In addition, 15 children born to HIV-1 negative mothers (NN) who were
also HIV-1 negative as determined by Abbott recombinant HIV-1/2 ELISA, were
also included as a control group. The NN children were also matched with the PP
children as described for PN children. The cognitive and motor assessment was
performed by a trained nurse blind for children's HIV status. The methods for the
assessment of the children included the Quaker arm circumference (determined by
the upper arm circumference divided by the height of the child xlOO), the Early
Childhood Screening profile (ECSP), and the Kaufman Assessment Battery for
Children (K-ABC) (Boivin et al., 1995).
The results of the assessment of these children have been reported elsewhere
(Boivin et al., 1995). In assessing the global ECSP indicator of cognitive or
language development, there was no significant differences among the PP, PN and
NN children except for the motor development. Both PN and NN children scored
higher than PP children (Table 3.3). The poor motor development by the PP children
could be explained by their impaired general physical development as indicated by
the QUAC (Boivin et al., 1995)
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TABLE3.3:Cognitiveandmotordevelopmentfchildr nborntHIVinfectedh sontrol PP(n=l1)N=15)N MeanSDp Language963)10302378> .05 Cognitive79.19.382 844 61 0>0.05 Motor8314.204.62 715 99 4<0.05 Between-groupcomparisonsfthev rticallyinfect dhildren(PP,n=l1),serorevertersboHIV-1m h rN= 5)and controlhildrenborntsero egativem th rs(NN,n=15)standa disedeasurefr mlyilc ingp filB vin etal.t1995). 101
3.2.2.4. ESTIMATION OF VERTICAL TRANSMISSION RATES
By the criteria of the Working Group on Mother-to-Child Transmission
(Dabis et al., 1993), 34 of the 209 offspring of infected women were infected, 108
were uninfected, and the remaining 67 were of indeterminate status. The lower
estimate of vertical transmission rate given by the direct method, making the
assumption that the indeterminates were not infected, was 16.2% (95% confidence
limits: 11.7, 22.1). The intermediate estimate, ignoring indeterminates, was 23.9%
(17.3, 32), and the upper estimate, assuming that all indeterminates were infected,
was 48.3% (41.4, 55.3). The indirect method, using the children's antibody results
and the excess mortality of children born to infected women, was 25.1% (16.8, 33.4).
Nine infants lost IgG antibody as measured by GACELISA and/or Abbott
ELISA and then became positive again. As none had received a blood transfusion,
they were assumed to have been infected postnatally as a result of breast feeding. Of
these children who lost maternal antibodies, two became positive again by the age of
6 months, two more by 9 months, a further two by 12 months and the remaining one
by 18 months. The rate of pre- and intranatal transmission, ignoring the presumed
postnatal infections, is 13.6% (9.1, 19.6), 18.8% (12.7, 26.7) and 50% (42.5, 57.4)




The rate of vertical transmission was 23.9% using the intermediate direct
method recommended by the Working Group on Mother-to-Child Transmission
(Dabis et al., 1993) and 25% by the indirect method. These figures are in the lower
part of the range found in developing countries, but are higher than in most reports
from industrialised countries (Mcintosh et al., 1994; Nesheim et al., 1994; Rodriguez
et al., 1996; Dabis et al., 1993). Ignoring babies who appeared to be postnatally
infected, the calculated rate for pre- and intranatal transmission, which accounted for
roughly three quarters of infections, was similar to vertical transmission rates in
industrialised countries.
Postnatal transmission due to breast-feeding was not thought to be important
in 11 of the 13 studies reviewed by the Working Group and in a subsequent Indian
study (Kumar et al., 1995; Dabis et al., 1993). However, late seroconversion or the
recurrence of positive status after a period of seronegativity indicated that vertical
infection due to breast-feeding occurred in studies in France and Uganda, as well as
in the present study (Blanche et al., 1989; Datta et al., 1994).
A review of transmission ofHIV through breast-feeding concluded that the
risk was greatest when the mother became infected post-natally (Dunn et al., 1992),
presumably because she is likely to have a high level of virus in body fluids,
including breast milk, shortly after being infected. The World Health Organisation
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and the United Nations Childrens' Fund have recommended that HIV infected
women should not breast-feed if artificial feeding is practicable and safe (World
Health Organisation, 1992). Breast-feeding by infected women is still advocated in
developing countries where death from other infectious diseases and malnutrition is a
greater threat than death from HIV. For our mothers and babies breast-feeding was
the only option.
Lower rates of breast-feeding in industrialised countries are likely to be one
reason for lower reported rates of vertical transmission in the latter. Another
contributory factor is the greater prevalence of vitamin A deficiency in developing
countries which increases the likelihood ofHIV-1 DNA being present in breast milk
and doubles the rates of vertical transmission overall (Semba et al., 1994; Nduati et
al., 1995). In addition, selection bias may exaggerate rates reported from developing
countries (Ryder and Behets, 1994). Most studies in the latter have been done in
major hospitals where women with symptomatic HIV infection are more likely to be
confined than asymptomatic women; symptomatic women are liable to have high
viral loads (Wang et al., 1995) and therefore to be transmitters (Dickover et al.,
1996).
The indirect method of estimating the rate of vertical transmission is of
particular value if lack of diagnostic facilities make it difficult to classify children of
HIV infected mothers as either infected or not. This was evident in a study in Haiti
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(Halsey et al., 1990), where the intermediate direct estimate of the vertical
transmission rate was 13%, compared with a more probable indirect figure of 21%
(Dabis et al., 1993). However, indirect estimates, because they rely on the difference
in mortality between the babies of HIV-infected and uninfected mothers, will be
biased ifmortality of babies is increased by infected mothers being too ill to feed or
care for their babies adequately. The Study Group recommended that in the indirect
method the control group of babies born to uninfected mothers should be at least as
large as the group from infected mothers. This was not so in our study, so the
confidence limits are probably wider than they would have been otherwise.
A minor source of bias in the direct method is that infected children are
classified by IgG antibody level at age fifteen months, whereas the uninfected are
classified at nine months. Thus, if there are many children between these ages at the
end of a study, the uninfected will be classified but the infected will be indeterminate,
so giving a falsely low transmission rate.
A number of studies have shown that vertical transmission is related to viral
load in the mother's blood (Peckham and Gibb, 1995; Dickover et al., 1996).
Attempts to measure this association was carried out in this study. Unfortunately,
pressed by shortage of funds and time, it was not possible to standardise our in-house
limiting dilution method. In addition, the fact that samples were collected from a
region with a high genetic heterogeneity (see chapter 5), some samples from known
HIV-1 infected individuals failed to be amplified although a wide range of different
primers was used (see materials and methods, page 62; 65-66). This difficulty was
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also encountered by Alaeus et al., (1997) in testing plasma from individuals infected
with different subtypes ofHIV-1.
Though chorioamnionitis appears to be associated with maternal HIV infection
and preterm birth by infected women and may predispose to vertical transmission
(Nelson et al., 1992; Gichangi et al., 1993; Nair et al., 1993), there was no indication
of this in the present study.
When maternal plasma was examined for neutralising antibodies directed
against V3 loop consensus peptides representing five HIV-1 subtypes, the samples
reacted with at least one peptide in most infected women (details in chapter 6). It is
possible that cross-reactivity of the antibodies inflated the number ofwomen
appearing to have antibodies to different V3 loop peptides, but it has been shown in
this thesis that a number of subtypes are present in this African population (Chapter
5). There was no evidence that any of the five antibodies protected against
transmission. Previous studies of the effect of anti-V3 loop antibodies on vertical
transmission have given conflicting results, but another report indicates that
antibodies of maternal origin may protect against transmission when present on the
infant's peripheral blood mononuclear cells (Wang et al., 1995).
This study has not identified factors whose modificationmight reduce
mother-to child transmission ofHIV. However, 9 of the 34 infected infants appeared
to acquire infection postnatally as a result of breast-feeding. As breast-feeding is
essential for most babies in developing countries, there is an urgent need for the




DIAGNOSIS OF VERTICALLY ACQUIRED HIV-1 INFECTION
BY CLASS-SPECIFIC IgG, IgM and IgA CAPTURE ASSAYS
4.1. INTRODUCTION
In any individual case, the timing and mechanism ofmother-to-child
transmission ofHIV are not clear. There is evidence for infection in utero (Specher
et al., 1986; Mano and Chermann, 1991), just prior to or during delivery (Krivine et
al., 1992), and by breast-feeding (Datta et al., 1994; Van de Perre et al., 1993;
Ziegler, 1993). In the developing world breast-feeding is recommended by the World
Health Organisation (World Health Organisation, 1992), but it nevertheless increases
the risk ofHIV transmission from mother-to-child (Dunn et al., 1992). A number of
laboratory tests, reviewed by Sison and Campos (1992), may detect transmission
which has occurred before or during the neonatal period, including polymerase chain
reaction (PCR), HIV culture, and in vitro antibody and in vitro antigen production.
However, most are expensive, technically demanding and unsuitable for use in
laboratories in developing countries. A possible exception is the detection ofHIV
p24 antigen. While Andiman et al. (1992) found only 20% of samples collected
from infected babies in the first month of life to be HIV antigen positive, Miles et al.
(1993), employing a preliminary acid dissociation step, reported p24 antigen in 80%
of HIV infected neonates. Ascher et al. (1992) enhanced the detection of p24 antigen
by acid pre-treatment of the sera to dissociate immune complexed antigen. However,
when Fauvel et al. (1993) further assessed the value of acid pre-treatment of the
sample they concluded that although a small improvement in sensitivity was possible
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in the first two months of life acid treatment of specimens made confirmation of
reactive samples essential. This increases the volume of specimen needed and the
cost.
The presence of IgA anti-HIV in at-risk infants has been shown to be
predictive ofHIV infection in the child. Immunoblots have been employed to
identify IgA and IgM anti-HIV in samples collected at and following birth, but
removal of competing IgG from the samples by absorption with protein G prior to
testing was necessary (Weiblen et al., 1990). Many of the published data have been
obtained using Western blot or immunoblots which incorporate recombinant HIV
antigens (Weiblen et al., 1990; Martin et al., 1991; Quinn et al., 1991; Portincasa et
al., 1992; Re et al., 1992). In these studies, when samples collected between birth
and 3 months have been tested, the sensitivity for IgA detection has been low (range
16 to 18%). In one study, however, IgA anti-HIV was detected in all 10 HIV-
infected children tested at birth and in 2 further infected children tested at 2 months
of age, but not in any of 5 uninfected children at risk (Portincasa et al., 1992). This
study assumes that maternal IgA anti-HIV does not cross the placenta in which case
transmission must have occurred in all cases long enough before birth for the babies
to mount an IgA response. This assumption conflicts with the current consensus that
a substantial proportion of transmissions occur perinatally (Ehrnst el al., 1991;
Krivine et al., 1992). In another study, however, IgA anti-HIV was detected in
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similar proportions of uninfected (12/37, 32%) and infected (4/12, 33%) neonates
born to HIV infected mothers (Connell et al., 1992). Its presence was associated
with strong IgA anti-HIV reactivity in the mothers' serum, suggesting that acquisition
of maternal IgA had occurred. With the exception of one study (Portincasa et al.,
1992), these studies indicate that IgA anti-HIV production commences in the infected
infants between 3 and 6 months (22 to 66% IgA anti-HIV positive), and that most are
producing IgA anti-HIV by 9 months (range 54 to 99%). IgA anti-HIV has rarely
been found in uninfected infants of 3 months and older.
In the present study, immunoglobulin class specific antibody capture EIAs for
IgA, and also for IgM and IgG anti-HIV were devised and evaluated for the diagnosis
ofHIV infection in children at risk of infection from their mothers. These assays are
simple, cheap and require only small volumes of untreated serum or plasma
specimens. They can be readily used by laboratory services in developing countries
where, because of breast-feeding, children continue to be at risk ofHIV infection into
the second year of life and beyond (Datta et al., 1992).
4.2. PATIENTS
Thirty-four children born to seropositive mothers were diagnosed as infected
(PP group) by the presence of IgG anti-HIV at eighteen months of age, the detection
of p24 antigen, AIDS defining illness before eighteen months of age, detection of
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proviral DNA or HIV-related death (Centers for Disease Control, 1987). There were
two control groups of children: 92 who did not develop the infection during the
period of follow up but whose mothers were HIV positive (PN group) and 21
children born to anti-HIV negative mothers (NN group). Plasma samples were
collected from the three groups of children in the neonatal period (cord blood and/or
peripheral blood) and at 3, 6, 9, 12, 18 and 24 months of age. Because no alternative
was available the mothers were not advised to stop breast-feeding.
4.3. RESULTS
4.3.1. OPTIMISATION OF THE ELISA CONDITIONS
For the IgG test (GACELISA), three negative controls (NCI, NC2 and NC3)
and 2 positive controls (PCI and PC2) were included in each test. The negative
controls were samples pre-calibrated by MUREX diagnostics, containing HIV-1
positive samples diluted in plasma from seronegative individuals (Dr Urszula
Beckford, personal communication). The positive controls were collected from HIV
infected individuals, CP1 from HIV-1 and CP2 from HIV-2 infected patients. On one
occasion, the negative control had an OD above 0.3. This value was rejected and the
calculation of the cut-offwas determined with two negative controls. The summary
of the performance of negative and positive controls in 51 ELISAs is shown in table
4.1.
Ill
TABLE 4.1. Repeatability ofnegative andpositive control results in 51 tests (G-EIA)
Controls Mean OD Minimum Maximum STD St. Error
NCI 0.192 0.109 0.687 008 001
NC2 0.186 0.131 0.336 0.045 0.006
NC3 0.183 0.109 0.291 0.043 0.006
HIV1 L532 0.707 2.438 05 0.072
HIV2 1.616 0.312 2.656 0.5 0.081
*Student's't', testing whether mean differs from zero.
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For the IgA and IgM tests, positive controls were kindly provided by Dr Jeff
Connel of the Public Health Laboratory Service, Colindale, London. The controls
were previously found to be reactive and were serially diluted to provide a
measurable scale (0.1, 1,3, 10 and 30 units). The threshold for positivity was
determined by adding the arbitrary value of 0.2 to the mean of three negative controls
for GACELISA, MACELISA and AACELISA. The positive controls had to be
reactive for the test to be considered as valid. For the AACELISA and MACELISA,
the positive results could be negative with the 0.1 units and weakly reactive on the 1
unit positive controls but the 3, 10 and 30 unit positive controls had to be positive for
the test to be valid.
4.3.2. IgA, IgM and IgG ANTI-HIV-1 IN CONTROL CHILDREN
A total of 142 sequential samples were collected from 21 anti-HIV negative
children born to HIV uninfected mothers. These samples were all negative when
tested by IgA, IgM and IgG ELISAs giving a 100% specificity of each of the tests.
4.3.3 IgA, IgM and IgG ANTI-HIV IN CHILDREN BORN TO HIV
INFECTED MOTHERS
The samples tested from children were collected at birth and at 6 weeks, 3, 6,
9, 12, 15, 18 and 24 months. During the phase I study, samples were not collected at
6 week and 15 months of age
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4.3.3.1. NEONATAL SAMPLES
A total of 261 samples (cord blood n=l 13 and venous blood n=T48) were
collected from neonates born to HIV-1 positive mothers during the perinatal period.
Ignoring the cord blood, the average age of the babies when the 148 venous blood
samples were taken was 2.9 days (median 3, minimum 0 and maximum 17 days).
Of 109 neonatal samples (56 cord and 53 venous blood) 3 samples (all cord)
collected from HIV-1 positive mothers were reactive when tested for anti-HIV-1 IgG
by Abbott recombinant HIV-1+2 and GACELISA (137/137). One of the three
children with a negative result in the cord blood sample was born to a mother who
was seroconverting around the delivery period. There was no obvious explanation
for the other two children in whom IgG was not detected in cord blood.
Nevertheless, one of these two children died of cryptococcal meningitis at the age of
three months, a strong indication of immunodeficiency at that age.
Surprisingly, IgM anti-HIV-1 antibodies were found in 61/103 and in 61/128
cord blood and samples collected perinatally from babies born to HIV-1 infected
mothers, respectively. Similarly, anti-HIV-1 IgA was detected in 58/129 (45%)
neonatal venous blood samples and in 63/103 (61.1%) cord blood samples from
babies ofHIV-1 infected mothers. The proportions of samples that were IgA positive
versus those that were IgM positive in cord or venous neonatal samples did not differ
statistically (Mantel-Haenszel test: p>0.5) (Table 4.2). While the proportion of
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samples that were IgM anti-HIV-1 positive did not differ significantly whether cord
or venous bloods were tested, there was a statistically significant higher proportion of
IgA anti-HIV-1 in cord blood than in neonatal venous blood (Mantel-Haenszel test,
p=0.014). However, the level of the reactivity for reactive samples was not
significantly different. Indeed, the mean of optical density over the cut offwas 1.9
(range: 1-6.9) for IgM and 2.2 (range: 1-8.7) for IgA. Sixteen (19.2%) samples
which were IgA anti-HIV positive were not reactive when tested for IgM anti HIV-1.
On the other hand, 13 samples were reactive with the IgM but not with IgA anti-HIV
capture assay.
The presence of class anti-HIV IgA and IgM in neonatal samples and the
outcome of HIV infection in children
The proportions of IgA and IgM detected in cord and venous blood of
children born to HIV positive mothers who subsequently were shown to be infected
(PP children) and PN children (born to HIV-1 positive mothers but not infected) are
shown in figure 4.1. In PP children, of 20 cord blood samples available, 17 (85%)
and 15 (75%) were reactive with anti-IgA and IgM assays, respectively. Samples
collected by venepuncture were also shown to be reactive by anti-IgA and anti IgM
assays [12/17 (70.6%) and 10/17 (58.8%), respectively). However, in PN children,
out of 47 cord blood samples available for testing, 30/47 (63%) were IgA positive
and 31/47 (66%) had detectable IgM. Half of the venous samples were positive for
both IgA and IgM (24/48; 50%). The proportion of infected children who had
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detectable IgA and IgM anti-HIV-1 in cord blood or in venous samples did not differ
statistically to that of PN children (p=0.07 for IgA; p=0.4 for IgM).
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TABLE 4.2: Comparison ofreactivity ofcord vs venous blood in IgA and IgM test
IgM IgA p value*
Cord blood 61/103 63/103 0.7
Venous blood 61/128 58/129 0.6
p value 0.06 0.014095
"p value calculatec by Mantel- laenszel test.
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FIGURE 4.1: Proportion ofIgA and IgM class anti-HIV in cord and venous blood
samples
Samples (cord blood and venous blood) were collected from children born to
HIV-1 infected mothers. The comparison was made between 20 children who
were infected with HIV-1 (PP) and 47 who were not (PN).
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TABLE 4.3. A. IgA and IgM class anti-HIV detected in cord and venous blood of infected (PP)
and uninfected (PN) children born to HIV-1 positive mothers.
PP CHILDREN PN CHILDREN
CORD VENOUS CORD VENOUS
IgA 17/20 (85%)(A) 12/17(70.5%)(B) 30/47 (63.8%)(C) 24/48 (50%)(D)
IgM 15/20 (75%)<E) 10/17(58.8%)(F) 31/47 (65.9%)(G) 24/48 (50%)<H)
Note high proprotion of IgA and IgM being in neonatal samples.
Comparison between proportions:
CELLS Chi2 D value
• A vs. B 0.44 0.508
• C vs. D 1.85 0.173
• E vs. F 1.1 0.294
• G vs. H 2.48 0.115
• A vs E 0.16 0.69
• B vs. F 0.52 0.47
• C vs. G 0.05 0.82
• D vs. H 0 1
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TABLE 4.3. B. IgA, IgMand IgG class anti-HIV in uninfected children born to HIV-1 infected
mothers (PN) at different ages.
AGE (at time of collection of samples)
6w 3m 6m 9m 12m 18m 24m
IgA 3/24 0/80 0/71 0/65 0/77 0/48 0/33
12.5% 0% 0% 0% 0% 0% 0%
IgM 6/24 0/80 0/70 0/65 0/77 0/48 0/34
25% 0% 0% 0% 0% 0% 0%
IgG 23/27 69/80 9/74 9/65 1/90 0/49 0/35
85% 86.2% 12.2 13.8% 1.1% 0% 0%
(PN, negative children born to HIV-1 infected mothers; w: weeks; m: months)
Note IgA and IgM detected at 6 weeks and not after, consistent with the suggestion
that there is passive transfer of IgA and IgM across the placenta. Also note gradual
decline of the proportion of IgG anti-HIV-1; no IgG anti-HIV-1 detected at 18 and 24
months of age.
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TABLE 4.3.C. IgA, IgMand IgG in positive children infected with HIV-1 born to mothers
(PP) who are also infected with HIV-1.
AGE
6w 3m 6m 9m 12m 18m 24m
IgA 1/7 4/31 17/29 20/27 22/30 28/28 9/12
14.2% 12.9% 58.6% 74% 73.3% 100% 75%
IgM 1/7 3/31 10/29 15/26 17/30 28/28 8/12
14.2% 8.3% 48% 57.7% 56.7% 100% 66.6%
IgG 7/7 24/27 19/26 21/22 24/30 28/28 12/12
100% 88.9% 73% 95.4% 80% 100% 100%
(PN, negative children born to HIV-1 infected mothers; w: weeks; m: months)
Because IgA and IgM anti-HIV were still detected in uninfected children at 6 weeks
of age (Table 4.3.b), detection of IgA and IgM from 3 months onwards was a strong
indication ofHIV infection in children.
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Class-specific IgA and IgM anti-HIV-1 in neonatal samples by maternal stage of
HIV-1 infection in mothers
Stratified data analysis was performed to determine maternal factors in HIV-1
infected mothers associated the presence of IgA and IgM in pediatric samples (Table
4.4). The factors included particularly maternal age, the stage of disease of the
mother and histological features of the placenta (funisitis, malarial parisite, malarial
pigment, and chorioamnionitis). Because samples from children born to seronegative
mothers were all non-reactive with the IgA and IgM capture assays, only maternal
factors ofHIV-1 positive mothers were considered in the present analysis.
Maternal Age (data not shown) and stage ofHIV infection (Table 4.4) were not
associated with presence of IgA and IgM in neonatal samples. There was no
statistically significant relationship between chorioamnionitis or funisitis and the
presence of IgA-class and IgM-class antibodies in pediatric samples (Table 4.4.a.). In
addition, no association was observed between the presence of IgA and IgM class-
specific antibodies in neonatal samples with malarial pigment found in placenta of
the mothers. However, there was an association between malarial parasite in
placenta and IgA in neonatal samples (p=0.0285) (Table 4.4.b). It is intriguing that
the presence ofmalaria parasite should prevent passage of IgA across the placenta. It
is likely that there are some other confounding factors which explain the association
between IgA and IgM in neonates.
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Tables 4.4: Placental histopathology, HIV stage and IgA/Mclass-specific antibodies in
neonatal samples
A. Association between placentatis and presence of IgM and IgA in neonatal
samples
Funisitis* Chorioamnionitis*
0 1 2 3 0 1 2 3
IgM Neg 13 1 1 2 8 2 4 3
Pos 21 3 3 1 19 1 4 2
P=0.6 P=0.3
IgA Neg 18 3 2 2 13 5 4 3
Pos 26 5 2 1 24 2 4 2
P=0.8 P=0.23
A. Association between malaria pigments and parasites in placenta and
presence of IgM and IgA in neonatal samples
M. pigment* M. parasite*
I o 1 2 3 0 1 2 3
IgM Neg 6 3 6 2 8 1 2 6
Pos 13 9 6 0 14 6 6 2
P=0.157 P=0.074
!
IgA Neg 12 5 5 2 11 4 2 7
Pos 18 8 8 0 21 5 7 1
P=0.36 P=0.0285 «•




IgM Neg 11 4 2
Pos 23 1 7
P=0.07
IgA Neg 21 2 2
Pos 27 3 7
P=0.48
* 0= no evidence, 1= minor changes, 2= moderate, 3= marked
** The stage ofHIV infection in mothers was classified by 0= uninfected, 1=
early seroconversion illness, 2=asymptomatic, 3=symptomatic pre-AIDS, 4=AIDS.
# M= malarial. Arrow indicates association.
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4.3.3.2. IgA, IgM and IgG CLASS ANTI-HIV-1 IN POST-NATAL SAMPLES
OF CHILDREN BORN TO HIV-1 POSITIVE MOTHERS
The samples were taken at 6 weeks of age from a small group of children
during the second phase of the study (between 1993 and 1995). In samples available
from 27 PN children at that age, IgG could still be detected in 23 (85.2%). In
comparison to what was found in neonatal samples, the proportions of specific IgA
and IgM in PN children showed a significant decline from 30/47 (63%) and 31/47
(66%), respectively, to 3/24 (12.5%) and 6/24 (25%) at 6 weeks. In seven HIV-1
infected children tested at 6 weeks, the IgG tests were all positive. Only one out
seven PP children was still reactive for IgM and IgA at 6 weeks of age. By the age of
3 months, while IgG anti-HIV-1 was still detectable in 69/80 (86.3%), none of the
samples from 80 PN children was IgA or IgM positive at 3 months (p<0.0001).
Infected children also had detectable IgG at 3 months at a similar proportion with the
PN children (24/27; 88.9%) but IgM and IgA anti-HIV were found in 3 (8.3%) and in
4 (12.9%), respectively, of 31 children tested.
At 6 months of age, 7 of PP 26 children (26.9%) were non-reactive for IgG as
tested by GACELISA and the commercially available Abbott recombinant HIV-1+2
while the remaining 19 samples were still reactive. At the same age, the proportions
of samples with IgA and IgM class anti-HIV were significantly higher than those
observed at 3 months in PN children and were 17/29 (58.6%) and 10/29 (48%),
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respectively. At 9 months of age, 21/22 (95.4%) PP children were IgG anti-HIV
reactive. The reactivity of the IgM test was relatively lower as 15 (57.7%) of 26
infected children were shown to have detectable antibodies. However, the IgA test
had a higher sensitivity to detect HIV-1 infection in children tested at 9 months of
age. With this assay, 20 of 27 (74%) samples from infected children were reactive
for IgA anti-HIV-1 antibodies. In addition, seroreversion was more apparent in the
PN children at 9 months. While 9 (13%) out of 65 PN children were still reactive
with IgG assay at 9 months, none of the PN group appeared to be reactive with IgA
and IgM assays.
Four PP children did not have detectable IgA anti-HIV in any sample
collected between 3 and 12 months of life. These children also lost IgG anti-HIV
reactivity during their first 12 months, suggesting that infection occurred well after
birth. Two of them had symptoms possibly due to HIV at 6 months, the third had
non-specific findings and the fourth child was asymptomatic throughout the first
year. The presence or absence of HIV-associated symptoms in the first year of life
did not correlate with the presence or absence of IgA anti-HIV. Sequential PCR
testing on children who lost maternal antibodies and were anti-HIV-1 IgA and IgM
negative between 6 and 12 months also showed transient negative PCR results before
the first PCR was positive.
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IsG, IsA and IsM in PP and PN children at 12 and 18 months ofase:
Whereas the reactivity of PP children at 12 months for IgG anti-HIV was 80%
(24/30), IgM was detectable in 17/30 (56.7%) and IgA in 22/30 (73.3%). At this age,
1 (1.1%) of 90 PN children still had detectable maternal IgG anti-HIV while neither
IgA nor IgM anti-HIV-1 was detected in 77 samples tested. Four samples were
available from PP children at 15 months and were IgG and IgA anti-HIV-1 reactive.
The control PN children were unreactive for IgG, IgM and IgA anti-HIV at 15
months of age.
IsG, IsA and IsM in PP and PN children at ase 18 months ofase and over:
None of the 90 seroreverters, was reactive with either IgG, IgA or IgM anti-HIV-1
assays. This provides a high specificity (100%) of these assays after seroreversion.
All 28 samples from the PP children were IgG, IgA and IgM positive at 18 and 24
months.
4.3.3.3 PROFILES OF IgG, IgM and IgA CLASS ANTI-HIV-1 IN CHILDREN
The profiles of IgG, IgM and IgA class anti-HIV in the three groups of
children (PP, PN and NN) are presented in figure 4.2. Anti-HIV-1 IgA (Figure
4.2.a), IgM (Figure 4.2.b) and IgG (Figure 4.2.c) antibodies were detected in children
born to HIV-1 infected mothers at birth. IgA and IgM showed a rapid decline to
complete clearance at 3 months of age in uninfected children. This suggested that the
IgA and IgM anti-HIV-1 detected in the infants' neonatal samples were ofmaternal
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origin. The presence of specific IgA and IgM from 3 months onwards was a strong
indication ofHIV infection in children. Clearance ofmaternal IgG was more rapid in
uninfected than in infected children.
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FIGURE 4.2. IgA (4.2.a), IgM (4.2.b) and IgG (4.2.c) class immunoglobulins
to HIV-1 in PP, PN and NN children.
4.2.a: IgA class anti-HIV-1 in PP, PN and NN children*
OD/Cut-off
5 -i r 1
*The analyses were performed on sequential samples collected at birth, 3, 6, 9, 12, 18
and 24 months of age from 21 HIV-1 infected children born to seropositive mothers
(PP), 21 seroreverters born to HIV-1 infected mothers and 21 seronegative children
born to HIV-1 negative mothers. The mothers of the control children (PN and NN)
were matched with the mothers of infected children for age, parity and stage of disease
(CDC stage). Antibodies were detected by in-house capture ELISAs. Standard error
bar: 95% confidence limit of the mean.
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4.2.b. IgM class anti-HIV-1 in PP, PN and NN children*
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* see note in figure 4.2.a
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Figure 4.2. (continued)
4.2.c. IgG class anti-HIV-1 in PP, PN and NN children*
OD/Cut-off
AGE (months)
* see note in figure 4.2.a.
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4.4. DISCUSSION
It is commonly accepted that 'only' IgG readily crosses the placental barrier
to the fetal circulation. This passively transferred antibody is important as it provides
immune protection to the newborn. Unfortunately, the presence ofmaternal IgG in
children confounds the use of assays for IgG class anti-HIV in the early diagnosis of
HIV-1 infection in newborns. An alternative is the detection in neonates and young
children of specific immunoglobulins such as IgA and IgM which 'do not' cross the
placental barrier (Portincasa et al., 1992; Sison and Campos, 1992; Miles et al.,
1993). The lack of passive placental transfer of IgA and IgM has been explained by
the fact that these antibodies are larger in molecular weight as a result of their
dimeric (IgA) and pentameric (IgM) structure (Avrech et al., 1994).
In this study, the investigation of IgA and IgM class anti-HIV-1 was carried
out in sequential samples collected from children born to HIV-1 infected and
uninfected mothers. These antibodies were found at high proportion in children born
to seropositive mothers, irrespective of whether they were subsequently shown to
have been vertically infected or seroreverted after losing maternal IgG. In an earlier
study of European babies, it was shown that the simple and inexpensive class-
specific antibody capture assays employed in this study were sensitive and specific
(Connell et al., 1992). In that study 20 (83%) of 24 HIV-infected babies of between
3 and 12 months of age were IgA class anti-HIV positive by AACELISA.
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Substantial proportions of uninfected infants between birth and 3 months of age, but
not older, also had IgA class anti-HIV in their blood and it was suggested that this
antibody had been passively transferred from the mother. The presence of IgA and
IgM class anti-HIV in the neonatal blood of some uninfected infants born to HIV
positive mothers was confirmed in this study of African children. In view of the
earlier findings, however, it was initially surprising to find an apparently lower
sensitivity for IgA and IgM anti-HIV detection in these Central African children who
were subsequently confirmed to be HIV infected. Overall, only 62 of 116 (53.4%)
bloods collected from them between 3 and 12 months (inclusive) of age were IgA
anti-HIV positive, many of them weakly so. Tests for the presence of IgM anti-HIV
also proved less sensitive and they seemed not to augment the IgA findings. The IgA
findings were also at variance with those of Quinn et al (1991) and Weiblen et al
(1990) who used immunoblot procedures to detect IgA anti-HIV in HIV infected
infants.
Why should this be? Two factors may have accounted for this discrepancy.
Firstly, all of the babies in this study, unlike others, were breast-fed by their mothers.
Whereas breast-feeding had been thought until recently to carry only a small risk of
mother-infant transmission ofHIV (Behets et al., 1991) it has now become apparent
that up to half ofmother-child transmissions in breast-fed children occur by this route
(Dunn et al., 1992). Such transmissions are delayed compared with those in utero
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and at birth so that IgA anti-HIV may appear later. Secondly, it was apparent in this
study and others (Re et al., 1992; Weiblen et al., 1990) that an IgA anti-HIV response
is absent in many, but not all, children who experience rapid HIV-disease
progression. This could account for poor IgA response in 3 of the HIV-infected
children studied here. In testing European children, for whom breast-feeding is
discouraged, it has not been shown thus far that a child who was subsequently
diagnosed as HIV-infected can lose reactivity for IgG anti-HIV and then regains it
(Dr JV Parry, personal communication). In the series of HIV-infected children
reported here, however, 8/34 (24%) children lost anti-HIV as measured by the
GACELISA and/or Abbott EIA at some stage in the first year of life; several others
became only weakly reactive. With the exception of 2 children who died, all later
became unequivocally seropositive. This is evidence that perhaps a quarter of the
HIV-positive infants studied here were infected well after birth, presumably through
breast-feeding, and is in accord with other findings (Dunn et al., 1992). The 4 infants
in whom an IgA anti-HIV response was not detected between 3 and 12 months all
showed transient loss of IgG anti-HIV reactivity over the same period.
For the PN group IgG anti-HIV reactivity was lost earlier in the GACELISA
assay than in the indirect (Abbott) assay. This confirms similar findings in another
study (Parekh et al., 1993) and may prove to be a useful feature. Particularly in
babies who have not been breast-fed the GACELISA may permit earlier
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identification of babies who have escaped HIV infection compared with a
conventional anti-HIV screening test.
Unfortunately, there is no information on the frequency or duration of breast¬
feeding in the earlier published work on IgA anti-HIV detection in at-risk children.
If, as seems likely, many children in these other studies were wholly or largely bottle-
fed, infection might only rarely have occurred postnatally. By contrast, in this study,
transmission could have occurred at any time from birth until the children who
escaped intrauterine or perinatal infection were completely weaned (Van de Perre et
al., 1993; Datta et al., 1992; Ziegler, 1993). Risk of transmission by breast-feeding
may accrue with time due to the duration of exposure of the child. It is possible that
the decline of the mother's immune competency can lead to higher levels of viral
replication and lower levels of partially protective maternal antibody and the
emergence ofmore transmissible strains ofHIV in the mother. Moreover, it might be
that the dynamics of the immune response in a child infected orally under 'cover' of
maternal antibodies is suppressed compared to that of adults or of children infected at
or before birth.
If it is the case that a specific IgA response is delayed or absent in breast-fed
babies infected postnatally, is there any value in attempting early diagnosis by IgA
antibody capture anti-HIV testing? I believe there is, for the following reasons.
First, in this study and others, it has been demonstrated that, when present, IgA anti-
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HIV (and IgM anti-HIV) in the blood of children of 3 months and older is highly
predictive ofHIV infection in that child. By contrast, other anti-HIV reactivity in
screening tests, predominantly IgG, is often present in uninfected children even
beyond 12 months of age, making it difficult to distinguish infected from uninfected
children. Second, the method employed in this study is robust and simpler and
cheaper than tests for IgA anti-HIV which require preliminary removal of IgG and
the immunoblot assay. The IgA antibody capture ELISA employs conventional
ELISA methods and its reagent costs should be no more than 2 to 3 dollars (US):
immunoblot reagents cost approximately 10 fold more. Third, although the precise
time of transmission was not known for 34 HIV-infected children in this study, it is
clear that postnatal transmission had occurred frequently. In such circumstances it
would not be possible to determine at what point other tests, e.g. for HIV p24 Ag or
proviral DNA might become positive relative to IgA anti-HIV seroconversion. It can
be assumed that p24 antigen detection and PCR would also have shown an
apparently low sensitivity in the first few weeks or months of life as, in some cases,
transmission would not yet have occurred. Fourth, even in situations where PCR and
HIV p24 antigen testing can be afforded and done to a high standard of accuracy,
some laboratories in developed countries have found it valuable to have a serological
method, such as detection of IgA anti-HIV, to confirm HIV infection in children who
are positive for these other markers ofHIV infection (JV Parry, personal
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communication). Fifth, in a previous study, Tosswill et al. (1994) have experienced
failures both ofHIV p24 Ag testing and PCR to diagnose HIV infection in HIV-
infected babies of over 3 months of age whose serum was shown to contain IgA class
anti-HIV. Sixth, it is often difficult to obtain sufficient blood from an infant or
young child to perform HIV p24 Ag testing and/or PCR. As the IgA capture method
requires only tiny volumes (5pl or less), it can be performed on specimens which are
insufficient for a p24 Ag test (often use 200pl of plasma). Although not formally
demonstrated here, the IgA capture assay, like the IgG capture assay, would probably
function equally well on eluates prepared from dried blood spots.
In summary, the main findings of this study were the observation that IgA and
IgM class anti-HIV can be passively transferred through the placenta like IgG. This
hampers early diagnosis ofHIV-1 in children. However, unlike IgG which can
remain detectable up to 12 months and beyond, passively acquired IgA and IgM clear
quickly. From three months of age their detection is a strong indication ofHIV
infection. A simple, inexpensive assay for IgA anti-HIV, such as described here,
would be ideally suited to laboratories that are unable to perform complex and
expensive tests, such as PCR and viral culture, to diagnose mother-to-child
transmission ofHIV. Although the sensitivity of the method in breast-fed infants is
imperfect, it is highly specific. In circumstances where other approaches are not
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available the method will, by 6 months of age, permit the identification of three-
quarter ofbabies who become infected in utero, perinatally or postnatally. Others
will need to be followed up for longer, especially if breast-fed. Early diagnosis can
reduce the stress to parents of not knowing their child's HIV status and and allow




MOLECULAR CHARACTERISTICS OF THE p17 gag REGION:
IDENTIFICATION OF DIFFERENT HIV-1 SUBTYPES AND THE ROLE OF
FUNCTIONAL NUCLEIC AND AMINO ACID SIGNATURES IN THE
MOTHER-TO-CHILD TRANSMISSION OF HIV-1
5.1. INTRODUCTION
Why some children born to HIV positive mothers become infected and others
do not is an area of intense investigation and much controversy. The risk factors that
affect the transmission ofHIV-1 from infected mothers to their offspring can be
assembled in two groups: the endogenous and exogenous factors. It is possible that
these factors influence transmission in a synergistic manner. This issue was discussed
in Chapter One. Briefly, the endogenous factors include all the variables related to
the host - the mother and to some extent, the child. For example, the clinical stage of
HIV infection of the mother is an important factor for vertical transmission ofHIV-1.
It has been shown that women with symptomatic HIV-1 infection or with low CD4
counts and those who had a previous child with AIDS may be at more likely to
transmit HIV to their offspring (Ryder et al., 1989; St Louis et al., 1993). St Louis et
al. (1993) examined various maternal factors and showed that the risk ofMCT
ranged from 7 to 71%. In that study, it was shown that when mothers had p24
antigenemia and CD8+ lymphocyte counts of at least 1.8xl09/L the risk ofmother-to-
child transmission was high. In addition, in women with neither high CD8+ nor low
CD4+ lymphocyte counts, placental membrane inflammation was strongly associated
with MCT. A role for maternal neutralising ability has been identified by some
groups (Goedert et al., 1989; Rossi et al., 1989), and not by others (Halsey et al.,
1992; Parekh et al., 1991; Robertson et al., 1992).
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On the other hand, there are exogenous factors which are the biological
properties of the agent: HIV-1. HIV-1 variants vary in the way they affect cells.
Some variants are fast replicating [with syncytium inducing (SI) phenotype] and
others cause little (or no) cytopathic effect [non-syncytium inducing (NSI)
phenotype]. NSI isolates appear to be transmitted preferentially from mother to
infant even when the mother's strain is predominantly SI (Scarlatti et al., 1993b;
Spencer et al., 1994). These biological phenotypes are mirrored in the genetic
sequences of the viruses.
The phylogenetic analysis ofHIV has identified two genetically distinct types,
HIV-1 and HIV-2. There is clear evidence that there are biological differences
between these two types. Although both cause AIDS, HIV-1 transmission has
resulted in a global pandemic, whereas HIV-2 has remained relatively isolated
geographically. In some areas ofWest Africa where the two viruses co-circulate, it
has been observed that the seroprevalence ofHIV-1 was increasing while that of
HIV-2 was decreasing (DeCock et al., 1993).
Strains ofHIV-1 have been grouped into at least eight genotypic subtypes (A-
D, F-I) within group M (main) and the more divergent outlier (O) group (Myers et
al., 1995). Another group M clade has been provisionally classified as 'J' and is
awaiting additional independent reports of strains with similar genetic features
(Leitner et al., 1995). Very little is known about the effect of genetic diversity on
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viral infectivity. Subtype B is the predominant subtype in Europe and North
America. It is intriguing to speculate why this subtype is rare in Africa where higher
numbers of infected people are found. More recent and more compelling evidence
about the functional differences ofHIV-1 subtypes, has shown that subtype B is less
able than subtype E to infect Langerhans' cells (SotoRamirez et al., 1996) which are
found in the mucosa of the cervix, the vagina and the penile foreskin. These findings
were suggested as an explanation for the preferential distribution of subtype B among
drug users and subtype E among sex workers in Thailand (Ou et al., 1993; Kalish et
al., 1995). More interestingly, a case control study of Thai men and their female sex
partners supported the suggestion that subtype E is more transmissible sexually than
subtype B. Using the differences between HIV-1 and HIV-2 and also the
transmissibility difference between subtype B and subtype E as a background, it was
decided to determine the distribution of genetic strains ofHIV among pregnant
women and their children in the present study of a Congolese population in Africa.
To date, most studies aiming to determine the functional significance of
different HIV-1 subtypes have been based on genetic information extracted from the
region encoding the envelope glycoproteins gpl20, particularly the hypervariable
region, the V3 loop (Briant et al., 1995; Wolinsky et al., 1992; Scarlatti et al., 1993b;
Mulderkampinga et al., 1993). The focus on this gene can be justified by its high
immunogenicity and its role in neutralisation by antibodies. For this reason, the
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envelope region constitutes an important target for the development of an HIV-1
vaccine (Keefer etal., 1996; Jelonek et al., 1996; Girard et al., 1995; Salmonceron et
al., 1995; Gorse et al., 1996; OToole et al., 1996; Ahlers et al., 1996; Belshe et al.,
1993; Shirai and Klinman, 1993; McElrath et al., 1996; Wagner et al., 1996).
Analysis ofHIV-1 quasispecies in mother-child pairs, has shown that either
minor or major viral variant can be transmitted from mother-to-child (Ahmad et al.,
1995; Wolinsky et al., 1992; Scarlatti et al., 1993b). Wolinsky et al. (1992) have
shown that sequences obtained from vertically infected babies lacked an N
glycosylation site that was present in maternal sequences, suggesting that the loss of
this site may in some way enhance the infectivity of the virus. However, only 3 of 7
children studied by Ahmed et al. (1995) and one of three children in another study
(Mulderkampinga et al., 1993) showed the absence of this N glycosylation site. Such
a feature was not observed in any of the V3 sequences of the 10 children studied by
Scarlatti et al. (1993b). These discrepancies between studies suggest that no specific
association can be made between genetic features studied within the env region and
the transmission ofHIV-1 from mother-to-child.
It is important to analyse other regions of the genome to determine their
relevance in MCT ofHIV-1. In the present study, the emphasis was mainly on the
pi7 region for such an investigation and the rationale for this choice is as follows.
First, it was shown by Demareuil et al. (1995) that the pi 7 region of an isolate from
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the former Zaire HIV-Indk interacted with the env gene to define the viral phenotype.
In that study, the variability in three regions, including pi7 gag matrix, correlated
with formation of large syncytia. It was suggested that the pi 7 matrix protein is
capable to influence virus-cell fusion during formation of syncytia (Demareuil et ah,
1995). Secondly, the pi7 region plays an important role during viral replication. It
has been suggested that the myristoylated N terminal region ofpi 7 gag plays an
important role during the assembly of the viral particle (Spearman et al., 1994;
Reicin et ah, 1995). In addition, the pi 7 region is involved in the formation of the
preintegration complex and in the genomic transport of the genome to the cell
nucleus, which allows the virus to infect non-dividing cells (Karageorgos et ah,
1993). Changes in the pi 7 region may affect the transport of the cytoplasmic
complex and hence influence viral infectivity. Gallay et al. (1995) demonstrated that
phosphorylation of the C-terminal tyrosine of pi 7 is a critical step during infection of
new cells. Thirdly, compared with the V3 region, the pi7 region is less variable and
more suitable for molecular epidemiological mapping ofHIV-1 (Holmes et ah, 1993;
Myers et ah, 1995). Finally, a study by Narwa et al. (1996) based on a small group
ofmothers and children, suggested that there are motifs within the pi 7 region which
may be associated with mother-to-child transmission ofHIV-1 (Narwa et ah, 1996).
This study has thus far not been confirmed.
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In the present study, sequences were determined ofHIV-1 variants from
infected mother-child pairs and were compared with sequences obtained from non-
transmitting mothers. The phylogenetic analysis was performed in order to
determine the subtype of each HIV-1 variant and additional analyses were carried out
to determine the association ofpi 7 amino acid motifs with vertical transmission of
HIV-1. It was also of interest to see whether one particular subtype was more
prevalent than others, and therefore responsible for the low and stable seroprevalence
and low MCT rates observed within the study population.
144
5.2. RESULTS
5.2.1. IDENTIFICATION OF HIV-1 SUBTYPES
A total of 72 sequences were determined, of which 63 were from
epidemiologically unlinked individuals' (57 mothers and 6 children) and 9 from
children born to seropositive mothers from whom sequences were also available. The
sequences (225bp) in the gag region were aligned with reference sequences
previously published, which are available in the Los Alamos database (Myers et al.,
1995). The nucleotide sequences were analysed to determine their placement in the
previously defined phylogenetic tree (Myers et al., 1995). As a prerequisite, it was
important to determine whether the length of these sequences (225bp) and the region
(gag) in which they were analysed were suitable for the classification ofHIV-1
strains.
To investigate the suitability of the length (225bp) and the region used in
phylogenetic analysis of Kimpese strains, a phylogenetic tree was constructed using a
dataset of 83 reference sequences aligned relative to that of the HIVhxb2 isolate.
These reference sequences were previously classified into well-defined subtypes by
analysis of the full gag and/or the full env gene (Myers et al., 1995). It was essential
1 Two individuals are designated as epidemiologically linked if there is a history of recent transmission of HIV
between them. For example, an HIV-1 infected blood donor and a recipient or a mother and a vertically
infected child can be so designated.
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that all the reference sequences cluster within their originally defined clades with
equidistance lineage and a star-like phylogeny (Myers et al., 1995; Kostrikis et al.,
1995; Leitner et al., 1995). Indeed, these requirements were met in that all the
reference sequences strongly clustered within their original subtypes as previously
documented (see appendix 4) (Myers et al., 1995). This suggested that the regions
and the length analysed were adequate for subtyping the HIV-1 strains in the study
population.
Phylogenetic analysis was then carried out on sequences from the present study
(length: 225bp) together with the Los Alamos sequences used here as references
(Myers et al., 1995). A Fitch-Margoliash tree was constructed using the maximum
likelihood distance method and is presented in figure 5.1. Interestingly, no subtype B
sequence was found in the Kimpese cohort. The sequences obtained from 63
epidemiologically unlinked individuals examined in this study clustered with
sequences grouped within 6 previously established subtypes (A, C, D, F, G and H).
Twenty-eight epidemiologically unlinked individuals were infected with subtype A.
These included 25 mothers (Sq3M, Sq6M, Sq9M, Sql 1M, Sql2M, Sql3M, Sq27M,
Sq29M, Sq31M, Sq32M, Sq34M, Sq36M, Sq37M, Sq38M, Sq39M, Sq40M, Sq43M,
Sq46M, Sq48M, Sq49M, Sq51M, Sq52M, Sq54M, Sq55M) and 3 children (Ped2,
PedlO and Pedl2). The average interhost-distance for sequences classified as
subtype A sequences was 12.9% (range: 4.8%-23.3%). A sequence obtained from
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mother Sql8M clustered with subtype C reference sequences and 5 mothers (Sq4M,
Sq20M, Sq21M, Sq23 and Sq41M) were infected with subtype D. Two other
sequences (Sql9M and Sq53M) were grouped with subtype F sequences (VI174,
BZ163 and VI69) (Myers et al., 1995). In addition, Sq7M, Sql7M, Sq47M and
Sq56M clustered together with two reference sequences, LBV217 and VII91,
previously classified as subtype G (Myers et al., 1995). Subtype H included a large
number of sequences from Kimpese, with 13 representatives (Sq5M, SqlOM,
Sql3M, Sql5M, Sql6M, Sq22M, Sq25M, Sq26M, Sq28M, Sq30M, Sq33M, Sq35M,
Pedl3). Thirty samples, which classified by the analysis of 215bp (figure 5.1), were
also analysed with longer sequences (315bp). The subtype inference with the later
dataset was the same as in the 215bp long dataset.
The Fitch-Margoliash tree shown in figure 5.1 was reconstructed as a
Neighbor-joining tree using the maximum likelihood distance method. The resulting
tree showed a similar topological distribution of sequences from Kimpese in clades
(data not shown). The Fitch tree and the Neighbor-joining trees agreed to 98.4% (of
total sequences, n- 63), as one sample (C.Sql8M) which was classified as subtype C
in maximum likelihood tree formed a separate branch.
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FIGURE 5.1. Phylogenetic tree ofHIV-1 variants from Kimpese.
This is a Fitch-Margoliash tree constructed using sequences in the pi7 region of
HIV-1 variants from the study population and Los Alamos reference sequences
(Myers et al., 1996). The phylogenetic analysis was based on an unambiguously
aligned 225bp region of the gag gene (position: 907-1131 in the HIVhxb2 genome).
Maternal sequences from this study are labelled by a letter showing the subtype
followed by SqN (Sq: Sequence, N: number) and the letter M (maternal sample).
Pediatric samples are labelled with a letter indicating the subtype, followed by 'Ped'
and a number. If a pediatric sample is followed by 'eP, it indicates that patient was
epidemiologically linked to a mother. The bootstrap values expressed in % are
shown close to the corresponding branch and indicate the robustness of the grouping
of a clade. Only bootstrap values ^75% are shown. Letters inside boxes indicate the
subtype. The scale bar indicates 10% of nucleotide substitutions. Note that at least
one sequence from the study population clustered among the reference sequences of
clades A, C-H and none among subtype B reference sequences.
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The degree of divergence of HIV-1 within the studied population was
estimated by the Kimura two-parameter distance estimation method (Kumar et al.,
1993). The nucleotide distances between sequences in this study are shown in
appendix 5. In summary, the interhost nucleotide distances between HIV-1 variants
obtained from epidemiologically unlinked individuals was on average 18.3% and
ranged between 1% (D.Sq21M-D.Sq23M, and H.Sq30M-H.Sq35M) to 37%
(D.Sq56M and H.Pedl3). The mean pairwise distance in 62 epidemiologically
unlinked individual sequences was 18.5% and ranged between 0.9% to 37.7%. The
degree of heterogeneity within the gag region of sequences from Kimpese is
relatively higher than the average pairwise distances previously documented by
Louwagie et al. (1993). In this study, the interhost distances within the same clade
A, D, F, G and H were on average 13%, 11%, 14.6%, 11.2 and 13% respectively
(Table 5.1; Appendix 5), higher than expected. The distance between individual
sequence and reference sequences of the same subtype was in all cases lower than the
distance of that sequence to reference sequences of a different subtype (Appendix 6).
The bootstrap resampling of the phylogenetic tree shown in Figure 5.1 was
carried out to test the robustness of each clade on the phylogenetic tree. Although the
statistical relevance of the bootstrap test has been debated (Felsenstein & Kishino,
1993; Hillis & Bull, 1993), the cut-off value of around 75% is generally considered
to establish confidence in the phylogenetic classification groupings (Simmonds et al.,
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1996). The clades A, B, C, F, G and H were supported with high bootstrap above the
cut-off value (Figure 5.1).
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TABLE 5.1. Average intersubtype and intrasubtype distances between classified HIV-1




D 21.0 18.0 11.1
F 25.6 23.6 18.9 14.6
G 21.7 22.8 24.6 30.5 11.2
H 18.6 18.0 22.6 25.1 25.9 13.0
A C D F G H
Subtype
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5.2.2. PHYLOGENETIC ANALYSIS OF HIV-1 NUCLEOTIDE SEQUENCES
FROM MOTHER-CHILD PAIRS
In most cases, nine sequences from vertically infected children (D.Ped3el,
A.ped4el, H.Ped5el, A.Ped6el, D.Ped9el, A.Pedl lei, APedl4el, A.Pedl5el and
Q.Pedl) were topologically closer to their corresponding maternal samples (D.Sq4M,
A.Sq9M, H.Sql6M, A.Sq32M, D.Sq45M, A.Sq52M A.Sq37M, A.Sq27M and
Q.SqlM, respectively) than to other samples to which they were unlinked. All
mothers were classified in the same subtype as their vertically infected children. As
depicted in figure 5.2, the distance between mother-child pairs was significantly
lower than epidemiologically unlinked sequences (p=0.0001). The average of
pairwise nucleotide distance between sequences of mothers and their vertically
infected children was 2.5% (range 0-5.1%), compared with 17.5% (range 5.1-33.5%)
which was the average pairwise distance between the sequences from the same
children and epidemiologically unlinked individuals. Therefore, HIV-1 variants from
vertically infected children were far more similar to their respective mothers than
those they were not epidemiologically linked.
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FIGURE 5.2. Distribution of the distances between sequences obtained




















The comparison was made between nucleotide distances between 9 children and
their mothers (epidemiolocally linked pairs) and distances between the same
children and unrelated mothers (unlinked). The nucleotide distances are expressed
in % of pairwise nucleotide differences. The distribution of nucleotide distances
between sequences shown: horizontal line inside the box represents the median and
the horizontal ends of the box represent the lower and upper hinges (the 25th and
75th percentiles). Asterisks represent outside values, which are data values outside
the inner fences.
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5.2.3. A NEW CANDIDATE SUBTYPE OF HIV-1
It was intriguing to find that HIV-1 variants from 4 patients (SqlM, Sq2M,
Sq24M, and Pedl) did not cluster with any on the gag gene subtypes documented in
the Los Alamos database (Myers et al., 1995) (Figure 5.3.). The sequences from
Kimpese formed a distinct clade, designated 'Q' (query).
To meet the criteria for the documentation of a new subtype (Kostrikis et al,
1995; Leitner et al., 1995), it was important to determine if these patients were
epidemiologically linked or not. Except patient Pedl, who was vertically infected
from patient SqlM, interview with the three other patients (SqlM, Sq2M, Sq24M,)
showed no evidence of possible transmission to each other. However, patient SqlM
was engaged in prostitution two years before the collection of the sample. Therefore,
it is possible that she could be linked, although indirectly, to other women, including
Sq2M and Sq24M, through her clients. The archival samples collected in 1988 and all
available pediatric samples were sequenced and subtyped.
The child born to Sq24M was shown to be infected by detection ofp24 Ag and
IgA class anti HIV-1 IgA in the plasma (Mokili et al., 1996). Samples from this child
were not available for PCR and sequencing. The child bom to Sq2M was shown to be
uninfected after 30 months. The demographic and clinical data including the CD4
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Phylogenetic analysis was carried out using longer sub-genomic regions of the
gag (337bp and 754bp, positions 904-1240 and 904-18981 in the HIVHxb2 genome) and
the env genes (409bp). In addition to the Los Alamos sequences (Myers et al., 1995),
the recently documented sequences, provisionally designated as subtype I {env) and J
{env and gag) (Kostrikis et al., 1995; Leitner et al., 1995), were also included in the
analysis. Sequences known to have mozaic genomes (e.g. MAL, K124, LBV2310)
were also used in the present analysis to assess their position vis-a-vis the Q clade.
Additional phylogenetic analysis of the sub-genomic fragments ofboth the gag and the
env genes consistently grouped the SqlM, Sq2M, Sq24M and Pedl into a separate
clade [Figure 5.4. (337bp), Figure 5.5., 5.6.]. The bootstrap value supporting this new
clade was always above 97%.
1 The SqlM sample was amplified and sequenced using primers (see table 2.2). Three subgenomic regions (904-
1144, 1233-1445 and 1589-1898) obtained were joined together. After gaps between these regions were
removed, the sequence was aligned, and phylogenetic analysis carried out as described in the text.
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The tree shown on FIGURE 5.3. was constructed using the maximum likelihood
distance estimation method. The Alignment (gene: gag; length: 225bp, position as in
Figure 5.1) included reference sequences from the Los Alamos database (Myers et al,
1996) and 4 sequences (Q.SqlM, Q.Pedl, Q.Sq2M and Q.Sq24M) from Kimpese.
Bold lines at both sides of the tree indicate different grouping of sequences of the
same subtype. Note the placement of sequences from 4 patients from Kimpese.
These sequences cluster separately from previously documented sequences (Myers et
al, 1996) and the cluster is supported on this tree by a bootstrap value of 99% of 500
resamplings. The scale bar represents 10% divergence.
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FIGURE 5.3. Maximum likelihood tree showing the placement of unclassified
sequences from 4 patients (Q.SqlM, Q.Pedl, Q.Sq2M and Q.Sq24M) in Kimpese.
10% DIVERGENCE
159
FIGURE 5.4. Placement ofQ sequences in neighbour-joining tree of the pi 7 gag gene
phytogenies (337bp).
The query (Q) sequences, SqlM, Sq2M and Pedl, were aligned relative to all published
full length sequences previously classified as subtype A and 2-3 representatives of the
other subtypes. These included the recently described subtype 'J'. Gag sequences of the
env subtype 'I' were not available . The gag gene phylogenetic tree is based on a 337bp
unambiguously aligned region (positions 904-1240 in the HIVHXB2 genome). The scale
bars correspond to 5 changes per 100 nucleotide positions. Bootstrap values, based on
2000 bootstrap replications, are expressed as a percentage.
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As shown in Figure 5.4, the branch grouping SqlM, Sq2m and Pedl clusters
distinctly from all other subtypes. Although closely related, the Q cluster was distinct
from the A clade as shown by the bootstrap support of 99.8% of2000 resamplings.
The bootstrap support for the A clade was 64.2%, probably due to the presence of
recombinant sequences such as MAL, in the dataset. The low bootstrap support for the
A clade observed in this study was comparable with a previous report by Louwagie et
al. (1993) using the whole gag gene (66%). The placement of the Q clade with 337bp
was consistent in two other phylogenetic analyses, the Fitch-Margoliash (Fitch and
Margoliash, 1967) and maximum likelihood methods (Felsenstein, 1981). With both
methods, the Q branch clustered distinctly from the A clade and all other subtypes (data
not shown).
A likelihood test was used to test the significance of the main branch grouping
together the A clade. This test was based on the neighbour-joining phylogeny which
included all subtype A sequences and representatives of other subtypes. The new tree
derived from the collapse of the A clade branch to 0 branch length was not significantly
worse than the original tree at a 5% level of significance. In addition, bootstrap
analyses using only sequences of the A, B and the Q clades showed similar bootstrap
values to those obtained in the tree shown in figures 5.3 and 5.4. The bootstrap values
for the A, B and Q clade were 67.3%, 100% and 98.3% respectively. The inclusion of
reference sequences belonging to subtype D, a close clade to the B subtype but distant
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from subtype A did not change the placement of the Q clade. Indeed, the bootstrap
support of the Q clade remained high (98.1%) with a relative increase of support for the
main A clade branch (69.2%).
Additional analysis was performed using a longer sequence (754 bp) of the gag
region. Four sets of primers (see Materials and Methods: Figure 2.2) were used for
PCR and sequencing of this fragment ofproviral DNA from patient SqlM. The
sequence from this isolate was aligned with the Los Alamos reference sequences
(Myers et al., 1996), relative to positions 904-1898 in the HIVhxb2 genome. Where
nucleotide sequences were not available, the gaps in those regions (position 1145-1132
and 1446-1589) were removed from the analysis. As shown in figure 5.5, all the
reference sequences clustered in their original clades. Again, SqlM does not cluster in
any other subtypes but forms a separate group with GBZ126B (Figure 5.5). GBZ126B
is a sequence from Brazil that was originally classified as subtype F based on the
analysis within the env and gag regions (Myers et al., 1995). A more recent analysis
from Los Alamos suggests that GBZ126B is a recombinant between A and C subtypes
(Dr Brian Follet, Los Alamos, personal communication, 1997). A similar phylogenetic
placement ofSqlM and GBZ126B was also resolved using both the Fitch-Margoliash
(Fitch and Margoliash, 1967) and maximum likelihood methods (Felsenstein, 1981)
(data not shown).
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FIGURE 5.5. Placement of SqlM sequence in neighbour-joining tree of
the gag gene phylogenies (754bp)
C.ZAM18
5% Divergence
Neighbour-joining tree of partial pi 7 gag gene showing the placement of the SqlM
relative to previously classified sequences (reference) and Ped7 (from this study).
The gag gene phylogenetic tree was based on a 754bp aligned relative to HIVHXB2
(positions 904-1898, gaps removed). The scale bar represents 5% diversity.
Bootstrap value (% of 2000 resamplings) shown near the related branch.
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The placement of the Q clade (patients SqlM, Sq2M and Pedl) in HIV-1 group
M phylogeny was further investigated by examining a region of the envelope gene. It is
worth noting that the env region is located 5kb away from the gag region which
resulted in phylogenetic trees presented in figures 5.1, 5.3-4). The env sequences of the
patients in this study were obtained from single DNA molecules by a limiting dilution
approach (Simmonds et al., 1990). Analysis of the hypervariable region (V3/V4) of the
envelope glycoprotein (gpl20) was performed as for the gag region (see Chapter 2:
Materials and methods). A phylogenetic tree was generated based on 409bp
unambiguously aligned sites (relative to positions 7030-7439 in the HIV-1Hxb2
genome). Fifty four sequences, representing 10 previously classified subtypes and
several unclassified and recombinant sequences were aligned and phylogenetic analysis
carried out with the Q sequences. The result of this phylogenetic analysis is shown in
Figure 5.6 and is consistent with the previous observation. All the previously
documented sequences (Myers et al., 1996; Louwagie et al., 1993a; Louwagie et al.,
1993b, Kostrikis et al., 1995, Leitner et al., 1995) clustered in their original clades
with high bootstrap values (B: 99%, C: 80%, D: 100%, E: 100%, F: 100%, G; 80%, I:
100% and J: 100%). As expected, the two clades, A and H, which show very high
values of intersubtype distances and have very close neighbouring branches of either
unclassified sequences or clades, had relatively low bootstrap values (44% and 63%,
respectively). The low bootstrap support for the clade A could be due to the presence
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in the dataset of recombinant variants (e.g. ZAM184, CAR4081, K124A), consistent
with previous studies (Louwagie et al., 1993a, Louwagie et al., 1993b). More
interestingly, the sequences from this study (SqlM, Sq2M and Pedl) clustered
separately from all other previously classified subtypes (Figure 5.6), with this clade
supported in 100% bootstrap replicates. Fitch-Margoliash (Fitch and Margoliash, 1967)
and maximum likelihood (Felsenstein, 1981) analyses confirmed a consistent
placement of the Q clade (data not shown).
The pairwise mean distances between Q sequences and the representative
sequences of the previously described subtypes within env were calculated. The
distances of the nucleotide variation within the V3/V4 region between the Q clade and
the previously recognized subtypes were on average 31%, ranging between 26%% (Q
to A clade) and 39.8% (Q to D clade). The distance between Q and A (26%) is
comparable to the inter-subtype distance between B and D (mean: 28%).
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A reconstructed Neighbour-joining ofHIV-1 env gene phylogeny showing the distribution of
54 previously publihed env subtypes. The phylogenetic tree is based on an unambiguously
aligned 409bp region of the env gene (position: 7030-7439 in the HIVHXB2 genome). The
scale bar corresponds to 5 changes per 100 nucleotide positions. Bootstrap values, based on
100 bootstrap replications, are expressed as a percentage.
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AMINO ACID SEQUENCE CHARACTERISTICS OF THE Q SEQUENCES
(SqlM, Sq2M and Pedl).
The predicted amino acid sequences of the SqlM, Sq2M and Pedl gag and env
sequences relative to those of the previously documented subtypes are presented in
Figures 5.7.a. and 5.7.b. Because of the observed proximity of subtype A sequences to
Q sequences (SqlM, Sq2M and Pedl) (Figures 5.3, 5.4, 5.5, 5.6), in addition to the A
consensus sequence, individual deduced amino acid sequences were also included.
Within the sequenced env region, the amino acids of the sequences from this study
(SqlM, Sq2M and Pedl) showed 4 residues which were not found in any subtype A
reference sequence (figure 5.7a.). These consisted of glutamine (Q), asparagine (N),
methionine (M) and threonine (T) at positions 12, 48, 111 and 113 respectively. In
addition, a glycine (G) at position 131 was found in all the 3 sequences (SqlM, Sq2M
and Pedl) but was absent from the A reference sequences, with the exception ofZ321.
The principal neutralising domain situated at the crown of the V3 loop region was
represented by the motif GPGQ in all three sequences. However, the 2 N-linked
glycosylation sites normally found at both ends of the V3 loop were absent in 2 of the 3
Q sequences examined. In addition, three residues found in all Kimpese sequences
(SqlM, Sq2M and Pedl), but absent from all subtype A reference sequences used in
the analysis, were identified in the sequenced gag region (Figure 5.7b.). These
consisted of an arginine (R) at position 19, lysine (K) at position 52 and cysteine (C) at
position 72.
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FIGURE 5.7.a. Env (V3/V4) deduced amino acid of Q sequences (Sql, Sq2 and
Pedl) relative to sequences of previously described subtypes1.
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A. Z321 . . I. . . . . . K. N T.M. . ....—IS.— R— . . F. . . . . T. .
A.RW020 DKA K . . . G— . . . . . G H...AK.
A.D687 .R .K. R .G. . N..N—.H. R.R . K ....A..
A. NI .AN. K . . .G—.H. ...KT..
A.RW009 .H .NET L . .S. . . . . . — .H. . . . V Y T.NGTK.
A.UG275A 7999799 TT. T <p . —S . . . K .I..A..
A.UG273A . . . L . . . TT. K .G. . . . T . — ... . . . . S . .
A.VI191A G .E. K .S. . ...G--IH. R— .... . .Q T. . . .I..T..
A.DJ264A ..N.... . . T. G . —T . . . K ....SK.
A.DJ263A .QN.... .A. R . —T. . . . . . . S . .
A.DJ258A ..N.... .T. R . . S . . .G. . .—T. . . ....SK.
A.CARGAN .K. N T. I. . . SRT ...R--WH. IDG....T... .K Y E.NTT..
A.CARSAS . N. S F ..RR—MH. R— . . I. .DA. . . . V. . . Y .... AT.
A.CAR405 KN. R .G. . ...G—IH. PGQ.I.. ...KA..
A.CAR286 DS . G .G. . ....—I. .MHI R—S . . . K. V- TINKAK.
A.CAR402 DS . T . .R.—M. . .—T. . . T . . . Y ...KE..
A.CAR423 DS . R . . . Y . . .M—IPT .GQVI.. . .K K Y .I.KA..
A.KENYA . . N. . . . FAE. K . . M . —I. . N. ....A..
Q.SqlM . . . . L. . .T. 9 . . I. . ...G—IH. — N N. .I..PL.
Q.Pedl . . . . L . . .TN 9 . . I. . . . .G—IH. N N. A .1..PL.
Q.Sq2M . K. 0 ..XG—IHL N.N ..XXSQ.
AAA A A
B CONS .NES F, 9 IH. . . . R— . . . T 9 999 .I..AK.
C CONS V H N?S F, V. . . . . —T . . . .I.9.K.
D CONS 9 .NES CN. . . ?Y? . ..QR-.TP. 9 T, m9 9R999 9 .I.?A?.
F CONS H .NES ....—I? . R—.... 9 K ...GTQ.
G CONS ..V.... NKSIE 9 ....—I?F 9
H CONS KTN.... .K? . 9 J 9 9 --9 9 9 9 9 9 X 9 9 9
H.CA13 T.N.... .KN. V ..R.MRIG. R .—T.H. I .A .I.GAK.
H.VI557 T.N.... .KS. P --IS. .K Y .IT.ED.
I.CYH031 T.N.... .AKA K .G. . . .R. — ... .V.—TW.. I .E EY. .I.END.
I.CYH032 T.N.... AKA K .G. . .... — .HL . —TW. . . . E .I.GND.
J.SE7887 . . N . . . . .NKT E X.N. . X..G--IHM . —VL. . . .E N. . F, . I.ERD.
J.SE7022 X.N.... NXT K V. . . . . Y. . ..E.—IHM . —VL. . . . E N. F . I.XRD.
' The region of the env gene corresponds to positions 7064-7405 in the HIVhxb2 genome. The sequences from this
study (labelled 'Q') are aligned relative to the consensus sequences of all previously characterised subtypes. In
addition to the A consensus sequence, all individual subtype A reference sequences are included within the
alignment. Where a subtype is represented by only two reference sequences, a consensus is not presented. Potential
N-linked glycosylation sites are shown with lAAA' under the 'Q' sequences. Identical amino acid sequences are
represented by a dot (.); deletion to allow alignment of sequences by a dash (-). A question mark (?) indicates there
was not a predominant amino acid to be considered as consensus at this site.
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71 81 91 101 111 121 131 141
CONS.A N7TLQ7VATQLR7- -7F777NKT-77IIF7NSSGGDLEITTHSFNCGGEFFYCNTS7LFNSTW?????? N7T
A.SF1703 .K. . G. . N. . KS . .Y.—S. .AS. . . D..G. GG S .
A.U455 .R.I . Q. . E. . KK. .K.—N. . . . —. . .AS. . . .T G. ..I. GS
A.Z321 .D. SK..A...K. .H.—V.TS.TD...A .V G. .G. .L G.
A.RW020 .D. RG..KK..E. .H. KNK.-T...EK... . T I G. ES S.
A.D687 • R. .Q..EH..K. .Y.—K.N. . —. . . AHH . . R . N. D S.
A.NI .K. HQ.V...KT. .Y.--K.T. . —. . .A.PL. .V K. DNS S.
A.RW009 .R. .K..EK.SH. .Y.-E-.I..-T...K G. SKR G.
A.UG275A .E. .K.VS...T. . H.-G- — . . .G . T .R D..G. . . . .NG TS
A.UG273A KE. .K.VK...T. .HW .T AG. NK DS
A.VI191A .K. HQ. . I. . . E . .H.ITK.T...NS... S..G. E G.
A.DJ264A .N. .Q..I...K. .HS .T...A.P.. . T E. DNSL— H.
A. DJ263A .R. • Q K. .H. . ...— .. .A. .. . . T E. S.
A.DJ258A .E. .K K. .H. .T. . — . . .A . T R . S. ss
A.CARGAN .Q. .Q.VKK..T. . YW — . N. TKP. . G. . .S.KNE D.
A. CARSAS .K. .M..EE..K. .Q. — . . . D. P. . .V G. .K. .WGP S.
A. CAR4 05 DN. .Q..KK.YE. .V. —VX.T.H. . . T R . TD. YNI G.
A. CAR286 • Q. .K..EK..G. I. —N — . . . T . H . . V V.LLQYIS. . .S.TDT S.
A.CAR402 .T. .K..KK.GT. .1.—S . .NS. . . V R , D..R. . . I .K D.
A.CAR423 KNM RK...K.ES. .K. . . S . — . T . DKP. . . T ..IY.. . K. K. K G.
A.KENYA .T. .K.V.K..E. .Y.-GN . K. A S.G. TNMQES S .
Q.SqlM • Q. YNITV...K. H . —K — . H . NS . . . . .M.T. . G. . G. . K D.
Q.Pedl • Q. YNITV..LK. H . —K — . H . NS . . . . .M.T. . . ..R...GQ .G. .K D.
Q.Sq2M • Q. .R..E..HK. Y . —K — . R. NS . . . . .M.T. . G. .G.RT X.
AAA AAA AAA AAA AAA
B CONS .N. KQI-VK. . E77Q. - V.NQ. . . . P . BM ..T...TQ. 999
C CONS .E. ...7KK.AE. . H . P ~.K. .7. . . R . . . .Y P7.7.G.
D CONS .K. .Q..7K.GD? . LL— -T. . .KP. . . P 999 9
F~CONS E..7A?.KS. .H..-..7..-..K.NS... ..M.... R 9 9
G CONS 7EM. N 999 9 .1 77. . .T.NS.A. R . G. 7N7S — N?
H CONS 9 9 9 99 9 H9-- 99 - 9 p 9 99 9 9 ?K. 9
H7CA13 .DM. TK GK. .HL ..S.-K.Q.KP... .1 .1..M.. .A. TK. TTNT-- GS
H.VI557 KR. HE.VQ...E. .H.--N.Q...EP... .M ..M.T.. R . K. V S.
I.CYH031 .N. KWISEE.EK. .H.--P — . K.APH
I.CYH032 .D. KVISEE.KR. .L. —P --.K.APP
J.SE7887 .N. RR...K..E. .H. . . .
J.SE7022 .N. RR...K..E. .X. . . .
Figure 5.7. a. (continued)
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FIGURE 5.7b. Gagpi 7 deduced amino acid ofQ sequences (Sql, Sq2 and Pedl) relative
to sequences ofpreviously described subtypes'.
1 11 21 31 41 51 61
A CONS ELERFALNPSLLETAEGCQQIMEQLQSALKTG7EELKSLFNTVATLYCVHQRIDVKDTKEALDKIEEIQN
A.U455 . . .K T...G. . T.G. . .P. .0 .T. .R. Y V .N. . .M. .
A.VI5 9 . .T. . . I. . . P. .T. R A V .1 .M. .
A.VI310 . .T. . . I. . . P. .T. R T V E
A.VI57 . .T. . . L. . . P. • T. V E D. . . .K
A.K112 . . .K . .T. . .T. R
A.K88 . .D. .T. R
A.K29 . . T . . . I. . . . P. .T. .R. E...A... .L. .
A. K7 . . T . R .T. . R. Y RQ E
A. K98 ....G. . .T. . . . K. 0 . T. . R. Y
A. K89 . .T. . . . P. .T. . R. w.. 0 N
A.VI32 . . D. . . K. . .E. . . T. I. . Y V F. . . .K.
A.VI415 . .D. ....G. .L. . . P. .T. I. . Y . .K.
A.CI4 . .T. . . .A. .T. .R. Y
A.G141 ..D.. . . .S. . K .LG. . . P. .S. Y A EI
A.LBV23 ....G. . .G. . .T. 0 .T. H V . .R. . . .K
A.TN243 ....G. . I. . . .T .S. w.. E .V. .
A.TN245 G. R . . . TR . . .T .S. . .V. w , E .V. .
A.TN240 F . I. . . .T .s. w.. E .V. .
A.CI20 . . .G. L. . . .AH R .s. T w.. .1 V. . .
A.CI59 ....G. . . .D. L. . p . s. AT V w.. .1 . . .L .V. .
A.LBV23' ....G. L. . R .s. T w.. . . .L
A.CI51 : . I. .s. .R. w.. .1 .. .s
A.CI32 . .S. . T.T . F. .T .G .s. R Y , T w. . R , EI
A.IC144 ....GF L. . . . .T .s. V. . T .. I . IR
A.DJ258 ....G. L. . G ESK Y T V w.. .1 AV. .
A.CM238 ....G. . .V. . . I . . . . .T . S. w.. E .V. .
A.UG266 . . .K . .T. . . .R .T,. . . P. • 0 .A. .R . Y V EI .M. .
Q.SqlM . R . T.G. . .P. .0 .T. T . . , K E . .IV .E. .
Q.Pedl R . LG. . . P. o .T. IR. K E .E. .
Q.Sq2M . .K. . , R . . T.G. . .P. .0 .T. T . . Y K E K. . .RV .K. .
B CONS .V..Q. . .S. . .R. .LG. . .PS • Q .S. .R. .Y E .E. .
C CONS G. . .S. . , K. , TK . .P. • 0 .T. R •p ?? E.R .E. .
D CONS G. . .s.. .K. . TG . .P. 10 .S. •? F,. E .E.M • E. .
F CONS .1..G. . .s.. .RK .IG. . .PS • Q .S. .R. .Y V . F. . .VE . . .L .E. .
G.LBV21" G. . .T. . .LQ. . .PS • Q .T. A. V W.I G . EEV KR.K
G.VI191 . . .K G. . .T. . . ,R . .p. .0 .T. T . . Y . T EI...Q.. • QEV KA.K
H.VI525 G. . .S. . .T>. . T . . .p. .T. • 0. T.T. V .1 .S. . .V. .
H.VI557 D. D . T.. T.T . . .p. .T. • 0. T.T. .E.LK.A..
J.SE788' . .D. G. • S.K. • LV. . .p. • Q .TX I.. .Y EI...T.. .E. .
J.SE7022 . .D. G. . S . K. . T.V . .p. .0 .T. T . . Y EI...T.. .E. . X. . .
' The region of the gag gene corresponds to positions 904-1121 in the HIVHXb2 genome. The sequences from this
study (labelled 'Q') are aligned relative to the consensus sequences of all previously characterised subtypes. In
addition to the A consensus sequense, all individual subtype A reference sequences are included within the
alignment. Where a subtype is represented by only two reference sequences, a consensus is not presented.
Identical amino acid sequences are represented by a dot (.); deletion to allow alignment of sequences by a dash (-).
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5.2.4. IDENTIFICATION OF SUBTYPE 'J' IN KIMPESE
HIV strains from 2 patients (Sq42 and Sq57) could not be shown to cluster
with the established (A-H) reference sequences of the Los Alamos database (Myers et
al., 1996). Additional phylogenetic analysis was performed using the Los Alamos
database sequences (Myers et al., 1996) and the provisionally classified subtype J1
published by Leitner et al. (1995). Interestingly, these sequences, Sq42, Sq57_l and
Sq57_2 (the latter two are from the same patient), clustered strongly with the
sequences published by Leitner et al. (1995) and are supported by a bootstrap value
of 89% of 2000 replicates (Figure 5.8.). The average distance between Sq42 and
Sq57 was lower with the subtype J reference sequences (12.8%) than with any other
subtypes (distance to subtypes A: 17.3%, B: 19.1%, C: 19.3%, D: 18.9%, F: 23.9%,
G: 25.3%, H: 19.5%) and the Q clade (16.4%). Data of the envelope from these
Kimpese subtype J sequences were not available to confirm their classification in the
present observation.
In addition, two sequences (Ped7_l and Ped7_2) from a vertically infected
child showed a separate branch topologically related to subtype A (Figure 5.8).
These sequences were relatively distant from each other (12.3% nucleotide
difference), although found in the same individual.
' The gag sequences of the newly characterised subtype I were not available (Kostrikis et al., 1995).
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FIGURE 5.8. Phylogeneticplacement ofKimpese subtype 'J'.
Unrooted neighbour-joining tree based on 225bp long sequences from Kimpese (in
bold) aligned with previously published sequences (Myers et al., 1996). Bootstrap (in


































































Scale: each is approximately equal to the distance of 0.02413
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5.2.5. GENETIC RECOMBINATION BETWEEN SUBTYPE A AND
SUBTYPE H
Analysis performed using sequences obtained from a 29 year old pregnant
woman (Sq22M) resident in Kimpese revealed that the virus she was infected with,
phylogenetically, was an A/H recombinant. Two regions of the genome, (a) region of
225bp (position1: 906-1131) and (b) 242bp (position 970-1212) within the gag gene
obtained by sequencing of PCR product, were analysed as described earlier (see
materials and methods). As depicted in figure 5.9., the sequence from Sq22M
clusters with subtype A when the section (b) was analysed with reference sequences
from the Los Alamos database (Myers et al., 1995). The bootstrap support for the
'A' branch which holds together Sq22 and the reference sequences was 73% (figure
5.9.a). Interestingly, the Sq22M sequence clustered together with subtype H when
the (a) region was analysed (figure 5.9.b).




Maximum likelihood trees showing the placement ofa recombinant sequence
10% divergence
1
The trees constructed from two alignments: 225 base-pair spanning between 906-1131 (Figure
5.12.a) and 242 base-pairs (positions: 970-1212 relative to HIVHxb2) (figure 5.12.b). The trees were
constructed with the PHYLIP programme using the maximum likelihood and the Neighbour-joining






















For figure legend, see footnote in figure 5.9.a.
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5.2.6. FUNCTIONAL SIGNIFICANCE OF SUBTYPES AND pl7 DOMAINS
IN MOTHER-TO-CHILD TRANSMISSION OF HIV-1
Are some subtypes more likely to be transmitted from mother-to-child than
others? To date there is still no clear answer to this question. To provide further
information, it was intended to sequence all the HIV-1 variants of the transmitting
and non-transmitting mothers and apply statistical tests for likelihood of transmission
ofHIV-1 subtypes. The subtypes identified in Kimpese were grouped by the MCT
status of the mother (or child) (Table 5.3). Because of the small numbers of
sequences in each group and sampling error, it was not possible to make direct
comparison between the groups. Overall, subtype A was the predominant subtype in
Kimpese and was found in 28 (50%) out of 56 epidemiologically unlinked
individuals. Of 18 transmitting mothers, 9 (50%) were infected with subtype A. The
sample size was too small for a similar comparison with other subtypes.
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TABLE 5.3. HIV-1 subtypes andMCT status
Subtype Transmitters Non-transmitters Not known Total
A 9 14 5 28
C 0 10 1
D 3 115
F 1 10 2
G 1 2 14
H 2 7 3 12
J 0 2 0 2
Q 2 10 3
Recombinant 0 0 2 2
Total 18 29 12 59
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An alternative approach to investigate viral selection during MCT of HIV-1
was to examine the deduced amino acids corresponding to the nucleotide sequences
in the pi 7 gag region ofHIV-1 variants from transmitting (n=20) and non-
transmitting mothers (n=31).
The alignment of the amino acid sequences ofHIV-1 matrix protein pl7
deduced from the nucleotide sequences ofHIV-1 variants from transmitting and non-
transmitting mothers is shown in figure 5.10. In a previous study, Narwa et al.
(1996) identified 2 amino acid residues (glutamic acid and valine) which seemed to
be sufficient to distinguish transmitting from non-transmitting mothers. The
equivalent positions for these amino acids are 54 and 65, respectively, in figure 5.10.
In the same study (Narwa et al., 1996), within the major antibody site
[(KE)ALDKIEE(EQ)] (position 59-70), the KIEEEQN motif (figure 5.10, position
64-70) was also associated with MCT ofHIV-1.
The overall comparison of the nucleic and amino acid data did not show clear
evidence of sequences grouping by transmitting and non-transmitting status of the
mothers. Some motifs were conserved and others were more related to some
particular subtypes. The N-terminal region was generally conserved. At the putative
pl7 polymerisation site (Chazal et al., 1995), the ELERFA motifwas conserved in
43 (81.1%) of 51 HIV-1 variants (Figure 5.10.). There was substantial variability at
the C-terminal and was subject to statistical analysis. The KIEEEQN motif (residue
180
64-70), which was previously associated with transmission phenotype (Narwa et al.,
1996), did not show the same effect in this study. This motif was found only in 1
transmitting mother (PP4M) infected with subtype D virus (figure 5.10).
Furthermore, the presence of glutamic acid and valine at positions 54 and 65,
respectively (Narwa et al., 1996) showed no association with infection phenotype in
children born to HIV infected mothers. Ten out of 20 (50%) transmitted viruses
compared with 16 out 31 non-transmitted HIV-1 strains had glutamic acid at position
54 with no statistical difference between the two groups (p=0.9). Similarly, 4 viruses
in transmitting and 4 in non-transmitting mothers had valine at the 65th residue
(figure 5.10.).
However, within pi7 major antibody binding site [(KE)ALDKIEE(EQ)]
(position 59-70) (Boucher et al., 1990), the isoleucine at position 69 was associated
with protection from mother-to-child transmission ofHIV-1. Five of 20 transmitting
mothers in comparison with 20 out of 31 non-transmitting mothers had isoleucine
• • .9
residue at this position (Mantel-Haenszel's Chi : 7.45; p=0.006).
181
Figure 5.10. Gagpi 7 deduced amino acid sequences ofHIV-1 strains in Kimpese'
1 2 2 4 5 6 7
123456789012345678901234567890123456789012345678901234567890123456789012345
B.HXB2R ELERFAVNPGLLETSEGCRQILGQLQPSLQTGSEELRSLYNTVATLYCVHQRIEIKDTKEALDKIEEEQNKSKKK
Q.PP1M L. . S A. . .A T. . TK. F , K. V. . . .IV. . • C.Q.
D.PP4M L. . K TA .AI K A F, ... .0
A.PP8M L. . A, . Q.LIE. ST.K .K. .ILI...C... ...DV... M. . • N.Q.
A.PP9m ?L. . S A. . Q. • IE. .A.K..T.GTK. F .K.GV... L.KR..Q.
H.PP16M ..D...L.. A. . T, IE. .ARK..T.. .O. F.L ...DVT.. V RT?QN
F.PP19M ????Y.LI?s .K. I. . . .A RRV. . F.A.W. .F. . .KVNV... r,.. ..QQ.
D.PP21M I. K . IK. . .A FK DVR. M
Q.PP24M L. M K . .A T. T .V. . . .RV. ..C.Q.
A.PP32M L. AA. • Q. .ME. ..T.RA... .IK .F W. . .KK .VR. • M. Q.
A.PP37M 77, .s.. .A. • Q. .ME. KA... .IK .F..T...W.. .RK DVR. .V. .T. •.?.Q.
D.PP45M LD .K. .T. ..A.K .F . F,K . V?N .F, .M. ...CT.
A.PP51M L. .E. 0 .ME. .SA.KA... . F T Q.
A.PP55M L. 7> *?•? .ME. ..A.K..T. . F K DVR. T .... OS
G.PP56M L. .s.. .T. • Q. .MS. ..AI...T. . .K .RK GV. . .EEV. KHKR7.QQ.
A.PPed2 L. 0 .ME. ...IK.... . F K D. . . T ..NQQ.
PPed7 1 L. .s.. • Q. .IS. ...IK..T. . .K .V. . F. .V. .R??GR
A.PPedlO L. .T. • Q. .ID. ...IK . .K .F W. . .M. . M. ..N.Q.
A.PPedl2 L. .s.. .A. .0. .ME ..A.K..T. . .K .F GV. . , T . ER..Q.
H.PPedl3 1 L. .s.. .AG .LK .IE. M ..A.K..T. ..Q .F.L..V . .G .V. . .G GT. ..ARLT
U.PPedl6 L. .A. O . IV. . .A . .K F HK .Q.QQ.
D.PPed3el L. K . IA. . .AI . .K A F Q
A.PPed4el L. .s.. .V. • 0. . TF, ..A.K..T. . .K .F , , K .V. . .T,. .R..Q.
H.PPed5el ...D...L. .A. T, . IE. ..ARK..T. • -Q .F.L DVT. s V ••RQQQ
A.PPed6el S.L. A?. • Q. .ME. ..T.RA... .IK .F W. . .KK .VR. .M. Q.
D.PPed9el LD .K. .T . . .A.K . .K .F . F,K .VR. , F, .M. ...R..
A.PPedllel L. .s.. .G. .K. . TF, . SA. R. . T. N.K DV. . .T,. Q.
A.PPedl4el L. .A. • Q. .ME. KA... .IK .F..T...W.. .R. DVR. .V. .T. ..Q.TQ
A.PPedl5el L. ..o
NON-TRANSMITTED STRAINS
Q.PN2M L. .s.. .K. . .A T. .TK , .K .V. . .K. . .RV. .K. ..C.Q.
H.PN5M L. • D. . .A. .0. T,. . ..A.K..T. . .0 .N.LITV . .G GV. . F,. . .F, .V. . T . .•.QQ.
A.PN6M L. .s.. . .A. .Q. . ?E ..A.K..T. .F .KQ.AV.. .1. .REQQ.
G.PN7M L. . ? . .T. .Q. • MS. ..AIK..T. . .K .VR. .EEV. KA. K..QQN
H.PN10M . .0
A.PN12M . . .D .s.. .G. .0. . .F,. ..A.K..T. . TK .F . .K . .R. .T,. Q.
A.PN13M L. .s.. . .T. • 0. ,MF, ..A.K..T. DV. . .T. QR
H.PN15M L. . .0
G.PN17M L. G 0 MS . .A T. K .V. . . F.F.V. KT K..QQ.
C.PN18M L. . .D • QR • IE. . .A. H..T. . .K . . .L .E. • VQ. KKL ...QQ.
D.PN20M I. A .K. . TF,. . . .1 IV..C.. , F,, DVQ. .F, .M. .K.
D.PN23M I. K TK FK DVR. M
H.PN25M L. SA T, . IE. ..AIR..T. V. .L DVG. F T krnqq.
H.PN26M L. ?. . .A. .L. .1. I ..A.K..T. . .Q . . .L CRI .V. . .G .T. •-NQQ.
A.PN27M L. .A. .L. .IE. I . .A.K . .Q .H .KA • V. . .K . I. .RN.QE
H.PN28M L. .T. .L. .IE. ..A.K..T. . -Q .F.L..V .V. . .E .K .1. ..NQQ.
A.PN29M L. • A. O TNK. .ST.K.... . .K .F..1...W.. DV. . T, M ....Q.
H.PN30M L. .s.. . SAG T, . IE. T ..A.K..T. . .Q .F.L..V.... P.K 0 T •NRQQT
A.PN31M L. A O MF, . . T . K. . . . .V. . T ....Q.
H.PN33M K.L. .A. .LH .IE. .K.A.SL..V . .Q . . .L F. . . .K • A. . .E .1. S..QQ.
A.PN34M SG?. .s.. . .A. • Q. .MK. .SA. K..T. . F .NT DV. . .ILHNNIQ.
A.PN36M S?L. • 0. .IKK...Q.
A.PN38M L. .0. Q.
A. PN40M L. . .D T, .MF. T ..AIR.... . .K ....I.V.... nv. . T ....Q.
D.PN41M L. K LIAHV A. . IS .VGFKV.. F M
J.PN42 SA ON T ..A....T. .??MKV.. T ....Q.
A.PN43M L. .s.. . , A. • 0. , MF, K .TK .F..T...W.. DVR. o.. .LK .1. . .Q.—
A.PN49M ..A....T. K .F R T ....Q.
F.PN53M
A.PN54M L. K .ME. ..AIK.... . .K A. . . . DVT. OK
PN57 1
1 The KIEEEQN motif (position 64-70) (Narwa et al., 1996) was not associated with transmission of HIV-1 from
mothers to their children.
5.3. DISCUSSION
5.3.1. VALIDITY OF THE P17 REGION FOR SUBTYPING HIV-1
Reliable phylogenetic analysis for subtype inference ofHIV-1 strains depends
on the lengths and the region of the genome analysed. Most studies of the molecular
characterisation ofHIV-1 subtypes have been using the gag and/or env section of the
genome. With the discovery of genetic recombination of different HIV-1 subtypes, it
was suggested that at least the full gag and full env genes should be sequenced for
accurate analysis (Sabino et al., 1994; Leitner et al., 1995; Diaz et al., 1995; Sharp et
al., 1994). However, recent studies by McCutchan et al. (1996) using the
bootscanning approach, demonstrated multiple recombination points in isolates
which were allocated to a single subtype based on the analysis of partial gag and env
sequences. It was suggested that the only way to obtain a firm subtype allocation is
by sequencing a full HIV-1 genome and then to search for recombination break
points. To obtain the full length genome for even one individual sequence is both
time-consuming and technically demanding. This makes it difficult, if not
impossible, to make any attempt to perform large-scale molecular epidemiology
studies ofHIV 1.
If the aim of the research is merely to determine the circulating subtypes,
regardless whether they are recombinant or not, then a partial length of the genome
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could be used. Indeed, it was demonstrated in this study that a gag region as short as
22 5bp was enough to determine the circulating subtypes in our study population. In
this study, the subtypes identified based on analysis of a partial genome ofHIV-1 are
not definitive, although the results are comparable with published reports based on a
similar approach. Nevertheless, if a subtype is found based on the analysis of a full
or partial genome, this establishes that the subtype is present in that population,
whether in a pure or recombinant form.
5.3.2. HIV-1 SUBTYPES AND TRANSMISSION
The epidemiology ofHIV-1, as for many communicable diseases, is not totally
dependent upon behaviour patterns of the population. For example, the biological
features of the infectious agent can be very important in determining the spread of the
epidemic. However, there are numerous factors that could influence transmission,
some related to the host and others to the agent.
In this chapter, the aim was to investigate the molecular characteristics of the
pi 7 gag region ofHIV-1 isolates in Kimpese and to determine if there was any
association between particular features and mother-to-child transmission. The pi7
region was used because (i) it plays a very important role during the replication of the
virus, (ii) is the source of cell tropism and (iii) determines viral phenotype. Direct
sequencing was performed on pi 7 region ofHIV-1 isolates from mothers and
children. This provided new information on the HIV-1 subtypes present in the region
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of Kimpese. In addition, the alignment of deduced amino acids was used in a
comparison of transmitting and non-transmitting mothers.
The background against which the present study of the molecular characteristics
ofHIV-1 in Kimpese was carried out consisted of (i) this is a rural population in a sub-
Saharan country, with (ii) a low and stable seroprevalence (Green et al., 1994) and (iii)
a relatively low mother-to-child vertical transmission rate. Against this background, it
could be postulated that the predominant virus in Kimpese might a less virulent
subtype. It was possible that, HIV-2 or similar virus, could be present in this
population. However, HIV-2 was not found in mothers and children studied here. In
some West African countries where both viruses co-circulate, it has been observed
that while the prevalence ofHIV-1 is increasing steadily, HIV-2 incidence was
falling dramatically (de Cock et al., 1993). Although these two viruses are genetically
similar, they have remarkable differences in their global distribution, their
transmissibility and pathogenic potential (Poulsen et al., 1989; Ancelle et al., 1987;
Kanki et al., 1992; Pepin et al, 1991). There is also evidence about the lower
heterosexual infectivity ofHIV-2 compared to HIV-1 (Kanki et al., 1994). The
degree of infectivity has also been studied among HIV-1 subtypes, particularly a
comparison of subtype B and subtype E. Based on in vivo studies, it has been been
proposed that subtype E has increased ability, compared to subtype B, to infect
Langerhans' cells, the possible target ofHIV-1 in the mucosa of the vagina, the
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cervix and the penile foreskin (Cohen, 1996a,b; SotoRamirez et al., 1996). However,
more recently, two independent reports by Pope et al. (1997) and Dittmar et al.
(1997) have not supported the preferential tropism of subtype E for epithelial
dendritic cells. This questions the early reports that the rapid heterosexual spread of
subtype E in Thailand was the result of its higher infectivity compared to that of
subtype B.
Phylogenetic analysis showed that the sequences from Kimpese isolates are
distributed among several clades, which correspond to their respective subtypes. At
least seven subtypes ofHIV-1 and another possible new subtype were found in the
Kimpese population. Subtype A, the predominant subtype was found in about half of
the sequences obtained in this study. In Kenya (Zachar et al., 1996) and in Cote
d'lvoire (Janssens et al., 1994) where subtype A is also predominant, the epidemic has
been rising rapidly in the last decade. If this indicates that subtype A is more
transmissible than the other subtypes, it would be expected that in locales with a low
and stable seroprevalence, such as Kimpese, this subtype should be rare. This was not
found in the study reported here.
Can the high heterogeneity ofHIV-1 subtypes we have observed in this
population suggest that the epidemic has reached its plateau level? Does the
heterogeneity ofHIV-1 subtypes suggest that the virus has been present in Kimpese for
a long time? Kimpese is situated on a main road and many people travel through every
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day ; thus it is possible that the subtypes found have been gathered here from different
sources including Kinshasa, and other major towns in the region. Our own studies have
shown that the seroprevalence was higher among individuals who lived in bigger cities
than those from rural regions (Green et al., 1992). As in Gabon where a high diversity
ofHIV-1 subtypes and a low and stable seroprevalence has been observed over nearly
10 years (Delaporte et al., 1996), the heterogeneity ofHIV-1 subtype does not provide
clear explanation of the trend ofHIV-1 epidemic in Kimpese.
Twenty-three subtype A sequences were identified, ofwhich 9 derived from
transmitting and 14 from non-transmitting mothers. Due to the small numbers of other
subtypes found it was not possible to make a direct comparison of their role in MCT.
5.3.3. GENETIC RECOMBINATION
Intersubtype recombination occurs when an individual is infected with at least
two subtypes. The rate of intersubtype recombination has been estimated to be about
2% per kilobase per replication cycle (Hu & Temin, 1990). With the high
heterogeneity ofHIV-1 subtypes observed in this study, the identification of
intersubtype recombinants was not surprising. As it was not possible to analyse more
isolates, it is possible that there may be many more recombinant subtypes circulating
in the Kimpese region. The allocation of an isolate to a subtype should not be
considered as definitive, if based on the sequencing of a subgenomic region, as was
carried out in the present study. Any subtype assignment based on a partial sequence
only relates to the nucleotide sequence of the region analysed. For example, a sample
classified as subtype A based on a partial region of the gag gene may be another
subtype in another section of the genome if the virus happens to be a recombinant. It
is possible that the proportions ofHIV-1 subtypes observed in Kimpese do not reflect
their real distribution. Although 50% of the isolates were subtype A and the rest was
falling into several other subtypes, it is not known which isolates were recombinants
since the sequencing was carried out only on a partial length of the genome. In
addition, the presence of recombinant subtypes can constitute a confounding factor
for any study which investigates the relative role of different subtypes in
transmission. In the previously published studies (SotoRamirez et al., 1996; Ou et
al., 1993; Kalish et al., 1995) which measured the relative ability ofHIV-1 subtypes
to infect Langerhans cells, there was no consideration about the advantages that
recombinant subtypes may have over non-recombinant strains. In fact, it has been
shown that specific inter-subtype recombination can lead to SI phenotype (more
virulent than NSI) compared to non-recombinant virus (Nyambi et al., 1996).
5.3.4. A NEW SUBTYPE OF HIV-1?
In this study, in addition to 7 previously described subtypes, the phylogenetic
analysis allowed the identification of another clade of sequences which appear to be
highly divergent, yet similar to each other. The topological presentation of the trees
were consistent both in the gag region and the envelope (754bp and 409bp of the gag
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and env regions, respectively). With the current knowledge of recombination in HIV-1
(Sabino etal., 1994; Leitner et al., 1995; Diaz et al., 1995; Sharp et al., 1994), every
report suggesting the identification of a new subtype must be interpreted with
circumspection. As suggested by McCutchan et al. (1996), unless the sequence of the
full genome of the virus is available, it is not possible to decide conclusively if the
isolates identified in this study belong to a new subtype, or whether they possess
mosaic structures. Additional investigations are needed to establish the full range of
subtypes present in Kimpese, DRC.
5.3.4. pl7 MATRIX PROTEIN MOTIFS AND MCT OF HIV-1
Most of the previous attempts to study the molecular characteristics of
transmitted and non-transmitted HIV-1 have focused on the hypervariable region of the
env gene, the gpl20 (Briant et al., 1995; Wolinsky et al., 1992; Scarlatti et al., 1993;
Mulderkampinga et al., 1993; Broliden etal., 1989; Rossi etal., 1989, Parekh et al.,
1991; Halsey et al., 1992; Wang et al., 1995; Robertson et al., 1992). However, the
results are conflicting. Not much work has been done using the matrix pi 7 region to
determine if there are any molecular factors associated with mother-to-child
transmission. The importance of studying the pi 7 region has been outlined in a
previous section (5.3.2.).
In this study, 51 amino acid sequences deduced from nucleotide sequences
were grouped by their transmitting and non-transmitting phenotypes. The alignment
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included two important functional domains, mainly the polymerisation site (mer 8 to
19) at the N-terminal (Chazal et al., 1995) and the antibody binding site (mer 59-70)
at the C-terminal (Boucher et al., 1990) (figure 5.9). The ELERFA motif at the N-
terminal of the polymerisation site was more conserved, irrespective of the MCT
phenotype. In addition, detailed statistical analysis of all residues between the
polymerisation site and the antibody-binding site showed no specific amino acids nor
motifs which were associated with transmission or protection. Detailed analysis was
carried out on the C-terminal ofpi 7 region, which showed a high degree of variation.
A previous study observed an association between some amino acid residues and
motifs with mother-to-child transmission phenotype ofHIV-1 isolates (Narwa et al.,
1996). In this study, there was a significant difference between the transmitted and
non-transmitted HIV-1 strains for the presence of glutamic acid and valine at positions
54 and 65, respectively, in the same partial gag region analysed by Narwa et al.
(1996). It was not evident that the KIEEEQN motif was sufficient to distinguish the
transmitting and non-transmitting mother, as shown by Narwa et al. (1996). Instead,
within the KIEEEQN motif, there was a statistically significant difference between
transmitted and non-transmitted isolates for isoleucine at position 69. The
mechanism by which isoleucine at position 69 may prevent the transmission ofHIV-
1 from mothers to children remains unclear. It is possible that anti-pl7 antibodies
may bind more effectively to the principal pi 7 antibody binding site which have
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isoleucine instead of other residues at position 69. The effective binding of
antibodies to this epitope could prevent the transmission ofHIV-1 from mothers to
their children. Indeed, it has been suggested that antibodies to pi 7 matrix can be
protective and their decline has been associated with rapid disease progression
(Ljunggren, et al., 1990). In addition, an induced mutation (deletion) within the
antibody-binding site ofpi 7 has a significant effect on viral entry during the
replication cycle (Yu et al., 1992). It is important that this early observation is
confirmed as it could lead to the development of simple and quick peptide-based
assays to detect antibodies to pi7 peptides.
In summary, this study has revealed a remarkable heterogeneity ofHIV-1
subtypes in a relatively small population of isolates sequenced. Although subtype A
seemed to be the predominant subtype in this region, it was not possible to make direct
comparison between subtypes to determine their relative transmissibility. There were
no specific nucleotide motifs which could be associated with mother-to-child
transmission ofHIV-1. However, the analysis of amino acid sequences showed a
statistically significant difference between isolates from transmitting and non-
transmitting mothers for isoleucine at position 69. The mechanism by which isoleucine
within the antibody binding domain of the pi 7 matrix affects transmissibility remains
unclear. Regarding the low and stable seroprevalence, several factors could have played
a direct role in maintaining the the epidemiology ofHIV-1 unchanged for several
years. The role played by different subtypes could not be demonstrated in this study.
However, the most important finding described in this chapter is the description of a
high heterogeneity of different HIV-1 subtypes in a rural district ofAfrica. This study
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has contributed in the global research of the mapping ofHIV-1 subtypes and laid
important foundations for future studies in the region including the development of any
proposed vaccine to protect against HIV-1 in this region. Thus, a vaccine may need to
include antigens from more than one subtype to be effective against multiple co-
circulating HIV-1 variants (Mascola et al., 1994). Because subtype B has thus far not
been found in Kimpese, it is theoretically possible that current candidate vaccines,
based on virus strains from North America and Europe (subtype B), may have little or
no protective effect if used in an area such as Kimpese. An HIV-1 vaccine may
therefore need to take the form of a 'subtype cocktail' which takes representative
antigenic patterns of all antigenic variants ofHIV-1 into account. However, although
cross-clade neutralisation may broaden the protective effect of such a vaccine, there is
no guarantee that it would protect against the challenge of every subtype. The
continual mutational changes and common occurrence of recombination (Velandia et
al., 1995) within the HIV-1 genome (Velandia et al., 1995) constitute two major
obstacles. Because some genomes have mosaic structure (Velandia et al., 1995), it is
not possible to make a direct comparison of the role of different subtypes in the spread








The use ofmolecular techniques such as nucleic acid sequencing (Chapters 2
and 5) and the heteroduplex mobility assay (HMA) (Delwart et al., 1993) are so far
the only accurate means of classifying HIV-1 into different subtypes. However,
sequencing is currently restricted to specialised laboratories, due to its complexity
and cost. Although HMA has been used as an alternative method to sequencing,
highly divergent subtypes like subtype A may be difficult to subtype (Delwart et al.,
1993; Delwart et al., 1994). Most, if not all previously published studies on
molecular subtyping ofHIV-1 are biased due to the small number of samples tested.
To overcome sampling bias there is a need for a simple, cheap and accurate
technique suitable for large scale epidemiological mapping ofHIV subtypes.
Therefore, the World Health Organisation Network for HIV Isolation and
Characterisation proposed the use of serological methods to determine subtypes of
HIV-1, using a consensus ofV3 loop amino acid sequences of each subtype as the
antigenic source for the detection of subtype specific antibodies (Cheingsong-Popov
et al., 1994). However, V3 loop consensus peptides are prone to high cross-
reactivity with antibody when they are used in indirect ELISA for subtyping ofHIV-1
(Pau et al., 1993; Ubolyam et al., 1994; Pau et al., 1994; Cheingsong-Popov et al.,
1994).
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Cheingsong-Popov et al. (1994) used a panel of subtype A to E monomeric
peptides in an enzyme immunoassay (MPEIA) and were able to predict the viral
subtype in some samples, but encountered several cases of cross-reactivity. In order
to solve this problem, it was necessary to retest samples using a peptide limiting
ELISA. With this, up to 90% correlation was achieved between serotype and
genotype (Cheingsong-Popov et al., 1994). These results need to be confirmed and
applied in a much bigger population. Kimpese is such an ideal setting to evaluate the
use of this method (Cheingsong-Popov et al., 1994), particularly in view of the high
heterogeneity ofHIV-1 subtypes present in this population (see chapter 5).
In a pilot study on samples from Kimpese, using the method as described by
Cheingsong-Popov et al. (1994), over 95 percent of samples were reactive with more
than one peptide. If all cross-reactive samples had to be retested with an additional
subtype limiting ELISA as suggested by Cheingsong-Popov (1994), this would be too
expensive and time consuming. Alternatively, a branched peptide competitive
ELISA (BPC-ELISA) was developed. The assay was based on a panel of peptides
containing consensus amino acid sequence of subtypes A, B, C, D, E and F. The
BPC-ELISA uses the principle of blocking cross-reactive antibodies to allow subtype
specific antibodies binding to subtype specific V3 loop peptides to be detected in
plasma ofHIV-1 infected individuals. The BPC-ELISA was based on the method
previously developed by Simmonds et al. (1993), which achieved the subtyping of
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hepatitis C virus by creating a similar competition between high concentrations of
peptides with type specific antigen.
The BPC-ELISA developed in this study has several advantages over the
previously described methods which use monomeric peptides without competition.
The advantages of BPC-ELISA include a high sensitivity (the test needs only 0.5pl of
plasma) and the ability to detect immunodominant antibodies by the inhibition of
cross-reactivity.
6.2. PATIENTS, MATERIALS AND METHODS
A total of 367 plasma samples were collected from 205 mothers during
pregnancy (158 samples) and soon after delivery (299 samples). Of 205 mothers, the
outcome of vertical transmission was known in 157 pregnancies: 34 children were
infected (MPP, mother positive and child positive, 61 samples) and 123 uninfected
(MPN, mother positive and baby negative, 214 samples) with HIV-1 as monitored by
follow up of antibody in sequential paediatric samples. Forty-seven HIV-1 positive
women gave birth to babies who were not followed up long enough to determine
whether they were infected or not (MPI, mother positive and indeterminate child, 77
samples). In addition, there were 5 stillbirths (9 samples). The control group
consisted of 22 HIV-1 uninfected mothers (38 samples).
Samples were tested initially by a monomeric peptide-based indirect ELISA
then with two branched peptide ELISAs (indirect and competitive ELISA). The
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indirect ELISA using monomeric peptides was the same as that described by
Cheingsong-Popov et al. (1994), except that the conjugate was diluted 1 in 10,000 in
stead of 1:100. The branched peptide based indirect ELISA was employed using the
same reagents as in the monomeric V3 loop peptide ELISA, except that the amount
of the peptide needed on the solid phase was 10 fold less than that used in
monomeric peptide based ELISA (lOpg/ml) (see chapter 2).
The hypothesis was that, samples from an individual infected with an 'X'
genetic subtype should have detectable antibodies to the consensus peptide of the
same peptide, an autologous peptide. Here, the concept 'autologous peptide'
designates consensus amino acid sequences deduced from nucleotide sequence of the
same subtype. After testing a sample with a panel of different subtype peptides, the
highest optical density over the cut off (OD/CO) was recorded and used to assign the
subtype of that peptide. The results of the serotype, which were determined by
indirect and competitive ELISAs, were compared with genetic subtypes (chapter 5).
197
6.3. RESULTS
6.3.1. SPECIFICITY AND SENSITIVITY OF INDIRECT AND
COMPETITIVE ELISAs
Of 39 samples collected from HIV-1 negative individuals (n=39) tested by the
commercially available Abbott Recombinant ELISA, 38 were non-reactive with any
of the monomeric and branched peptides (A-E) used in the indirect ELISA and
competitive ELISAs. The sample which was reactive with the branched peptides (A-
F, lng/well) was non-reactive with all the monomeric peptides in the A-E panel. RT-
PCR performed on this sample was positive suggesting that this sample was a false
negative by the screening assays (Abbott 2nd and 3rd generation ELISAs) and also by
the monomeric (A-E) V3 indirect ELISA. This suggests that the branched peptide
based ELISAs developed here are highly specific.
The sensitivities of the ELISAs using monomeric (A-E) (92%) and branched-
peptides (A-F) in indirect (92.7%) and competitive assays (95.6%) did not differ
significantly (p>0.05). Substantial cross-reactivity was observed in indirect V3
ELISAs with branched or monomeric peptides in 289 of 305 (94.8%) and 260 of 332
(78.3%) reactive samples, respectively. Only 9 (4.4%) of 204 reactive samples
remained cross-reactive after inhibition of non-specific antibodies in competitive
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ELISA. An example of cross-reactivity as was often observed in indirect ELISA is
shown in figure 6.1 [note inhibition of cross reactivity in 6.1 (2)].
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FIGURE 6.1. Difference between indirect (1) and competitive (2) ELISAsfor HIV-1
serotyping
The same samples were tested twice by indirect ELISA and by competitive ELISA.
The solid phase of both assays were identical: Each well of the rows A, B, C, D, E
and F were coated with lng of peptides A, B, C, D, E and F, respectively, in
carbonate coating buffer. The wells in SPC (sample's positive control) and SNC
rows (sample's negative control) were coated with lng of a cocktail of equal volume
ofA-F peptides. The liquid phase of the indirect ELISA (1) contained 0.5pl of test
negative control (TNC, columns 1-4) patient samples (columns 5-12) in lOOpl of
sample diluent. Only diluent was put in the SNC wells to act as negative control for
the sample in indirect ELISA. For the competitive ELISA (2), the sample mix (0.5pl
sample + 100pi diluent) was preincubated with lOng of equal volume of all the
peptides minus the one found in the solid phase. The SPC wells of the competitive
ELISA did not have the competitors added. HIV-1 positive samples were expected to
show reactivity in the SPC. In the SNC well, a cocktail of all the peptides (A-F) was
added to achieve maximum competition with the sample. The ELISA procedure was
carried out the same way as described in Chapter 2: Materials and metods. Note





6.3.2. AGREEMENT BETWEEN GENETIC SUBTYPE AND V3 SEROTYPE
Plasma samples from individuals infected with HIV-1 variants of known
genotype (n=58) as determined by the sequencing of the HIV-1 proviral DNA within
the pi7 gag region were tested by ELISA to determine the subtype serologically. The
serotype of each sample was determined as previously described (Cheingsong-Popov
et al., 1994): by assigning to the sample the subtype of the peptide which shows the
highest reactivity in comparison with other peptides on the panel. The reactivity of
the sample (serotype) was noted and compared with the genetic characteristics
determined by sequencing (genetic subtype). The results of this comparison are
depicted in table 6.1. Overall, there was a low degree of agreement between the
sample genetic subtype and the serotype. In testing samples with the monomeric
peptide-based ELISA, only 5 (13.8%) of 36 samples gave a subtype which matched
the genetic subtype. Twenty-two further samples obtained from individuals infected
with subtype F, G, H, J, Q and recombinant A/H and F/H showed reactivity to
heterologous (A-E) peptides present on the panel. If the the genotype of these
samples was not known, they could be assigned to the wrong subtype by serological
ELISA.
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TABLE 6. l.a. HIV-1 serotype (indirect ELISA) and genotype (sequencing)
SEROTYPE (determined by monomeric peptide-based-V3 loop ELISA)
Genot A A/C B B/D C D E NEG Total
A 2 1 3 0 20 2 0 2 30
D 1 0 1 0 1 3 0 0 6
F 0 1 0 0 0 0 0 0 1
G* 1 0 0 0 0 1 0 0 2
H* 3 1 4 1 1 2 0 1 13
J* 0 0 0 0 1 0 0 1 2
Q* 1 0 0 0 0 0 1 0 2
A/H* 1 0 0 0 0 0 0 0 1
F/H* 0 0 0 0 0 1 0 0 1
Total 9 3 8 1 23 9 1 4 58
genot: genotype; * peptide of these genetic subtypes not available.
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Serotype (determined by branched peptide-based-V3 loop ELISA)
13
re
A A/C B c CF F NEG NT Total
A 1 0 3 10 2 4 0 0 20
D 0 0 0 0 0 1 0 5 6
F 0 0 0 0 0 1 0 0 1
G* 0 0 1 0 0 2 0 0 3
H* 2 0 1 1 0 0 1 5 10
J* 0 0 0 0 0 0 0 2 2
Q* 0 2 0 0 0 0 0 2 4
A/H 0 0 0 0 0 0 0 1 1
F/H* 0 0 0 2 0 0 0 0 2
Total 3 2 5 13 2 8 1 15 49
genot: genotype; * peptide of these genetic subtypes not available. NEG: negative;
NT: not typable
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6.3.3. V3 (A-F) SEROTYPE AMONG HIV-1 TRANSMITTERS AND NON-
TRANSMITTERS
Despite the poor agreement between the genetic subtype and the serotype
observed in this study and elsewhere (Pau et al., 1994), the reactivity to V3 loop
produced the grouping of samples in what has been recognised as 'V3 loop serotype'.
The V3 loop serotype was therefore considered independently from the genetic
subtype. Using both the indirect and/or the competitive ELISAs with monomeric or
branched peptides, samples were classified into several HIV-1 V3 loop serotypes.
The distribution ofHIV-1 V3 loop serotypes was compared between mothers who
transmitted (n=34) and those who did not transmit (n=l 17) HIV-1 to their offspring
(Table 6.2). There was no statistical difference between the transmission status of
the mothers and the V3 loop HIV-1 serotype as determined by the serological assays.
There were 137 mothers whose samples were serotyped as subtype A, B, C, D and E
using the monomeric peptides but there was no statistically significant preferential
transmission of one serotype over the others (p=0.48). Similary, the competitive
ELISA for more precise detection of the immunodominant V3 serotype confirmed
this observation with a p value of 0.42 for the distribution of different subtypes
among transmitting and non-transmitting mothers (table 6.2).
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6.3.4. LEVEL OF ANTI-V3 LOOP ANTIBODY AND TRANSMISSION OF
HIV-1
The reactivity of the sample to a given subtype consensus peptide is
expressed as the highest optical density over the cut off to a peptide. This was the
criterion for assigning the serotype of the patient. The reactivities of antibodies to
V3 loop peptides were identified in maternal blood samples, as shown in Table 6.3
and figure 6.2.
Overall, the level of antibody, as expressed by the highest optical density
value over the cut-off, in samples collected from transmitting mothers and non-
transmitting mothers did not differ significantly. The means of the highest OD/CO
values (against V3 loop peptides) in 62 samples from transmitting mothers and 205
non-transmitting mothers were 7.8 (range 0.3-21.9) and 8.4 (range 0.26-21.75).
When samples were grouped by the time of collection (i.e. during pregnancy or soon
after the birth of the child, there was no statistically significant difference between
transmitting and non-transmitting mothers, with regard to their reactivity to V3 loop
peptides. These values did not differ from those recorded from mothers with
indeterminate children. Even if the indeterminate mothers could be classified, it is
unlikely that the difference in the reactivity to V3 loop peptide between transmitting
and non-transmitting mothers will become significant.
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FIGURE6.2.ReactivitytoV3lo ppeptidesinsamplesfrHIV-1infectedmoth rs(PP,PNa d)ncon rols(NN). Samplesobtain dfromHIV-1infected(PP,n=34;PNl12andI,n=48)a dunifectecontr lm thers(NN,n=32)wetest dagai s apanelofV3looppeptides(A-F).Thehig stticaldens yov rthcutff(ODMAX)wasre orded.T eODM Xvalu sinsample fromPP,NIandNchildrenarsummarised.Thehorizontallininsidtheb xrepres tstm diathoriz t lendth boxrepresentthlow randuphinge(th25thand7 percentiles).Thdiffer ncbetw einfect dmothersw otransmi t dHIV-1
totheirchildrenandn n-transmittingm thewasn ts atis icallysignifica t(p>0.5).
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FIGURE6.2.ReactivitytoV3looppeptidesinsamplfrHIV-1nfec edmother(PP,PNnI)c rolNN) NNPI MaternalstatusPP
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6.4. DISCUSSION
The use of serological methods for the identification of antibodies to the V3
loop has been of interest for the measurement of the level of antibodies available to
hamper transmission ofHIV-1 from mother-to-child. These methods are also useful
for the mapping ofHIV-1 subtypes in different populations. Unfortunately, the data
so far remain controversial between different research groups. The data presented in
this study provide important background information for future in Kimpese or similar
settings in Africa.
6.4.1. LACK OF CORRELATION BETWEEN GENETIC SUBTYPE AND
SEROTYPE
Because the tools used for genetic characterisation of different subtypes
remain restricted to specialised laboratories, the widespread mapping ofHIV-1
subtypes remains a goal still to be reached. It was important therefore to evaluate a
simple serological assay based on well-defined principles for characterisation of
immunodominant antibodies which bind to synthetic peptides. Peptides derived from
the V3 loop consensus sequences have been proposed as antigens for indirect ELISA
to detect subtype specific antibodies (Cheingsong-Popov et al., 1993; Pau et al.,
1993; Pau et al., 1994; Cheingsong-Popov et al., 1994; Baillou et al., 1993). In all
these studies, the detection by indirect ELISA of subtype specific antibodies in the
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plasma ofHIV-1 infected individuals was masked by the presence of cross-reactive
antibodies (which reacted with different V3 loop peptides). In a previous study,
using an indirect V3 peptide ELISA and another assay to discriminate cross-reactive
antibodies, Cheingsong-Popov and coworkers (1994) were able to predict the correct
genotype in approximately 90% of cases of genotype A, B, C and E. This method
was applied in this study (Cheingsong-Popov et al., 1994), using the A-E consensus
peptides. Recently, the genetic sequencing ofHIV-1 strains in Kimpese suggests that
there are highly divergent subtypes circulating within our study population. There
were additional subtypes such as F, G, H, J and another as yet unpublished new
subtype. The peptides for these subtypes were not included in the Cheingsong-Popov
study. Ignoring the samples ofwhich the peptides were not available (subtype F, G,
H, J and Q; see chapter 5), only 5 (13%) out of 37 plasma were correctly subtyped
using the Cheingsong-Popov method. The remaining samples showed a high degree
of cross-reactivity and the use of peptide limiting ELISA (Cheingsong-Popov et al.,
1994) did not improve the test. As high as 70% tested by indirect V3 loop
monomeric ELISA and 90% by branched peptide ELISA needed additional peptide
limiting ELISA, another time consuming step for serotyping of cross-reactive
samples. A one-step method, a competitive V3 loop ELISA, was therefore devised to
solve this problem.
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In a previous study, Simmonds et al. (1993) achieved the subtyping of
hepatitis C using a competitive assay (Simmonds et al., 1993). A similar peptide
competitive ELISA was developed to detect immunodominant antibodies to one
particular subtype-specific V3 loop consensus peptide, by blocking cross-reactive
antibodies with an excess of other subtype-specific peptides. In theory, complete
inhibition of cross-reactive antibody would allow serotyping of samples and the
results could be correlated with genotyping data. In contrast, while we have blocked
non-subtype specific antibodies, in most cases, there was a lack of correlation
between serotype and genetic subtype ofHIV-1. This means that the
immunodominant antibodies detected after inhibition of cross-reactive antibodies
using the currently proposed panel of peptides are not subtype-specific. Why is there
such a mismatch between the results by serotyping and genotyping in this study?
Several factors could explain this mismatch. Firstly, subtyping by sequencing
depends on the analysis of several hundred nucleotides of at least the gag and the env
genes ofHIV-1 whereas the serotyping assay uses only a small region of the genome
at the tip of the V3 loop. With the emergence ofmany recombinant strains,
subtyping with a small section of the viral nucleic acid provides only a partial
classification. Only the analysis of the full genome ofHIV can determine a pure
subtype and rule out the possibility of genetic recombination. Therefore, it is
213
unlikely that the serotyping assay, based on a restricted region of the V3 loop subtype
consensus peptide, would produce accurate results.
Secondly, there may be a lack of subtype-associated-blocking activity. HIV-1
neutralisation depends not only on the association of antibodies with linear epitopes
but also with conformational epitopes within the monomeric and oligomeric forms of
the envelope glycoprotein (Earl et al., 1994; Ho et al., 1991; Moore et al., 1994;
Stamatatos and Chengmayer, 1995). The icosahedral-symmetry of the envelope
glycoprotein (Gelderblom et al., 1987) may give rise to complex epitopes which may
give unpredictable associations between antibody activity and the genetic subtype. If
there is such a thing as a subtype-specific epitope, it is still unclear how the intra- and
inter-clade variation would affect its structure and its presentation to antibodies.
Thirdly, the intra-clade cross-reactivity and the lack of correlation between
genetic subtypes and serotype could be caused by the similarity of the peptides
currently being used in the serotyping ofHIV-1. For instance, the consensus peptides
for subtype A and subtype C have the same tetramers GPGQ and differ only at 2 sites
of 14 amino acids found at the crown of the loop. The GPGQ is the main feature for
subtype A, C, D, E and is supposed to be important in the neutralisation ofHIV-1.
The drive to use the V3 loop region for subtyping derives from early observations of
constraints on sequence variation among isolates in the United States (LaRosa et al.,
1990). The conservation within the tip of the V3 region, as suggested by LaRosa et
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al (1990), is probably more relevant to vaccine development than for serological
subtyping ofHIV-1 as demonstrated in the present study.
Finally, could the length of the peptide explain the discrepency between
genotype and V3 loop serotype? Previously, it was suggested by Barin et al. (1996)
that the low cross-reactivity observed by Cheingsong-Popov et al., and others
(Cheingsong-Popov et al., 1993; Pau et al., 1994; Cheingsong-Popov et al., 1994)
could be due to the use of short V3 sequences. The lesser extent of cross-reactivity
between subtype specific V3 loop peptides observed in these studies may explain
why some studies have observed a correlation between serotype and genotype. The
same peptides were used in the present study but with different results1. It is
therefore concluded that the length of the branched peptide was irrelevant in the
accuracy of the V3 peptide based ELISA for serotyping ofHIV-1.
6.4.2. POTENTIAL FOR INTRA-CLADE CROSS-REACTIVITY
It is recognised that the third hypervariable domain, the V3 loop of the env
glycoprotein, is biologically important during HIV-1 infection. It induces an
antibody response with restricted neutralization activity in vitro (Harrowe and
Chengmayer, 1995; Vancott et al., 1995; Poignard et al., 1996; Pinter et al., 1993;
Kliks et al., 1993). A broad reactivity of peptides made from consensus sequences of
1 The testing was carried out by myself at Dr RC Cheingsong-Popov laboratory at St. Mary's Hospital, in
London. I received technical help from Mr Simmon Lister, a co-author of the studies which used the
monomeric peptide ELISA (Cheingsongpopov et al., 1993; Pau et al., 1994; Cheingsongpopov et al., 1994).
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different subtypes was observed in this study. For example (Table 6.4), with a single
consensus peptide representing subtype A, it was possible to detect about 69.6% and
80% ( with monomeric peptide and branched peptide, respectively) HIV-infected
individuals. Even with a peptide derived from the consensus amino acid of subtype
B sequences 88 (61.5%) of 143 patients tested appeared to have antibodies against it.
Subtype B is the predominant clade in Europe and North America, but thus far not
found in Kimpese (Chapter 5). The reactivity was increased to 86% when a cocktail
ofA-F peptides was employed in the solid phase of the ELISA plate (Table 6.4). A
similar observation was reported by Baillou et al. (1994), who found that V3
consensus sequences representing North American/European and African isolates
were also highly cross- reactive, binding 94% and 77%, respectively, of sera
collected from HIV-1 individuals originating from various parts of the world.
The broad reactivity of sera to heterologous peptides of the same and different
clades may have relevance to the future development of an HIV-1 vaccine. If cross-
clade reactivity also reflects cross-clade neutralisation, a vaccine against HIV-1 based
on one particular clade should be able to induce protection against the challenge of
any other HIV-1 clades. However, as is the case of Influenza virus, if every single
clade or variant has a specific neutralising epitope, an HIV-1 vaccine would have to
take into account all the variants circulating in a region. From the data presented
here, it can be postulated that V3 consensus sequences able to induce broadly
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reactive antibodies to neutralisation region, irrespective of the clade of the virus,
represent the best candidates for vaccines.
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TABLE 6.4. Reactivity ofmonomeric and branchedpeptides-basedELISA
A. BRANCHED PEPTIDES
ELISA RESULTS
PEPTIDE POSITIVE (%) NEGATIVE (%)
A fl4 (79.7) "29 (20.3)
B 88 (61.5) 55 (38.5)
C 112 (78.3) 31 (21.7)
D 73 (51.0) 70 (49.0)
E 19 (13.3) 124 (86.7)
F 116 (81.1) 27 (18.9)




PEPTIDE POSITIVE (%) NEGATIVE (%)
A HO (69.6) ~48 (30.4)
B 76 (48.1) 82 (51.9)
C 112 (77.2) 36 (22.8)
D 79 (50) 79 (50)
E 86 (54.4) 72 (45.6)
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6.4.3. LACK OF ASSOCIATION BETWEEN LEVEL OF MATERNAL
ANTIBODY TO V3 LOOP AND THE PROTECTION OR ENHANCEMENT
OF VERTICAL TRANSMISSION
Early in vitro studies suggested that antibodies to the envelope gpl20 protein
may have some effect in preventing the binding of the virus to cellular receptors
(Skinner et al., 1988; Linsley et al., 1988). This observation was extrapolated to in
vivo situations to suggest that antibodies might be effective in preventing infection in
adults and in children. However, interpretation of the results of studies remains
controversial, particularly about the role played by maternal antibodies to the
envelope V3 loop in the prevention ofmother-to-child transmission ofHIV-1.
Whereas some reports have suggested that anti-V3 loop antibodies have a role in
reducing transmission (Broliden et al., 1989; Rossi et al., 1989), others (Parekh et al.,
1991; Halsey et al., 1992; Wang et al., 1995; Robertson et al., 1992), do not support
this observation. All the previous studies differ in the methods used to detect
maternal antibodies to the V3 loop. This is particularly the case for the peptide used
on the solid phase in ELISAs as often only one peptide derived from one strain was
used as the basis for comparison of reactivity. It is possible that patients with low or
no antibodies to the peptide on the solid phase may be infected with another highly
divergent strain. Also, the use of different peptides could possibly explain the
conflict between different studies.
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A different approach is, however, to use peptides whose structure suggests
they would be more likely to detect antibodies to V3 loop irrespective of the number
of different HIV-1 subtypes circulating in the studied population. In the present
study, the structure of the peptides had two specificities to provide an alternative way
to assess the relative association between the level of maternal antibodies and the
transmission ofHIV-1 from mothers to their children. Firstly, the peptides were made
from consensus sequences of amino acids derived from HIV-1 subtypes. Previous
studies suggested that the use of consensus sequences rather than isolated specific
sequences improves the sensitivity ofV3 peptides assays (Baillou et al., 1993;
Cheingsong-Popov et al., 1994). Secondly, the peptides were constructed in a
branched format. Peptides constructed in such way have an advantage over
monomeric peptides in being able to detect traces of antibodies in biological fluids
(Marsden et al., 1992). Despite the attempt to increase the sensitivity and specificity
to detect the antibodies in the plasma, there was no association between the presence
and level of maternal antibodies to V3 loop to either protect children from, or make
them more susceptible of acquiring HIV-1 from their mothers. In addition, de novo
peptides based on indigenous sequences were used, but the level of antibodies to V3
loop was similar in transmitting and non-transmitting mothers (figure 6.2.). This
study produced no evidence to support the proposal that pregnant HIV-1 infected
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mothers should be passively immunized with antibodies to V3 loop in order to
prevent the transmission of the virus to their offspring.
6.4.4. EFFECTIVENESS OF COMPETITIVE ASSAY FOR THE
DETECTION OF IMMUNODOMINANT ANTIBODIES AGAINST V3 LOOP
CONSENSUS PEPTIDES
Cross-reactivity is common in assays to detect antibodies to peptides of the
V3 loop ofHIV-1. This was observed elsewhere (Baillou et al., 1993; Barin et al.,
1996) and in this study. It has been shown also that cross-reactivity impairs accurate
serological subtyping ofHIV-1 (Barin et al., 1996; Pau et al., 1994; Cheingsong-
Popov et al., 1994). Therefore, a method to inhibit cross-reactive antibodies was
considered as an alternative means of serotyping HIV-1. In this study, a significant
reduction of cross-reactivity from 78% and 90% (in indirect ELISA with monomeric
and branched peptides, respectively) to 4.4% was achieved when samples were tested
by a de novo competitive method. Barin et al. (1996) have used a similar cross-
reactive antibody inhibition method but cross reactivity was still a problem in 26% of
samples tested. The persistence of cross-reactivity in some samples could be due to
infection with recombinant subtypes or with two or more different subtypes. It was
evident that the immunodominant antibody to the principal neutralising domain of
HIV-1 is not subtype specific and these findings are in accord with previous studies
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(Moore et al., 1996; Kostrikis et al., 1996) but conflict with those ofCheingsong-
Popov et al. (1994).
222
CHAPTER 7:
GENERAL DISCUSSION AND CONCLUSION
223
Risk factors are important both in forecasting the the course of the epidemic
and also in defining possible types of intervention. At the start of the study, Kimpese
presented two unique epidemiological features. Firstly, the town of Kimpese is
located in a rural part of an African country, where no other HIV studies have been
conducted. Secondly, we have previously observed a low and stable seroprevalence
over a 5-year period (Green et al., 1994) and a low MCT rate, for which the reasons
have been unclear. It was planned to carry out a multidisciplinary study of risk
factors associated with HIV transmission in Kimpese. On the one hand, it was
important to study the behavioural factors of pregnant women in Kimpese in order to
define potentially relevant host factors1. On the other hand, it is necessary to study in
parallel the factors associated with the virus and to link them with host-associated
factors.
The aims of this project were to: (i) develop a simple and inexpensive method
for early diagnosis ofHIV-1 infection in children (Mokili et al., 1996), (ii) to
investigate the distribution ofHIV-1 subtypes in Kimpese, and to establish their
biological significance in mother-to-child transmission. Because of the large number
of cases studied in this project, the determination ofHIV-1 subtypes by sequencing
was too expensive and time consuming. A serological method to subtype large
1 Dr Louise de la Gorgendiere, of the Department of Sociology, University of Edinburgh, visited Kimpese to
carry out a pilot study on social behaviour. No funding was available for the continuation of the study.
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numbers of samples containing antibodies to the principal neutralising domain of
HIV-1 was developed.
Serological methods for the identification ofHIV-1 infected individuals
(adults) are readily available and relatively simple to perform. The sensitivity and
specificity for most of these techniques are often very high, approaching 100%. These
methods, however, particularly those based on the detection of IgG antibodies in
biological secretions have little diagnostic significance in children born to HIV infected
mothers. This is due to the presence ofpassively acquired maternal IgG in children
which can be detected at 12, or even 15 months of age, and so delay the diagnosis of
HIV-1 infection until 18 months (Newell et al., 1995). Highly sensitive techniques
for the diagnosis ofHIV-1 in children such as the polymerase chain reaction (PCR)
and virus culture are not always available in most African countries. As mentioned
previously in this study (chapters 1 and 4), there are other highly sensitive techniques
which can achieve early diagnosis ofHIV in children. However, they require a high
level of technical support and expertise, which are a limiting factor for most
laboratories in developing countries. The development of a simpler diagnostic tool
was a prerequisite for the identification ofHIV-1 in children in this population
(Mokili et al., 1996).
The physical and functional properties of immunoglobulins were taken into
account for the development of diagnostic assays to detect HIV infection in children.
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The generally accepted principle, that IgA and IgM 'do not cross' the placental barrier,
suggested that the detection of these antibodies in children born to HIV-1 positive
mothers indicates infection with HIV-1. In testing children born to HIV infected
mothers, it was not expected that IgM and IgA anti-HIV would be detected in neonatal
samples. One of the most important findings in this study was the detection of IgM and
IgA in neonatal samples of children born to seropositive mothers beyond 3 months of
age. Below this age some uninfected children did give positive results for specific IgA
and IgM. Is maternal contamination of the babies' samples the likely explanation?
Simple cross-contamination at collection of cord blood is not relevant as there was no
significant statistical difference between cord blood and other neonatal samples. The
analysis of sequential samples showed a decline and complete loss of IgA and IgM by 3
months of age, despite the continuing detection of IgG antibodies. This indicates that
the IgA and the IgM results were not due to cross-reactivity with IgG. Leakage of
maternal antibodies into the fetal circulation is a possibility and may be due to the
placental infections noted in both transmitting and non-transmitting pregnancies.
Therefore it was concluded, based on the evidence from this study, that IgA and IgM
class anti-HIV-1 do cross the placenta (Mokili et al., 1996). The observation of IgA
and IgM in neonates was also found in another HIV MCT study of a small number of
European children (Connell et al, 1992). Other studies that have not found IgA and
IgM in neonatal samples may have used less sensitive methods than the capture assays
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used in the present study. In the light of the findings, it is not surprising that the results
ofmost assays for detection of IgA and IgM, which are often used for the diagnosis of
various congenital infections (including Rubella, Syphilis, toxoplasmosis, CMV, EBV
etc.) are often confusing. Although not demonstrated in this study, it is possible that
maternal IgA and IgM (probably also IgE) raised against any other infectious agents in
mothers may cross the placenta. Results of tests where IgA antibodies and more often
IgM are routinely used for diagnosis of congenital infection should be interpreted with
caution.
Although IgA and IgM assays were not very useful for diagnosis with neonatal
samples, their detection in the blood of children of 3 months and older ages is highly
predictive of infection. By contrast, other anti-HIV reactivity in screening tests,
predominantly IgG, is often present in uninfected children even beyond 12 months of
age, making it difficult to distinguish infected from uninfected children. The method
employed in this thesis was shown to be not only robust, but more importantly,
simpler and cheaper than most tests for IgA anti-HIV which require preliminary
removal of IgG and an immunoblot assay. At present, the cost for an IgA test should
not be more than 2 to 3 dollars (US): immunoblot reagents cost approximately 10-
fold more.
In addition, the fact that it was not possible to determine accurately when
children became infected affected the overall sensitivity of the IgA capture assay.
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Indeed, PCR positivity was also delayed in children suspected to have become
infected postnatally. Therefore, it was not surprising to find that the sensitivity of the
IgA capture assay in breast-fed infants was imperfect. In circumstances where other
diagnostic tests (PCR, culture, etc.) are not available, the IgA capture method, by 6
months of age, would identify three-quarters of babies who have been infected in
utero, perinatally or postnatally.
After identification of infected patients, the characterisation ofHIV-1 in
mothers and children was studied. Two approaches (molecular and serological) were
employed for this purpose. The molecular work included the phylogenetic analysis
of the pi 7 region ofHIV variants found in mothers and children. The main
objectives were to identify which HIV-1 subtypes were present in the population and
to examine in infected children, transmitting and non-transmitting mothers and to
determine whether there were intrinsic differences in transmission between different
HIV-1 subtypes. The analysis of the genetic sequences from this population was
compared with the Los Alamos database (Myers et al, 1996)1. Interestingly, a high
degree of genetic heterogeneity ofHIV-1 was observed with 7 subtypes and another
outlier clade. No clear differences between transmitting and non-transmitting mothers
1 Some of these sequences have now been removed as there is now an emphasis on
the use of full length reference sequences for subtype allocation. The most recently
published reference sequences were used to re-analyse the data from Kimpese and the
results were consistent with those included in the thesis (figure 7).
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were observed within the pi7 gag region, although a single isoleucine was found to
be associated with protection against MCT ofHIV-1. Although a high heterogeneity
ofHIV-1 subtypes was observed in the study group, it would require a large sample
size to make a direct comparison between the different subtypes and MCT.
Sequencing using a large number of samples is not only time consuming, but
expensive and requires specialised expertise.
A serological method, developed by Cheingsong-Popov et al. (1994) for
detection ofV3 subtype specific antibodies, was applied in this study. The method
was modified by the use of highly sensitive branched peptides (Marsden et al., 1992),
in a newly developed competitive ELISA based on a well characterised approach of
inhibition of cross-reactive antibodies (Simmonds et al., 1994). It was shown that
the immunodominant antibodies to the principal neutralising domain of theV3 loop
ofHIV-1, are not subtype specific. In addition the level ofmaternal antibody to PND
was not associated with either transmission or protection of the babies.
The lack of correlation between genetic subtype and serotype could be due to
various factors, including the similarity ofV3 loops from different subtypes
(Cheingsong-Popov et al., 1994, Myers et al, 1996). It is also possible that the lack
of correlation between serotype and genetic subtype may be due to genetic
recombination.
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In the future, the full-length sequencing ofHIV-1 subtypes present in this
population is required. Such a study will allow the identification of 'pure' HIV-1
subtypes (as opposed to recombinants) and determine their relative risk of transmission
from mother-to-children. A serological approach may still be relevant if alternative
immunodominant domains within the HIV-1 genome are identified. However,due to
the high level of recombination, the same difficulties encountered in this study may
arise.
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FIGURE 7: Re-analysis of sequence data with the newly published reference sequences
(Leitner et al., 1997) j~pj
Neighbour-joining pi 7 gag gene phylogeny showing the distribution of this study sequences relative
to A-H and J reference sequences . The phylogenetic tree is based on an unambiguously aligned
330bp region of the gag gene (positions 907 to 1236 in the HIVHXB2 genome) and distance estimated
using the maximum likelihood method with transition/transversion ratio of 3. The major clades are
designated by capital letters and are boxed. Reference sequences are represented by lower case letters
as follows : subtype A : a, VI32 ; b, K89 ; c, 92UG037 ; d, U455. subtype B : e, RF ; f, OYI; g,
JRFL ; h, HXB2. subtype C : i, 92BR025 ; j, ZAM18 ; k, UG268 ; 1, ETH2220. Subtype D : m,
ELI; n, NDK ; o, Z2Z6 ; p, 94UG114. subtype F : q, VI69 ; r, 93BR02 ; s, BZ162 ; t, VI174.
subtype G : u, 92NG003 ; v, 92NG083 ; subtype H : w, 90CF056 ; x, VI557 ; subtype J : y,
SE7022 ; z, SE7887. Sequences from patients in this study are lebelled with numerical numbers in the
tree and were as follows : subtype A :Mothers : 1, Sq3M ; 2, Sq6M ; 3, Sq8M ; 4, Sq9M ; 4*, Ped4el;
5, Sql 1M ; 6, Sql2M ; 7, Sql3M ; 8, Sq27M ; 8*, Pedl5el; 9, Sq29M ;10, Sq31M ; 11, Sq32M ; 11*,
Ped6el; 12, Sq34M ; 13, Sq36M ; 14, Sq37M ; 15, Sq38M ; 16, Sq39M ; 17, Sq40M ; 18, Sq43M ;
18*, Pedl4el; 19, Sq49M ; 20, Sq51M ; 20*, Ped8el; 21, Sq52M ; 21*, Pedl lei; 22, Sq54M ; 23,
Sq55M ; 24, Sq59M ; 25, Ped2 ; 26, Ped7 ; 27, PedlO ; 28, Pedl2; subtype C : 29, S18M ; 30, Pedl6;
subtype D : 31, Sq4M ; 31*, Ped3el; 32, Sq20M ; 33, Sq21M ; 34, Sq23M ; 35, Sq41M ; 36, Sq58M;
subtype F : 37, Sql9M ; 38, Sq53M; subtype G: 39, Sq7M ; 40, Sql7M ; 41, Sq47M ; 42, Sq56M ;
subtype H : 43, Sq5M ; 44, SqlOM ; 45, Sql4M ; 46, Sql5M ; 47, Sql6M ; 48, Sq25M ; 49, Sq26M ;
50, Sq28M ; 51, Sq30M ; 52, Sq33M ; 53, Sq35M ; 54, Sq60M ; 55, Pedl3; subtype J : 56, Sq42 ; 57,
Sq57M. The samples (58, SqlM ; 58-*, Pedl ; 58-2*, Pedlb-el; 58-3*, Pedlc-el; 59, Sq2M ; 60,
Sq24M) from patients which did not accurately cluster with any of the published sequences were
grouped in the 'Q' (query) clade. The scale bar corresponds to 5 changes per 100 nucleotide positions.
Bootstrap values (shown if above 70%) are based on 100 bootstrap replications.
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Paediatric/Reproductive Medicine Ethics of Medical Research Sub-Committee
Protocol 33/87: The Natural History of Human Immunodeficiency (HIV) Virus
Infection in Rural Zaire
The Standard Form of Application, Protocol, Information Sheet and Consent
Form, submitted by you in respect of the above project have been considered
by the Ethics of Medical Research Sub-Committee, and I am pleased to advise
you that the Sub-Committee have agreed to grant ethical approval to this
project.
Please note that if new ethical issues arise you should consult with
the Chairman or myself to ascertain if a reapplication requires to be made.
APPENDIX 2: Consent form for entry in the study
(Translated from Lingala and Kikongol
It is very good children are in good health. However, children can catch disease and
even die as a result of it. There are several diseases, which can cause damage to
children. These include measles, malaria, tuberculosis and AIDS.
At Institut Medical Evangelique, there is a project, which provides service for children
to help them have to fight various diseases. The projects carried out research on these
diseases, including AIDS, and information obtained will help the researchers to
understand these diseases and to provide policy for better care for Zairian children.
The health of the mothers is also very important for their children. If they carry some
infectious agents when they are still pregnant, they can pass the disease to their children
during the pregnancy, at delivery or later through breast-feeding (the breast milk is the
BEST food for the baby).
To be invited to join the project is very important for you and your baby. The project
team members will provide immunisation for your baby. Immunisation will protect
your child against measles, tuberculosis, poliomyelitis, tetanos and diphteria.
The project will cover the cost of the delivery at IME hospital, CIZA, Cite and Lamba.
The project medical team will examine the baby at birth, at 3, 6, 9, 12, 15, 18 and 24
months and every time when the baby is unwell. No money will be asked for the care
provided. The project will also pay for the transport to and from the hospital
Consent: The project was clearly explained to me. I understand that the project will
provide care for my child and carry out research during the first 2 years from birth. I
will bring the baby to the scheduled clinic for immunisation and routine examination





APPENDIX 3: Classification for HIV infection in children (CDC, 1992).
CLASS P-0. INDETERMINATE INFECTION
Infants <15 months born to infected mothers but without definitive evidence ofHIV
infection or AIDS
CLASS P-l. ASYMPTOMATIC INFECTION
Subclass A. Normal immune function
Subclass B. Abnormal immune function
Hypergammaglobulinemia, CD4 lymphopenia, decreased CD4-to-CD8 ratio, or absolute
lymphopenia
Subclass C. Immune function not tested
CLASS P-2. SYMPTOMATIC INFECTION
Subclass A. Nonspecific findings (at least two for >2 months)
Fever, failure to thrive, generalised lymphadenopathy, hepatomegaly, splenomegaly,
enlarged parotid glands, persistent or recurrent diarrhoea
Subclass B. Progressive neurologic disease
Loss of developmental milestones or intellectual ability, impaired brain growth, or
progressive symmetrical motor deficits
Subclass C. Lymphoid interstitial pneumonitis (LIP)
Subclass D. Secondary infectious diseases
Category D-l. Opportunistic infections in CDC case definition
Bacterial: mycobacterial infection (noncutaneous, extrapulmonary, or disseminated);
nocardiosis
Fungal: candidiasis (oesophageal, bronchial, or pulmonary), coccidiomycosis, disseminated
histoplasmosis, extrapulmonary cryptococcosis
Parasitic: P. carinii pneumonia, disseminated toxoplasmosis with onset >1 month of age,
chronic cryptosporidiosis or isosporiasis, extraintestinal strongyloidiasis
Viral: cytomegalovirus disease (onset >1 month of age), chronic
mucocutaneous/disseminated herpes (onset >1 month age), progressive multifocal
leukoencephalopathy
Category D-2. Unexplained, recurrent, serious bacterial infections (two or more in 2 years),
Sepsis, meningitis, pneumonia, abscess of an internal organ, bone/joint infections
Category D-3. Other infectious diseases including persistent oral candidiasis, recurrent
herpes stomatitis (at least two episodes in 1 year), multidermatomal or disseminated herpes
zoster
Subclass E. Secondary cancers
Category E-l: Kaposi's sarcoma, B cell non-Hodgkin's lymphoma, or primary lymphoma of
brain
Category E-2. Other malignancies possibly associated with HIV
Subclass F. Other conditions possibly caused by HIV: including hepatitis, cardiopathy,
nephropathy, hematologic disorders, dermatologic diseases.
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APPENDIX 4: Phyloqenetic tree showing the placement of previously
documented sequences
A reconstructed maximum likelihood tree of a partial length ofpi 7 gag gene
phylogeny showing the distribution of 83 representatives gag subtypes. The
phylogenetic tree is based on an unambiguously aligned 225bp region of the gag
gene (position: 907-1131 in the HIVhxb2 genome). The scale bar corresponds to 5
changes per 100 nucleotide positions. The reference sequences were as follows:
Subtypes A: 1.U455, 2.IBNG, 3.VI59, 4.VI310, 5.VI57, 6.K112, 7.K88, 8.K29,
9.K7, 10.K98, 11.K89, 12.VI32, 13.VI415, 14.CI4, 15.LBV23, 16.TN2431,
17.TN245, 18.TN240, 19.CI20, 20.CI59, 21.LBV2310, 22.CI51, 23.IC144,
24.DJ258, 25.TN238, 26.G266; Subtype: B: 27.SF2, 28.BZ167, 29.PH153,
30.PH136, 31.TBI32, 32.BZ190, 33.LAI, 4.HXB2R, 35.MN, 36.JH31, 37.JRCSF,
38.JRFL, 39.0YI, 40. NY5CG, 41.NL43, 42.CDC41, 43.HAN, 44.CAM1, 45.RF,
46.D31, 47.UG280, 48.YU2, 49.BCSG3C, 50.P896, 51.3202A12, 52.3202A21,
53.GAG46, 54.MANC, 55.GAG314, 56.GAG22, 57.GAG15, 58.WEAU160;
Subtype C: 59.UG268, 60.SM145, 61.ZAM18, 62.ZAM19, 63.ZAM20, 64.DJ259,
65.VI313; Subtype D: 66.ELI, 67.Z2Z6, 68.NDK, 69.VI205, 70.G109, 71.K31,
72.UG274, 73.UG270, 74.SE365, 75.VI203; Subtype F: 76.VI174, 77.VI69,
78.BZ163B; Subtype G: 79.LBV217, 80.VI191; Subtype H: 82.VI525, 83.VI557.
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APPENDIX 5: Evolutionary distance between sequences collected in
Kimpese, Democratic Republic of Congo.
The distance matrix was obtained using the two-parameter Kimura method contained
in the MEGA software (Kumar et al., 1993). The distance between two sequences is
situated at the intersection point inside the rectangle of the main diagram. The
sequences are represented by numbers (1-62) shown in bold on the far left column
and the far bottom row and were as follows: 1. A.Sq3M, 2. A.Sq6M, 3. A.Sq8M, 4.
A.Sq9M, 5. A.Sql 1M, 6. A.Sql2M, 7. A.Sql3M, 8. A.Sq27M, 9. A.Sq29M, 10.
A.Sq31M, 11. A.Sq32M, 12. A.Sq34M, 13. A.Sq36M, 14. A.Sq37M, 15. A.Sq38M,
16. A.Sq39M, 17. A.Sq40M, 18. A.Sq43M, 19. A.Sq46M, 20. A.Sq48M, 21.
A.Sq49M, 22. A.Sq51M, 23. A.Sq52M, 24. A.Sq54M, 25. A.Sq55M, 26. A.Ped2,
27. A.PedlO, 28. A.Pedl2, 29. C.Sql8M, 30. C.Pedl6, 31. D.Sq4M, 32. D.Sq20M,
33. D.Sq21M, 34. D.Sq23M, 35. D.Sq41M, 36. D.Sq45M, 37. F.Sql9M, 38.
F.Sq53M, 39. G.Sq7M, 40. G.Sql7M, 41. G.Sq47M, 42. G.Sq56M, 43. H.Sq5M, 44.
H.SqlOM, 45. H.Sql4M, 46. H.Sql5M, 47. H.Sql6M, 48. H.Sq22M, 49. H.Sq25M,
50. H.Sq26M, 51. H.Sq28M, 52. H.Sq30M, 53. H.Sq33M, 54. H.Sq35M, 55.






4 16.2 112 15.0
5 20.1 14.9 15.4 17.1
6 16.0 152 182 9.6 16.4
7 15.6 9.1 10.7 10.7 132 13.5
8 18J 142 16.6 152 17.6 212 13.8
9 17.7 14.9 9.0 152 152 182 11.6 17.0
10 16.2 13.9 10.1 122 13.7 14.4 8.1 16.8 132
11 192 15.1 122 14.6 142 15.6 122 172 11.1 11.7
12 16.5 10.1 142 152 16.4 162 11.1 17.7 142 142 16.6
13 15.7 13.9 9.6 112 13.8 14.4 10.7 14.4 11.1 8.7 122 12.7
14 175 12.0 12.0 132 13.6 13.7 12.1 182 10.9 14.4 10.0 152 13.5
15 17.8 10.1 11.7 112 10.0 12.7 6.6 13.8 10.6 10.1 10.6 12.7 9.1 9.9
16 16.5 13.7 11.1 11.1 112 13.7 8.0 142 12.1 10.6 13.7 142 10.1 12.0 55
17 18.9 17.8 12.7 16.7 152 182 11.1 172 14.5 9.0 142 17.7 122 142 10.6 12.1
18 17.1 152 112 16.6 13.6 16.4 13.0 19.9 122 14.7 13.7 17.0 15.9 4.9 142 14.1 152
19 11.8 9.0 14.0 9.0 12.7 13.4 6.3 162 15.1 10.1 14.1 13.4 135 13.7 10.6 105 132 14.4
20 25.0 202 202 222 19.4 22.8 132 23.9 18.8 172 212 20.7 19.8 202 15.6 16.7 155 21.4 14.6
21 132 10.6 11.1 112 13.1 12.7 82 13.7 102 11.7 122 11.1 10.1 12.0 85 10.0 13.7 152 112 16.6
22 14.9 10.1 11.1 12.3 12.6 12.8 8.0 14.9 10.0 8.6 9.6 105 9.1 10.9 75 95 132 14.7 10.1 15.4 65
23 132 11.7 10.0 11.7 14.7 142 7.1 162 12.6 11.7 13.8 13.7 112 13.1 75 10.0 132 152 105 15.0 10.0 10.1
24 19.9 142 142 15.4 13.6 15.5 10.0 18.1 142 12.1 152 175 11.1 14.6 95 10.0 11.6 16.0 142 17.5 115 115 12.1
25 18.4 10.4 12.5 10.4 13.5 13.0 5.7 15.8 13.0 102 12 0 112 115 112 6.8 8.7 13.0 12.8 7.6 15.4 8.7 85 105 115
26 14.9 9.0 11.1 122 12.1 132 8.0 142 11.0 10.1 11.1 11.6 9.6 92 75 10.0 10.6 11.9 9.0 17.1 8.0 6.5 12.1 10.5 85
27 16.7 14.9 10.5 14.5 152 15.4 11.6 17.1 10.0 122 11.7 165 122 132 11.1 132 155 13.6 14.0 20.1 9.0 10.6 145 12.6 13.0 8.0
28 14.4 8.6 11.6 6.1 12.6 11.1 5.6 12.6 11.6 9.6 122 11.6 9.7 105 5.0 8.0 12.1 13.0 5.3 16.6 8.0 8.0 8.0 11.0 7.7 9.0 125
29 23.2 21.4 18.8 20.1 23.4 20.4 17.0 25.0 232 17.0 20.6 22.4 17.7 26.5 17.5 205 182 23.5 18.6 25.6 17.6 20.0 18.7 21.0 18.7 18.8 21.7 15.5
30 18.8 20.7 18.8 18.3 21.0 18.7 18.8 242 21.5 16.0 212 235 15.5 23.9 17.1 16.5 19.9 22.9 17.4 25.0 14.3 17.0 17.7 16.8 195 185 20.6 18.2 14.7
31 19.3 20.6 17.0 182 15.6 19.6 16.4 21.8 21.0 15.4 19.4 22.3 15.4 22.5 14.8 16.5 17.6 222 16.7 212 14.7 16.4 16.4 15.9 18.7 155 185 17.6 145 12.6
32 262 21.8 17.6 22.4 21.1 262 182 25.0 21.6 16.4 21.8 23.0 19.4 22.7 19.3 20.0 192 21.8 20.3 27.0 19.3 19.9 21.7 21.1 19.3 19.4 21.1 21.1 15.1 17.0 10.5
33 22.0 19.5 152 192 182 192 16.6 232 212 16.0 19.6 19.4 16.6 21.5 1S.4 19.0 202 23.1 18.6 22.6 17.7 18.9 185 17.7 16.5 17.1 21.3 20.1 15.9 155 5.0 8.0
34 23.0 19.2 17.4 192 172 19.7 162 23.1 202 15.1 16.6 19.7 15.7 20.0 15.0 15.7 20.4 21.6 18.3 22.3 16.0 18.0 175 175 16.6 165 20.3 19.8 16.1 15.0 8.1 6.6 0.9
35 28.7 29.4 24.1 28.1 25.4 27.8 25.3 27.5 28.4 22.8 302 312 23.6 312 24.8 27.3 25.7 30.9 26.8 315 23.4 26.7 275 24.6 285 25.4 26.6 26.6 24.7 20.4 15.4 155 14.2 13.9
36 23.8 21.9 23.0 20.0 21.6 222 21.1 25.1 242 172 212 23.7 18.8 25.3 175 22.3 23.0 24.5 19.3 23.7 21.1 215 21.6 19.8 19.3 19.4 21.8 215 18.1 17.4 10.5 135 95 9.3 195
37 31.9 25.4 29.7 24.8 3C.8 28.8 26.1 33.5 312 24.6 30.7 29.4 24.7 29.5 232 28.5 24.6 33.3 26.2 34.9 26.8 26.1 25.1 25.9 25.0 24.2 32.0 27.4 26.1 26.6 215 23.8 20.1 20.4 26.3 21.9
38 26.4 22.4 242 23.1 222 25.6 21.7 26.3 23.6 20.6 26.4 255 21.9 25.4 18.9 22.5 20.5 272 205 27.6 20.0 215 225 225 21.5 15.3 23.6 22.4 225 225 155 17.0 14.9 14.0 19.9 15.8 14.5
39 23.1 20.4 24.9 212 25.0 21.4 17.4 282 24.6 18.0 242 22.0 21.4 24.3 19.7 22.0 225 25.3 15.5 25.6 19.7 19.7 20.9 215 17.5 17.9 195 215 23.3 215 22.1 26.0 20.1 19.5 29.5 24.0 32.0 27.8
40 22.9 17.8 202 192 222 19.6 15.5 22.5 20.6 14.9 19.6 15.5 162 21.4 15.4 18.5 20.1 22.4 17.0 22.6 14.9 15.5 185 21.7 164 16.0 18.4 17.4 195 175 20.1 21.8 U2 17.4 27.4 225 285 27.1 7.1
41 24.1 22.9 252 21.0 27.6 21.5 19.1 30.0 25.5 202 26.7 24.6 21.7 24.1 20.5 232 24.1 24.4 18.9 24.6 20.9 24.0 205 21.1 215 18.4 19.6 205 235 235 22.6 255 22.6 225 30.8 24.4 32.9 29.8 8.1 9.1
42 28.8 24.0 28.1 242 252 24.4 22.1 32.8 28.4 24.0 292 26.4 23.0 26.0 235 26.6 27.4 27.8 215 25.8 205 255 22.7 22.1 235 21.4 22.0 22.1 255 21.5 255 305 26.0 25.7 33.1 275 37.1 33.6 115 115 4.1
43 23.4 22.1 152 19.0 222 22.6 17.5 20.1 21.7 17.8 22.6 25.0 17.5 22.6 17.6 182 17.6 23.0 16.9 22.6 185 20.1 17.0 21.0 20.7 20.1 235 16.0 17.6 19.4 195 22.4 215 20.9 24.7 21.8 275 23.6 25.8 20.3 265 295
44 19.0 18.4 142 17.5 162 192 16.6 17.8 20.6 15.0 18.4 225 15.0 17.7 142 16.0 14.9 18.7 15.7 215 17.1 16.6 15.4 15.1 185 16.0 20.8 16.0 14.8 14.8 145 15.5 16.5 165 24.7 15.1 255 21.8 255 20.4 245 275 12.5
45 163 18.4 14.3 16.6 15.1 20.6 16.0 19.4 18.8 17.7 17.7 20.0 16.6 152 16.0 16.4 16.8 18.1 162 25.6 17.1 185 15.9 20.4 17.0 17.1 185 15.4 17.0 185 18.1 21.7 20.6 205 30.7 225 27.4 25.6 255 22.5 27.6 315 13.8 11.7
46 19.6 16.7 13.7 16.1 17.0 182 15.5 16.1 19.4 142 19.0 19.4 145 18.9 12.1 15.5 16.6 192 14.0 225 145 155 145 16.6 155 14.9 155 13.8 155 17.0 155 225 19.9 19.6 275 195 25.9 225 245 19.1 25.6 285 10.6 8.6 6.5
47 21.8 182 202 19.4 21.6 21.1 21.8 21.0 25.4 15.7 242 24.5 205 232 18.7 22.5 20.4 25.0 19.9 29.1 21.1 22.4 20.4 22.7 20.6 21.5 255 19.3 21.0 21.6 19.7 24.6 22.1 21.9 305 21.6 265 255 255 25.0 30.8 34.4 15.5 12.6 12.1 11.0
48 19.0 16.6 15.4 14.4 182 15.4 14.4 172 182 13.8 15.4 18.8 11.7 155 11.0 142 13.7 192 145 20.1 12.7 145 13.7 16.4 14.1 14.8 185 12.7 155 17.0 14.7 205 17.7 17.4 26.7 195 23.5 23.0 23.0 175 245 275 145 11.6 145 10.0 14.5
49 22.0 16.6 16.0 19.6 18.1 23.0 15.4 18.8 21.7 17.7 15.7 192 16.6 22.6 17.0 192 17.7 21.7 16.5 25.8 16.4 17.0 165 195 155 15.4 20.0 165 17.0 195 175 195 18.7 18.4 29.5 225 295 26.7 22.6 19.1 27.4 27.5 155 135 11.1 10.1 14.8 16.0
50 19.8 172 132 17.4 17.6 202 14.4 162 17.7 162 172 20.7 15.0 19.0 12.7 165 175 20.6 155 22.7 145 15.6 14.4 185 17.1 145 16.6 15.0 16.0 15.4 17.1 215 20.1 19.5 27.6 20.6 25.0 225 23.4 195 25.8 295 125 10.8 8.6 5.6 155 12.5
51 19.7 16.7 13.5 162 17.6 18.9 14.4 16.6 19.4 142 18.4 19.4 16.1 19.0 132 17.0 142 18.7 135 22.6 14.9 155 14.8 16.9 155 145 175 13.8 15.4 185 16.4 23.0 20.0 19.7 28.7 20.7 24.6 21.8 24.6 19.5 25.7 29.0 10.1 8.1 8.1 5.1 12.1 11.7
52 21.4 172 20.0 17.i 21.8 192 17.6 19.4 23.6 20.7 212 23.1 195 20.0 165 21.0 20.6 23.8 17.6 29.1 17.6 185 175 22.7 15.1 17.6 225 17.1 225 225 215 295 255 25.1 35.7 255 29.1 25.4 285 235 28.0 32.1 165 145 135 10.1 165 17.0
53 212 202 172 192 212 22.8 18.7 22.4 22.8 152 18.5 24.7 165 21.1 15.5 19.8 18.6 25.4 155 255 19.8 18.7 175 205 19.1 18.6 225 18.6 18.0 20.4 195 24.6 215 215 335 22.8 28.4 275 275 23.1 29.1 31.1 17.6 12.1 14.7 12.1 18.0 13.6
54 21.6 15.1 182 16.1 20.7 20.1 16.6 18.4 222 19.6 202 21.4 18.4 18.8 155 195 195 22.6 165 275 17.5 18.4 165 21.6 rr:o 17.7 22.7 16.0 215 23.1 21.7 28.1 245 23.9 34.4 24.4 275 245 27.7 22.7 26.8 305 155 135 125 9.1 15.1 16.0
65 17.8 172 16.0 20.0 16.6 23.4 172 19.7 21.8 172 22.0 192 17.4 16.6 15.5 155 17.1 19.7 192 23.7 15.8 195 155 17.7 19.1 19.9 215 165 185 16.6 17.7 215 195 185 25.8 19.0 24.8 225 21.6 175 215 205 12.7 95 14.0 115 165 145
64 22.4 19.4 23.6 212 26.1 26.1 21.7 23.0 272 25.0 27.6 26.1 25.0 24.4 21.8 24.6 245 26.4 19.4 31.1 225 23.6 21.6 255 225 23.6 265 205 235 265 24.6 315 28.6 28.4 34.7 26.4 31.4 24.8 32.0 30.0 33.6 37.7 18.8 17.1 15.4 12.7 16.0 215
57 17.1 142 17.7 122 17.6 12.7 132 192 172 132 16.1 15J 12.7 142 11.6 142 17.0 16.4 12.5 205 12.7 13.8 14.5 155 11.4 13.7 185 11.6 17.6 185 14.7 21.1 165 165 23.4 16.8 19.4 195 195 17.7 155 215 185 17.0 17.6 155 20.4 12.6
58 192 15.4 18.9 13.8 18.7 13.8 12.1 192 18.1 142 172 182 145 152 12.6 142 17.6 16.8 12.7 195 13.8 13.5 15.4 155 115 145 185 12.6 195 215 17.6 23.7 195 18.6 26.7 21.0 235 225 20.7 18.4 19.4 215 20.6 20.6 21.1 18.7 255 14.8
59 19.0 16.0 16.4 15.1 182 14.9 11.6 20.1 17.6 132 172 182 15.6 172 132 13.8 17.7 195 122 19.0 13.3 12.7 15.4 145 125 13.7 17.7 <35 18.8 20.1 155 215 17.8 16.8 235 205 24.5 21.1 19.0 17.8 20.1 23.3 20.1 19.4 225 18.6 24.1 16.1
80 18.1 13.4 20.4 15.7 202 19.7 142 19.7 202 16.3 21.1 19.8 165 185 15.0 175 19.9 19.5 13.0 18.7 17.4 15.0 15.0 16.1 165 14.1 175 15.1 24.1 245 17.4 255 205 19.4 285 18.3 29.1 22.8 185 20.5 18.0 21.0 245 155 24.0 19.1 215 185
61 22.4 19.9 18.6 18.1 20.3 17.4 16.3 23.6 212 142 20.4 19.6 15.7 21.8 15.7 165 21.0 24.1 16.5 19.9 155 18.6 15.7 19.6 16.1 19.1 225 16.9 15.6 165 14.4 19.0 13.9 14.1 195 195 24.9 21.7 235 17.4 21.7 23.0 16.5 15.1 19.0 165 215 15.1
62 22.0 182 15.3 14.4 23.5 15.6 17.8 23.1 22.4 142 192 212 14.9 202 16.6 17.7 17.6 22.5 18.1 215 15.0 15.3 17.8 21.7 17.6 185 215 16.0 185 13.7 17.0 19.5 16.4 175 24.7 19.1 255 25.0 25.0 17.9 245 255 17.7 17.0 19.9 17.0 21.6 13.8
1 2 3 4 5 C 7 8 9 10 11 12 13 14 18 14 17 18 18 20 21 22 23 24 25 26 27 28 28 30 31 32 33 34 35 38 37 38 39 40 41 42 43 44 45 44 47 48
APPENDIX 6: Distance between individual sequences from rural
Democratic Republic of Congo and previously established subtypes
(Myers et al., 1995).
(Distance estimated by the Kimura two-parameter model).
REFERENCE SUBTYPES
SAMPLES A B C D F G H
A. EPIDEMIOLOGICALLY UNLINKED
SUBTYPE A
1 A.Sq3M 15.91 22.6 24.4 23.1 26.8 23.2 21.0
2 A.Sq6M 12.88 21.7 20.8 21.9 25.2 22.7 19.0
3 A.Sq8M 12.55 20.0 24.2 20.3 24.0 23.2 17.4
4 A.Sq9m 13.72 20.5 22.4 20.2 24.6 22.4 18.6
5 A.Sql 1M 15.44 19.6 22.8 21.6 26.4 26.1 19.7
6 A.Sql2M 15.15 19.5 20.3 21.9 26.8 21.7 20.8
7 A.Sql3M 7.66 17.5 19.7 17.8 23.2 20.2 17.4
8 A.Sq27M 17.85 23.4 26.1 23.1 29.2 29.2 21.5
9 A.Sq29M 13.53 21.7 23.8 24.1 26.0 22.4 21.5
10 A.Sq31M 12.20 17.1 20.7 16.8 19.8 20.8 17.3
11 A.Sq32M 13.35 20.0 20.9 21.5 27.5 23.8 22.5
12 A.Sq34M 14.28 23.5 23.5 23.4 27.3 24.1 21.8
13 A.Sq36M 11.81 17.9 19.3 18.3 20.6 22.7 17.7
14 A.Sq37M 12.36 22.2 24.4 23.9 27.9 23.5 22.0
15 A.Sq38M 10.93 15.7 19.1 17.7 21.9 21.0 16.2
16 A.Sq39M 11.27 17.1 23.0 19.7 23.8 22.2 19.6
17 A.Sq40M 13.56 20.1 22.5 19.8 22.3 23.7 17.0
18 A.Sq43M 15.05 24.6 23.6 24.2 29.1 23.1 21.7
19 A.Sq46M 11.22 18.6 20.4 19.4 23.4 20.0 17.1
20 A.Sq48M 16.74 21.3 25.0 23.1 30.8 27.3 22.2
21 A.Sq49M 11.03 17.7 19.7 18.6 22.6 17.5 16.5
22 A.Sq51M 10.13 18.5 22.6 20.5 22.2 20.8 17.9
23 A.Sq52M 9.79 20.1 21.6 19.9 23.5 22.6 18.2
24 A.Sq54M 12.45 17.7 19.5 17.8 23.7 23.2 18.9
25 A.Sq55M 10.57 17.7 20.1 19.8 22.7 22.0 16.7
26 A.Ped2 10.91 17.0 19.9 19.0 21.1 20.8 17.8
27 A.PedlO 13.61 21.4 23.5 21.4 27.7 20.4 20.9
28 A.Pedl2 9.39 18.9 20.7 19.5 24.8 20.3 17.7
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SUBTYPE C
29 C.Sql8M 21.45 19.6 14.0 17.4 21.2 21.0 16.9
SUBTYPE D
30 D.Sq4M 19.03 9.8 14.5 7.5 15.0 22.9 16.4
31 D.Sq20M 23.01 14.1 16.9 10.8 16.5 25.8 21.3
32 D.Sq21M 21.55 10.7 13.4 8.7 15.9 24.9 18.4
33 D.Sq23M 20.96 10.0 13.0 8.3 14.8 24.0 18.4
34 D.Sq41M 28.60 17.0 20.2 14.2 20.3 29.2 26.5
35 D.Sq45M 23.50 15.3 18.1 12.4 17.5 28.0 19.8
SUBTYPE F
36 F.Sql9M 28.95 20.0 24.6 21.6 14.1 33.1 23.3
37 F.Sq53M 24.30 13.2 22.6 16.6 7.3 26.8 21.1
SUBTYPE G
38 G.Sq7M 22.29 24.3 21.0 20.8 24.7 11.7 25.1
39 G.Sql7M 19.05 21.2 20.0 20.0 24.6 11.7 22.6
40 G.Sq47M 21.04 25.7 22.6 23.2 28.1 12.2 26.4
41 G.Sq56M 23.56 28.5 25.7 25.9 31.3 14.9 30.4
SUBTYPE H
42 H.Sq5M 20.38 21.1 21.8 19.7 21.5 23.4 13.2
43 H.SqlOM 18.56 17.4 18.2 17.2 20.8 25.5 11.1
44 H.Sql4Ml 18.52 21.9 21.0 21.7 24.9 25.8 11.4
45 H.Sql5M 18.14 19.6 20.2 19.1 22.1 24.2 10.1
46 H.Sql6M 25.09 24.3 24.7 22.7 26.9 30.2 13.7
47 H.Sq22M 15.97 18.1 17.7 17.4 22.1 22.8 14.8
48 H.Sq25M 20.51 22.2 19.9 20.5 25.2 26.5 13.8
49 H.Sq26M 17.79 19.1 19.9 19.8 22.7 23.3 13.1
50 H.Sq28M 17.12 20.7 20.9 20.3 21.3 22.3 9.3
51 H.Sq30M 19.45 24.8 27.4 26.8 26.8 27.9 13.8
52 H.Sq33M 21.02 22.8 25.3 23.1 27.2 29.0 16.4
53 H.Sq35M 18.68 24.3 26.3 25.7 26.1 27.5 13.3
54 H.Sq50M 18.85 20.3 23.3 19.3 22.8 21.1 13.6
55 H.Pedl3 23.56 26.5 28.4 27.2 28.5 30.3 16.5
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B. EPIDEMIOLOGICALLY LINKED CHILDREN
(associated-maternal sequences are shown between brakets)
A B c D F G H
56 D.Ped3el
(D.Sq4M)
19.03 9.8 14.5 7.5 15.0 22.9 16.4
57 A.Ped4el
(A.Sq9M)
11.74 18.6 19.3 18.8 23.1 20.3 16.6
58 H.Ped5el
(H.Sql6M)
23.35 24.8 25.0 23.8 27.2 28.5 12.1
59 A.Ped6el
(A.Sq32M)
13.56 20.8 21.9 22.1 28.5 24.6 23.0
60 D.Ped9el
(D.Sq45M)
21.19 12.8 16.0 10.4 16.0 25.4 17.9
61 A.Pedllei
(A.Sq52M)
10.39 20.2 21.2 19.9 24.5 24.1 18.7
62 A.Pedl4el
(A.Sq37M)
14.88 23.7 26.2 24.4 30.1 24.6 22.9
63 A.Pedl 5el
(A.Sq27M)
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Abstract
Background: Babies born to HIV-infected mothers retain anti-HIV of maternal origin until 15-18 months of age.
Because of this, HIV proviral DNA and p24 antigen measurements have become the methods of choice for timely
diagnosis of HIV infection in infancy. They are, however, too expensive for widespread use in the developing world.
Objective: To evaluate a simple, inexpensive serological method for diagnosing mother-child transmission of HIV,
in an African population, which takes account of the effects of placental transfer of maternal antibody and continued
exposure to HIV through breast-feeding.
Study Design: Plasma specimens for a prospective study of mother-to-infant transmission of HIV in rural Zaire
were collected at birth, 3, 6, 9, 12, 18 and 24 months from 21 infected infants (PP group), 21 uninfected infants (PN
group) born to seropositive mothers and 21 control infants (NN group) born to uninfected mothers. The specimens
were retrospectively tested for IgG, IgM and IgA anti-HIV by immunoglobulin class-specific capture EIAs, and by
a commercial anti-HIV EIA.
Results: In neonatal specimens, IgA and IgM anti-HIV were present, respectively, in 13 of 14 (97%) and 8 of 14
(57%) of the PP group and in 6 of 11 (55%) and 2 of 11 (18%) of the PN group. Later, at 3 months and older, IgA
and IgM anti-HIV were only detected in the PP group. They peaked at 18 months (93%) and 24 months (67%)
respectively. Of the 21 PP group children, 8 (38%) were transiently IgG anti-HIV-negative in the first year, indicating
that infection had probably taken place after birth; four of the 8 had no detectable IgA anti-HIV during the first year.
None of the specimens collected from the NN group babies were reactive for IgA, IgM or IgG anti-HIV.
Conclusions: IgA and IgM anti-HIV may be passively transferred across the placenta. Where breast-feeding is
prevalent, about half of the transmissions may occur after birth, thus delaying the diagnosis of mother-child
transmission. Nevertheless, this simple, cheap IgA anti-HIV, EIA identified 65% of transmissions by 9 months of age,
and 93% at 18 months of age. It is a more useful marker than IgM anti-HIV, and gave a much more rapid answer
than did tests for IgG anti-HIV seroreversion.
Keywords: HIV vertical transmission; IgA anti-HIV; IgM anti-HIV; Breast-feeding; HIV diagnosis
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1. Introduction
The timing and mechanism of mother-child
transmission of HIV are not clear. There is evi¬
dence for infection in utero (Courgnaud et al.,
1991; Mano and Chermann, 1991), just prior to
or during delivery (Ehrnst et al., 1991; Krivine
et al., 1992) and by breast-feeding (Stiehem and
Vink, 1991; Van de Perre et al., 1992; Datta et
al., 1992; Ziegler, 1993). In the developing
world, breast-feeding is recommended by the
WHO (World Health Organisation, 1992), but it
nevertheless increases the risk of HIV transmis¬
sion from mother to child (Dunn et al., 1992).
A number of laboratory tests, reviewed by Sison
and Campos, 1992, may detect transmission
which has occurred before or during the neona¬
tal period, including polymerase chain reaction
(PCR), HIV culture, and in vitro antibody and
in vitro antigen production. However, most are
expensive, technically demanding and unsuitable
for use in laboratories in developing countries.
A possible exception is the detection of HIV
p24 antigen. While Andiman et al., 1992 found
only 20% of samples collected from infected ba¬
bies in the first month of life to be HIV anti¬
gen-positive, Miles et al., 1993, employing a
preliminary acid dissociation step (Ascher et al.,
1992), reported p24 antigen in 80% of HIV-in¬
fected neonates. However, when Fauvel et al.,
1993 further assessed this modification they con¬
cluded that, although a small improvement in
sensitivity was possible in the first two months
of life, acid treatment of specimens made confir¬
mation of reactive samples essential. This confir¬
mation increases the volume of specimen needed
and the cost.
The presence of IgA anti-HIV in at-risk in¬
fants has been shown to be predictive of HIV
infection in the child. Immunoblots have been
employed to identify IgA and IgM anti-HIV in
samples collected at and following birth, but re¬
moval of competing IgG from the samples by
absorption with protein G prior to testing was
necessary (Wieblen et al., 1990b). Many of the
published data have been obtained using West¬
ern Blot or immunoblots which incorporate re¬
combinant HIV antigens, and the reported
findings are similar (Wieblen et al., 1990a; Mar¬
tin et al., 1991; Landesmann et al., 1991; Quinn
et al., 1991; Re et al., 1992). In particular, when
samples collected between birth and three
months have been tested, the sensitivity for IgA
detection has been low (range 16-18%). In one
study, however, IgA anti-HIV was detected in
all ten HIV-infected children tested at birth and
in a further two infected children tested at 2
months of age, but not in any of five uninfected
children at risk (Portincasa et al., 1992). This
study assumes that maternal IgA anti-HIV does
not cross the placenta in which case transmis¬
sion must have occurred, in all cases, long
enough before birth for the babies to mount an
IgA response. This conflicts with the current
consensus that a substantial proportion of trans¬
missions occur perinatally (Ehrnst et al., 1991;
Krivine et al., 1992). In another study, however,
IgA anti-HIV was detected in similar propor¬
tions of uninfected (12/37, 32%) and infected (4/
12, 33%) neonates born to HIV-infected mothers
(Connell et al., 1992). Its presence was associ¬
ated with strong IgA anti-HIV reactivity in the
mothers' sera, suggesting that transfer of mater¬
nal IgA had occurred. With the exception of
one study (Portincasa et al., 1992), these studies
indicate that, in the infected infants, IgA anti-
HIV production commences between 3 and 6
months (22-66% IgA anti-HIV-positive), and
that most are producing IgA anti-HIV by 9
months (range 54-99%). IgA anti-HIV has
rarely been found in uninfected infants of 3
months and older.
We evaluated the suitability of immunoglobu¬
lin class-specific antibody capture EIAs for IgA,
and also for IgM and IgG anti-HIV, for the
diagnosis of HIV infection in Zairian children at
risk of infection from their mothers. Our assays
are simple, cheap and require only small vol¬
umes of untreated serum or plasma specimens.
They can be readily used by laboratory services
in developing countries where, because of
breast-feeding, children continue to be at risk of
HIV infection into the second year of life and
beyond (Datta et al., 1992).
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2. Patients and methods
2.1. Patients
In a longitudinal prospective study of mother-
child transmission of HIV in rural Zaire, 21 chil¬
dren born to seropositive mothers were diagnosed
as infected (PP group) by the presence of IgG
anti-HIV at 18 months of age, the detection of
p24 antigen, AIDS defining illness before 18
months of age or HIV-related death (Centers for
Disease Control, 1987). There were two matched
control groups of children: 21 who did not de¬
velop the infection during the period of follow up
but whose mothers were HIV-positive (PN
group), and 21 children born to anti-HIV-nega-
tive mothers (NN group). Signed consent was
obtained from all mothers prior to admission to
the study. Plasma samples were collected from the
three groups of children in the neonatal period
(cord blood and/or peripheral blood) and at 3, 6,
9, 12, 18 and 24 months of age. For some chil¬
dren, both cord blood and peripheral blood speci¬
mens collected in the neonatal period (usually
< 14 days) were available. In these cases the
findings were identical and were thus treated as if
they were a single specimen. Because no alterna¬
tive was available, the mothers were not advised
to stop breast-feeding.
2.2. Methods
Samples from the PP group («=123), PN
group (n = 128) and the NN group (n = 135) were
tested for IgG anti-HIV by an IgG antibody-
capture enzyme linked immunosorbent assay
(Connell et al., 1993), Wellcozyme HIV 1+2
GACELISA (Code VK61, Murex Diagnostics,
Dartford, UK). Specimens were also investigated
for the presence of HIV-specific IgA
(AACELISA) and IgM (MACELISA) by similar
class-specific antibody capture ELISAs. In
AACELISA, anti-human IgA (Dako code No.
A092, Dako, High Wycombe, UK), and in
MACELISA anti-human IgM (Dako code No.
A425), replaced anti-human IgG on the solid
phase (Connell et ah, 1992). The procedures were
similar to that of GACELISA except that human
sera with known IgA and IgM anti-HIV reactivity
were included as positive controls. Each sample
was originally tested by the Abbott recombinant
HIV1/HIV2 EIA (No. la80-24, Abbott Diagnos¬
tics, Maidenhead, UK).
3. Results
3.1. PP group (21 infected children born to
HIV-positive mothers)
IgA anti-HIV: Of the 14 neonatal samples 13
(93%) contained IgA anti-HIV, but this propor¬
tion declined to 2 of 17 (12%) at 3 months (Fig. 1
and Table 1). After 3 months, an increasing pro¬
portion of samples contained IgA anti-HIV: 6 of
13 (46%) and 16 of 19 (84%) were positive in
AACELISA at 6 and 12 months respectively and
13 of 14 (93%) were positive at 18 months. Four
(19%) of the 21 children did not have detectable
IgA anti-HIV in any sample collected between 3
and 12 months of life (Table 1). These four IgA
anti-HIV-negative children also lost IgG anti-HIV
reactivity during their first 12 months, suggesting
that their infection occurred well after birth. Two
of them had symptoms possibly due to HIV at 6
months, the third had non-specific findings and
the fourth child was asymptomatic throughout
the first year. The presence or absence of HlV-as-
sociated symptoms in the first year of life did not
correlate with the presence or absence of IgA
anti-HIV.
IgM anti-HIV: Of the 14 neonatal specimens
eight (57%) contained IgM anti-HIV; but none of
the 17 specimens collected at 3 months did (Fig.
1). After 3 months, an increase in the proportion
of samples containing IgM anti-HIV was ob¬
served to a maximum of six of nine (67%) samples
obtained at 24 months. Of the 21 PP group
children 11 (52%) did not have detectable IgM
anti-HIV at any time between 3 and 12 months;
eight of these were symptomatic and three were
asymptomatic.
IgG anti-HIV: All samples collected before 3
months of age were positive when tested by
GACELISA and Abbott HIV 1/2 (Table 1 and
Fig. 2). At 3 months IgG anti-HIV was detected
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Fig. 1. IgA and IgM anti-HIV reactivity, measured by class-specific antibody capture EIAs, in sequential plasma specimens collected
from 42 children born to HIV-infected mothers; 21 children were HIV-infected (PP group) and 21 were not (PN group).
in 15 of 17 (88%) samples by GACELISA and 16
of 17 (94%) by Abbott HIV 1/2. Of samples
collected at intervals after 3 months of age, simi¬
lar proportions were reactive in GACELISA and
Abbott HIV 1/2. Of the 21 PP group children
eight (38%) had at least one sample unreactive in
GACELISA HIV 1/2 and/or Abbott HIV 1/2
during the first year (Table 1); four of the eight
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GACELISA
ABBOTT HIV 1/HIV 2
Age (months)
Fig. 2. IgG anti-HIV reactivity, measured by IgG antibody capture EIA and the Abbott HIV 1/2 EIA (second generation), ir
sequential plasma specimens collected from 42 children born to HIV-infected mothers; 21 children were HIV-infected (PP group'
and 21 were not (PN group).
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had no detectable IgA anti-HIV throughout this
period. Between 6 and 9 months of age only one
of seven infants who lost IgG anti-HIV had de¬
tectable IgA anti-HIV whereas ten of 11 infants
with persistent IgG anti-HIV were IgA anti-HIV-
positive (Table 1).
3.2. PN group (21 uninfected children born to
HIV-infected mothers)
IgA anti-HIV: Of 11 neonatal samples, six
(55%) contained IgA anti-HIV. This was lost by 3
months of age (Fig. 1), after which time all speci¬
mens were unreactive in AACELISA.
IgM anti-HIV: Two (18%) of 11 neonatal spec¬
imens contained IgM anti-HIV, but none of the
specimens collected later were reactive in
MACELISA (Fig. 1).
IgG anti-HIV: All ten neonatal samples that
were tested in both GACELISA and Abbott HIV
1/2 were reactive (Fig. 2). Another neonatal speci¬
men, unreactive in GACELISA, was not tested in
Abbott HIV 1/2; tests on the mother's plasma
indicated that she was probably seroconverting
around the time of delivery. GACELISA reactiv¬
ity decreased more rapidly than Abbott HIV 1/2
reactivity: at 6 months only four of 19 (21%)
specimens were reactive in GACELISA compared
to 12 of 19 (63%) in Abbott HIV 1/2. At 12
months, no sample contained IgG anti-HIV when
tested by GACELISA but 20% were still positive
by Abbott HIV 1/2.
3.3. NN group (21 uninfected children born to
HIV-negative mothers)
All 135 plasma samples collected from 21 anti-
HlV-negative children born to uninfected moth¬
ers, at ages between 0 and 24 months, were
unreactive in AACELISA, MACELISA,
GACELISA and Abbott HIV 1/2 assays.
4. Discussion
An earlier study of European babies has
demonstrated that the simple and inexpensive
class-specific antibody capture assays employed in
this study were sensitive and specific (Connell et
al., 1992). In that study, 20 (83%) of 24 HIV-in¬
fected babies of between 3 and 12 months of age
were IgA anti-HIV-positive by AACELISA. Sub¬
stantial proportions of uninfected infants between
birth and 3 months of age, but not older, also had
IgA anti-HIV in their blood and it was suggested
that this antibody had been passively transferred
from the mother. The presence of IgA and IgM
anti-HIV in the neonatal blood of some unin¬
fected infants born to HIV-positive mothers was
confirmed in this study of Zairian children. In
view of the earlier findings, however, we were
initially surprised to find an apparently lower rate
of positivity for IgA and IgM anti-HIV in those
Zairian children who were subsequently confi¬
rmed to be HIV-infected. Overall, only 35 of 66
(53%) bloods collected from them between 3 and
12 months of age were IgA anti-HIV-positive,
many of them weakly so. Tests for the presence of
IgM anti-HIV were also less often positive and
they seemed not to augment the IgA findings. The
IgA findings were also at variance with those of
Quinn et al. (1991) and Wieblen et al. (1990a)
who used immunoblot procedures to detect IgA
anti-HIV in HIV-infected infants.
Why should this have been? We believe that
two factors accounted for this discrepancy.
Firstly, all of the babies in this study, unlike
others, were breast-fed by their mothers. Whereas
breast-feeding had been thought, until recently, to
carry only a small risk of mother-infant transmis¬
sion of HIV (Ryder et al., 1991), it has now
become apparent that up to half of mother-child
transmissions in breast-fed children occur by this
route (Dunn et al., 1992). Such transmissions are
delayed, compared with those in utero and at
birth, so that IgA anti-HIV may appear later.
Secondly, it has been our experience, and that of
others (Wieblen et al., 1990a; Landesmann et al.,
1991; Re et al., 1992), that an IgA anti-HIV
response is absent in many, but not all, children
who experience rapid HIV-disease progression.
This could account for a poor IgA response in
three of the 21 HIV-infected children studied by
us.
In testing European children, for whom breast¬
feeding is discouraged, we have so far not seen
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any child, who was subsequently diagnosed as
HIV-infected, lose reactivity for IgG anti-HIV
and then regain it. We had, therefore, concluded
that this was an infrequent occurrence. In the
series of HIV-infected Zairian children reported
here, however, eight of 21 (38%) children lost
anti-HIV, as measured by the GACELISA and/or
Abbott EIA, at some stage in the first year of life;
several others became only weakly reactive (Table
1). With the exception of two children who died,
all later became unequivocally seropositive. This
is evidence that perhaps a half of the HIV-positive
infants studied by us were infected well after
birth, presumably through breast-feeding, and is
in accord with others' findings (Dunn et al., 1992).
In the four infants in whom an IgA anti-HIV
response was not detected between 3 and 12
months, all showed transient loss of IgG anti-HIV
reactivity.
For the PN group, IgG anti-HIV reactivity was
lost earlier in the GACELISA assay than in the
indirect (Abbott) assay. This confirms similar
findings in another study (Parekh et al., 1993) and
may prove to be a diagnostically useful feature.
Particularly in babies who have not been breast¬
fed, it may permit earlier identification of babies
who have escaped HIV infection than when em¬
ploying a conventional anti-HIV screening test.
Unfortunately, there is no information on the
frequency or duration of breast-feeding in the
earlier published work on IgA anti-HIV detection
in at-risk children. If, as seems likely, many chil¬
dren in these other studies were wholly or largely
bottle-fed, infection might only rarely have oc¬
curred post-natally. By contrast, in this study,
transmission might have occurred at any time
from birth until the children who escaped in¬
trauterine or perinatal infection were completely
weaned (Stiehem and Vink, 1991; Van de Perre et
al., 1992; Datta et al., 1992; Ziegler, 1993). Risk
of transmission by breast-feeding may accrue with
time, due to the duration of exposure of the child
(de Martino et al., 1992), the possible decline of
the mother's immune competency—leading to
higher levels of viral replication and lower levels
of partially protective maternal antibody—and
the emergence of more transmissible strains of
HIV in the mother. Moreover, it might be that the
dynamics of the immune response, in a child
infected orally under 'cover' of maternal antibod¬
ies, are suppressed compared to that of adults or
of children infected at or before birth.
If it is the case that an IgA response is delayed
or absent in breast-fed babies infected post-na¬
tally, is there any value in attempting early diag¬
nosis by IgA antibody capture anti-HIV testing?
We believe there is, for the following reasons.
First, we and others have demonstrated that,
when present, IgA anti-HIV (and IgM anti-HIV)
in the blood of children of 3 months and older is
highly predictive of HIV infection in that child.
By contrast, other anti-HIV reactivity in screening
tests, predominantly IgG, is often present in unin¬
fected children even beyond 12 months of age,
making it difficult to distinguish infected from
uninfected children. Second, the method we have
employed is robust, simpler and cheaper than
tests for IgA anti-HIV which require preliminary
removal of IgG and immunoblot. The IgA anti¬
body capture ELISA employs conventional
ELISA methods and its reagent cost should be no
more than US$ 2-3—immunoblot reagents cost
approximately ten-fold more. Third, although the
precise time of transmission was not known for
our 21 HIV-infected children, it is clear that post¬
natal transmission had frequently occurred. In
such circumstances it would not be possible to
determine at what point other tests, e.g. for HIV
p24 Ag or proviral DNA might become positive,
relative to IgA anti-HIV seroconversion. It can be
assumed that p24 antigen detection and poly¬
merase chain reaction (PCR) would also have
shown an apparently low sensitivity in the first
few weeks or months of life as, in some cases,
transmission would not yet have occurred.
Fourth, even in situations where PCR and HIV
p24 antigen testing can be afforded and done to a
high standard of accuracy, we have found it valu¬
able to have a serological method, such as detec¬
tion of IgA anti-HIV, to confirm HIV infection in
children who are positive for these other markers
of HIV infection. Fifth, we have experienced fail¬
ures both of HIV p24 Ag testing and PCR to
diagnose HIV infection in HIV-infected babies of
over 3 months of age whose serum was shown to
contain IgA anti-HIV (Tosswill et al., 1994).
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Lastly, it is often difficult to obtain sufficient
blood from an infant or young child to perform
HIV p24 Ag testing and/or PCR. The IgA capture
method requires only tiny volumes (< 5 /tl) and
can be performed on specimens which are insuffi¬
cient for a p24 Ag test. Although not formally
demonstrated here, the IgA capture assay, like the
IgG capture assay, would probably function
equally well on eluates prepared from dried blood
spots (Tappin et al., 1991; Thongcharoen et al.,
1992).
A simple, inexpensive assay for IgA anti-HIV,
such as we have described, would be ideally suited
to laboratories that are unable to perform com¬
plex and expensive tests to diagnose mother-child
transmission of HIV. Although the sensitivity of
the method in breast-fed infants is imperfect, it is
highly specific. In circumstances where other ap¬
proaches are not available the method will, by 6
months of age, permit the identification of the
majority of babies who had become infected in
utero or perinatally. Especially if breast-fed, other
babies will need to be followed up for longer,
perhaps until at least 6 months after their last
exposure. For many families, the stress to parents
of not knowing their child's HIV status could be
removed, and appropriate prophylactic therapy
and monitoring of the infected child initiated.
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Fourteen asymptomatic HIV-infected Zairian children under 2 years of age displayed social and
motor developmental deficits on the Denver Developmental Screening Test when compared with
20 HIV-negative cohorts born to HIV-infected mothers and 16 control children. In a second study,
11 infected children over 2 years of age had sequential motor and visual-spatial memory deficits on
the Kaufman Assessment Battery for Children and motor development deficits on the Early
Childhood Screening Profiles. HIV infection affects central nervous system structures mediating
motor and spatial memory development, even in seemingly asymptomatic children. Furthermore,
maternal HIV infection compromises the labor-intensive provision of care in the African milieu
and undermines global cognitive development in even uninfected children.
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When one considers what specific domains of development
are affected by pediatric HIV infection, language and motor
skill deficits have been noted for children tested with the
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Scales of Children's Abilities, quantitative, verbal, and memory
ability deficits have also been documented with infected
children and are particularly significant for those children with
accompanying neurological impairment from the virus (Leven-
son, Mellins, Zawadzki, Kairam, & Stein, 1992). Condini et al.
(1991) observed that HIV-l-positive children showed signifi¬
cant delays in language development in comparison with
HIV-negative cohorts, as indicated by mean length of utter¬
ance obtained by observation of natural child-parent interac¬
tions. In addition, deficits of visual-spatial integrative ability
and memory have been identified with the Kaufman Assess¬
ment Battery for Children (K-ABC; Belman et al., 1988;
Diamond, 1989; Diamond et al., 1987).
With respect to the developmental effects of pediatric HIV
infection, investigators have noted the environmental influ¬
ences of the risk factors associated with the infection in
parents, particularly among the inner-city poor, impoverished
and minority populations among which HIV infection is
concentrated (Diamond et al., 1990; Levenson et al., 1992;
Ultmann et al., 1985; Ultmann et al., 1987). Such risk factors
can include parental intravenous drug use and associated
deficient or nonexistent antenatal medical care and poor
nutrition. Even in the absence of HIV infection, such character¬
istics of the home environment can significantly compromise
the cognitive and behavioral development of a child over the
long term (Mellins, Levenson, Zawadzki, & Kairam, 1991).
Irrespective, HIV-positive children infected by blood transfu¬
sion neonatally still demonstrate significant deficits in school
achievement and in neuropsychological tasks that emphasize
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motor speed, visual scanning, and cognitive flexibility (Cohen
et al., 1991). The children in Cohen et al.'s study were not
disproportionately more likely to be prenatally subjected to
illicit drug or alcohol exposure or nurtured in impoverished
home environments than were their noninfected counterparts.
Thus, it is likely that the direct effects of the virus on the brain
and central nervous system produce neuropsychological defi¬
cits independent of the quality of the perinatal developmental
milieu, but such deficits are likely compounded by the develop¬
mental risk factors pre- and postnatally that are conducive to
parental HIV infection in the American urban setting.
There is an additional means of developmental impairment
less often considered in the context of the neuropsychological
effects of pediatric HIV infection, that exists apart from the
lifestyle issues that place a parent at risk for infection. These
involve the direct effects on the child of having key family
members, especially the mother, chronically ill from the
disease. These effects can be especially severe among more
impoverished socioeconomic classes in developing countries.
For example, in rural areas of much of sub-Sahara Africa,
where the family must rely on labor-intensive subsistence
agriculture to provide for its nutritional needs, maternal HIV
disease can severely disrupt the nutritional resources of the
family and undermine this vital aspect of the early develop¬
ment of the children.
Furthermore, chronic illness on the part of any family
member in the absence of a national or universal health-care
insurance system or social welfare safety net can quickly drain
the meager financial resources of the family as it seeks to
provide for the expenses of treatment. This is an important
consideration in light of the significant relation between
overall economic well-being for the family and the long-term
development of cognitive ability and performance that has
been documented in such African environments (Boivin &
Giordani, 1993; Boivin et al., 1993). Hence, when AIDS or any
serious long-term illness ravages a family in a developing
country, it has the potential of profoundly influencing the
neuropsychological development and well-being of both in¬
fected and noninfected children within the family.
As a means of differentiating among these effects, HIV-1-
positive and -negative children born to infected African
mothers were compared directly for cognitive and motor
developmental differences. Both groups were subsequently
compared to a third group of HIV-negative children born to
noninfected mothers in order to better assess some of the
second-order effects of the epidemic on the development of
children who are not themselves infected, but who bear the
consequences of the disease in the form of illness of the
primary caregiver (mother), and the economic hardship that
this imposes on the entire family. Such factors are expected to
be especially severe for nonaffluent families in developing
countries, such as in the major urban centers of sub-Sahara
Africa where the disease is epidemic (Goodgame, 1990;
Novicki, 1988).
An additional important aspect of this study is that the
analysis of primary and second-order effects of pediatric HIV
infection can take place apart from the effects of antiretroviral
drug treatments (e.g., AZT). Unlike American and European
children, the vast majority of pediatric HIV cases in Africa are
never given these drugs because of inaccessibility and expense.
Although tragic, this fact allows for the effective study of the
natural course of the infection in children unaffected by the
medical treatment protocols—something that is no longer
possible for such children in most industrialized nations.
Study 1: Comparing HIV-Positive and HIV-Negative
Children on the Denver Developmental Screening
Test During the First 18 Months
Method
Respondents. Women undergoing prenatal evaluation at a 300-bed
hospital near Kimpese, a commercial center in lower Zaire, were
screened for HIV-1 and HIV-2 infection with the ELISA recombinant
DNA enzyme-linked immunoassay test (Abbott Laboratories, Delken-
heim, Germany). Confirmation of a positive test was obtained with the
Wellcozyme (enhanced antigen sandwiched enzyme-linked immunoas¬
say) assay (Murex Diagnostics, Dartford, United Kingdom) on the
same specimen. Positive cases were subsequently retested for HIV-1
p24 antigen and core antibody in the Regional Virus Laboratory
(University of Edinburgh, Edinburgh, United Kingdom). This series
has an estimated predictive positive value of over 99% in the
identification of HIV-1 or HIV-2 infection. All of the infection cases
identified in this study were of the HIV-1 variety.
Confirmed HIV-positive women were recruited for participation in
a 2-year longitudinal study beginning at the time of birth of the child.
The health, immunological, and developmental status of the child born
to the HIV-positive mother were evaluated on a monthly basis. About
a third of the women identified as HIV-positive during the prenatal
examination chose to participate in the project, and about half of those
women had completed the entire 2-year study with their child at the
time of this research.
A second group ofwomen was recruited for the 2-year study through
the prenatal clinic at the hospital. These women were HIV-negative
and were matched to the HIV-positive mothers in terms of maternal
age, residential neighborhood, socioeconomic status, and parity. The
children born to these mothers constituted the control group in this
analysis.
All of the infected women in the project who had completed the 2
years of evaluation with their child on a reliable basis were included in
this analysis. Of the cohort of children born to HIV-positive mothers,
14 children maintained the HIV-positive status throughout the 2 years,
and 20 were confirmed HIV-negative (sero-reverters). Sixteen chil¬
dren were in the control group. There were no significant complica¬
tions reported at birth for the children included in this analysis, and
the HIV-positive children remained pre-AIDS (Stage PI) according to
World Health Organization (WHO) criteria (Newell, Peckham, &
Lepage, 1990) for pediatric HIV infection.
Measures and materials. In this study a physician assessed psycho¬
motor development as part of the comprehensive health examination
during one of the monthly project sessions. The mother was present
throughout the evaluation to respond to questions from the nurse or
pediatrician. The psychomotor development measures at 3, 6, 9, 12,
and 18 months of age are included in the repeated measures analysis.
The developmental measures for the children were obtained with
the most recent version of the Denver Developmental Screening Test
(DDST; Frankenberg, Fandal, Sciarillo, & Burgess, 1981) in the four
main areas of development (personal-social, language, fine motor-
adaptive, and gross motor). To enhance the statistical analysis of these
measures, the ordinal rankings typically used in this screening battery
were replaced by an interval (quantitative) measure that uses a scoring
system developed for the Woodside Developmental Assessment Bat¬
tery (Eu, 1986).
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If a Zairian child demonstrated a developmental item on the DDST
that is performed by less than 25% of the normative American sample
for that age group, the child received four points added to his or her
total for that developmental domain. Demonstrating an ability per¬
formed by 25%-50% of the normative sample resulted in a score of
three, one performed by 50%-75%, in a score of two, and one
performed by over 75%, in only a score of 1. Likewise, failing to
demonstrate an ability that over 90% of the American normative
sample could perform at that age resulted in four points subtracted
from the total in that developmental domain for a Zairian child.
Failing an item demonstrated by 75%-90% of the normative sample
resulted in a score of —3; failing an item demonstrated by 50%-75% of
the normative sample resulted in a score of -2; failing an item
performed by 25%-50% of the sample resulted in a score of -1; and
failing an item that less than 25% of the normative sample could do
resulted in a score of zero. The total pass/fail score for each of the four
developmental domains of the DDST is then divided by the total
number of tasks or items that are applicable from birth to that age of
the child in order to arrive at a final score.
Results
When the three groups of children were compared in a
one-factor repeated measures analysis of variance (ANOVA)
for the developmental assessment scores at 3, 6, 9, 12, and 18
months of age, there were significant between-group (main
effect) differences for the domains of personal-social, fine
motor-adaptive, and gross motor development (see Table 1).
For the personal-social and gross motor summary measures,
the between-group differences remained significant atp < .01
even when a Bonferroni correction was applied for the number
of simultaneous statistical comparisons within a single experi¬
mental design. Subsequent pairwise comparisons revealed that
in each of these areas, the HIV-positive children scored
significantly lower than both the HIV-negative and control
children, and there were no differences between the HIV-
negative and control children.
The Main Factor (HIV status) x Repeated Measure interac¬
tion effect for the ANOVA was statistically significant for the
domains of personal-social, language, and gross motor (Table
1). These effects remained significant even when the signifi¬
cance values were adjusted according to the Greenhouse-
Geisser method of profile analysis in order to account for the
possibility of compound symmetry in the repeated measure.
The Greenhouse-Geisser epsilon values were 0.62, 0.80, and
0.66 for the repeated measures in the developmental domains
of personal-social, language, and gross motor, respectively.
The interaction effect plots of the cell means for this analysis
clearly indicate that for gross motor development, this effect is
Table 1
Comparison ofHIV-Positive, HIV-Negative, and Control
Children on the DenverDevelopmental Screening Test
Measure HIV group3 Repeated measure5 Interaction1
Personal-social 7.61*** 7.76*** 3.70***
Language 3.00 22.76*** 8.24***
Fine motor-adaptive 4.47* 1.10 0.82
Gross motor 7.12*** 6.96*** 2.79**
°dfs = 2,236. bdfs = 4,236. cdfo = 12,236.
*p < .05. **p < .01. ***p < .001.
largely due to a significant lag in development for the HIV-
positive children that progresses across the periodic 3- and
6-month assessments, as compared with the HIV-negative and
control children (see Figure 1).
Study 2: Comparing HIV-Positive and HIV-Negative
Preschool Children on the Kaufman Assessment
Battery for Children and the Early Childhood
Screening Profiles
Method
Respondents. From the information database for the mothers and
infected and noninfected children who had been enrolled in the
assessment project, irrespective of how reliably they had completed
the 2 years of assessment, a list of those mothers who had a home
address in the Kimpese area near the hospital center with project
children at least 2 years of age was generated. From this list of about
200 infected mothers, 26 children who had been confirmed HIV
positive and 26 children who had been confirmed HIV negative at the
end of the assessment were identified.
These 52 children represented almost all of the children in the
project who lived in the vicinity.
Of the 26 HIV-positive children, we were able to complete the
assessment protocol with only 4 of the children. The remaining
children had died, were too sick to test, were not sufficiently responsive
for valid assessment, or had moved to elsewhere to live with members
of the extended family after the death of one or both parents. Of the 26
HIV-negative children in the original sampling frame, 15 eventually
completed the assessment protocol. Clearly, the HIV-positive children
were disproportionately more likely to have died or to be too ill or not
sufficiently responsive for cognitive and motor assessment than the
HIV-negative children, x2(4,N = 52) = 23.77,p < .01.
In order to obtain additional cases of pre-AIDS HIV-positive
children perinatally infected, another list of 26 eligible children was
compiled from an information base for pediatric HIV-positive cases at
the hospital; these children had not been enrolled in the 2-year
postnatal evaluation study. Of these 26 children, 7 completed the
assessment protocol. Therefore, we had a total of 11 perinatally
infected HIV-positive children over 2 years of age. These 11 children
did not present any of the major signs and no more than three of the
minor signs of AIDS (according to WHO criteria; Newell et al., 1990)
at the time of testing. The major signs consist of significant weight loss
and failure to thrive, persistent fever, and persistent diarrhea. The
minor signs consist of oropharyngeal candidiasis, repeated common
infections, generalized lymphadenopathy, persistent cough for more
than a month, generalized dermatitis, and confirmed maternal HIV
infection.
In addition to the HIV-positive and HIV-negative children born to
infected mothers, we sought a control group comparison of HIV-
negative children born to noninfected mothers. Mothers with children
from a village area that had participated in a previous study (Boivin et
al., 1993) were recruited for assessment. We selected from this
sampling frame 15 children who matched the HIV-positive children on
the indicators of age, gender, educational level of the mother, and
general economic status of the home environment as assessed from a
home evaluation (described by Boivin et al., 1993). Both children and
their mothers were screened for HIV infection with the HIVchek blot
test (Dupont Pharmaceuticals, Wilmington, DE) and all 15 children
and their mothers tested negative. This group of HIV-negative
children born to HIV-negative mothers constituted the control group.
Instruments and assessment. Usually the children who were evalu¬
ated were brought to the project clinic at the hospital by the mother,
who remained throughout the assessment. The children were tested































Figure 1. Group means and standard errors on the four domains of the Denver Developmental Screening
Test (scored according to the Woodside system) for the HIV-positive, HIV-negative, and control children
in Study 1. Data are plotted against the normative mean.
individually by one of four Zairian teachers trained in the administra¬
tion of the instrument and enlisted as members of the research team.
The training and supervision of the Zairian teachers for the administra¬
tion of the K-ABC is described in Boivin et al. (1993). A principal-
component factor analysis completed on K-ABC data from Zairian
children in previous studies (Boivin & Giordani, 1993; Boivin et al.,
1993) revealed that although the instrument had been administered in
Kituba (the regional trade language), the internal factor structure of
the subtests remained the same and supported the validity of the
instrument when administered in this cultural setting. In this study the
examiners readily communicated with the parents in the local lan¬
guage of Kikongo (a dialect related to Kituba) or the urban language
of Lingala. For the HIV-positive and -negative groups born to infected
mothers, the examiners did not know the infection status of the
children.
After the child was examined and the mother was interviewed about
the presence of major and minor AIDS symptoms (Newell et al., 1990),
weight, height, head circumference, and arm circumference were
measured. The overall nutritional and developmental status of the
children was scored according to the nutritional surveillance scheme
presented by Brown (1987) for Zaire. The single criterion denotes
whether a child's upper-arm circumference is at least 80% of standard
arm circumference for the child's height (based on standards originat¬
ing in Nigeria) and is referred to as the Quaker arm circumference
(QUAC). For statistical comparisons between groups in this study, the
QUAC measure is equal to Upper Arm Circumference -h Height x
100. For the physical development measures, the percentile ranks
based on standardized normative values for age were also evaluated.
Weight, height, and weight standardized according to height percen¬
tiles were obtained from normative values provided by the WHO
(1983), arm circumference values were obtained from norms provided
by Jelliffe and Jelliffe (1989), and head circumference values were
provided by McCammon (1970).
Early Childhood Screening Profiles (ECSP). We adopted portions
of the ECSP (Harrison et al., 1990). From the Cognitive/Language
Profile, the children were scored in the areas of verbal concepts, visual
discrimination, logical relations, and basic school skills. Instructions
and test items were administered in Kikongo, the major dialect in this
region of Zaire and the primary language of fluency for the children.
The motor profile portion of the ECSP was also administered, which
consists of the subtests of gross motor skill and fine motor skill.
Kaufman Assessment Battery for Children. The K-ABC (Kaufman
& Kaufman, 1983a, 1983b) has been proposed as the test of choice for
researchers who wish to measure specific domains of cognitive ability
within a cross-cultural context (Moon, 1988; Utairatanakit, 1987) and
has already been used in other health-related assessment research
with Zairian children (Boivin & Giordani, 1993; Boivin et al., 1993).
The mental processing portions of the K-ABC (sequential and
simultaneous processing) were administered (Easels 1 and 2), and all
of the subtests were attempted with all of the children in the study
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Table 2
Between-Groups Comparisons of the HIV-Positive (n = 11), HIV-Negative (n = 15), and
Control (n =15) Children in Study 2 on the Standardized Measures from the Early
Children Screening Profiles
HIV-positive HIV-negative Control
Measure M SD M SD M SD F(2,38)
Cognition/Language 81.8 12.6 91.8 14.9 90.4 18.2 1.11
Cognition 96.0 10.3 102.3 13.9 97.5 18.6 0.54
Language 79.1 9.3 82.8 7.4 84.6 14.0 0.54
Motor 83.0 14.2 104.6 24.7 115.2 29.4 4.69*
*p < .05.
correlated to the number of immunity deficiency symptoms
reported over the final 6 months of the 2-year assessment
project. For HIV-positive children who were not enrolled in
the project, this measure was compiled from their medical
charts if it was available. This medical information was not
available for 3 of the HIV-positive and 3 of the HIV-negative
children. Although the HIV-negative children did display
some of the symptoms of immunity deficiency, presumably
because of other health-risk factors and infectious pathogens
that they were exposed to, they tended to be fewer in number
and corresponded to higher QUAC development measures
than for the HIV-positive children, r(2l) = -.54,p < .01 (see
Figure 2).
Kaufman Assessment Battery for Children. The HIV-
negative children for both the infected (HIV-negative group)
and noninfected mothers (control group) scored significantly
higher than the HIV-positive group on all of the K-ABC global
mental processing measures (see Table 4 and Figure 3). These
included sequential processing, simultaneous processing, men¬
tal processing composite, and nonverbal performance total.
For the sequential processing, simultaneous processing, and
mental processing composite, the between-group differences
remained significant at p < .01 even when a Bonferroni
correction was applied for the number of simultaneous statisti-
Table 3
Physical Development Descriptive Statistics and Between-Groups Comparisons for the
HIV-Positive (n = 11), HIV-Negative (n — 15), and Control (n — 15) Children
HIV-positive HIV-negative Control
Measure M SD M SD M SD F(2, 38)
Age (in months) 54.8 8.6 34.8 14.2 46.2 12.0 2.81
Weight (in kilograms) 13.0 3.9 12.5 2.1 14.5 3.4 3.69*
Height (in centimeters) 94.6 14.7 86.1 10.2 103.7 9.4 15.53***
Head circumference (in centimeters) 47.8 2.5 45.3 8.5 49.3 1.9 1.98
Arm circumference (in centimeters) 13.7 2.1 16.8 8.4 14.8 1.5 1.04
Quaker Arm Circumference (Arm Cir¬
cumference Height) 14.7 1.8 19.7 10.4 14.4 1.5 3.02*
Age-standardized percentile rank scores
Weight 6.1 8.6 18.5 17.7 32.5 29.8 4.89*
Height 14.6 29.5 12.6 22.9 63.2 34.0 13.88***
Head circumference 11.5 24.4 10.6 13.3 39.7 38.2 5.17*
Arm circumference 78.2 11.5 88.4 6.1 84.1 15.8 2.37
Weight x Height 16.8 17.1 50.6 29.0 16.5 22.7 9.52***
Note. Percentile ranks are based on data from the World Health Organization (1983).
*p < .05. **p < .01. ***p < .001.
except for the photo series subtest. This subtest proved too difficult for
most of the children because of their age and the cultural specificity of
the depicted activities and events.
Results
Early Childhood Screening Profiles. For the global ECSP
indicators of cognitive or language development, no significant
differences emerged among the three groups except on motor
development (see Table 2). Pairwise comparisons for the
significant between-group differences on motor development
revealed that both the HIV-negative and control groups scored
higher than the HIV-positive group (Fisher's protected least
significant differences [PLSDs] = 21.14 and 21.42,p < .001).
One factor that may have contributed to the poorer motor
development by the HIV-positive children was that their
general physical development was impaired, as indicated by
the QUAC (see Table 3). The infected children were also
significantly below their noninfected counterparts born to
infected mothers on their age-standardized percentile rank
measures for weight (Fisher's PLSD = 17.32, p < .01), arm
circumference (Fisher's PLSD = 9.51, p < .05), and weight
standardized by height (Fisher's PLSD = 19.31,p < .01).
For both HIV-positive and -negative children born to
infected mothers, the QUAC measures were significantly
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Immunity deficiency symptoms
Figure 2. Relation between the number of immunity deficiency
symptoms reported during the final 6 months of the 2-year assessment
and the Quaker Arm Circumference measure (Arm Circumference -t-
Height), an indicator of physical development and nutritional well-
being. The data are from the HIV-positive and HIV-negative children
in Study 2 and have a Pearson product-moment correlation coefficient
of -.54 (df= 25),p < .01.
cal comparisons within a single experimental design. Among
the various subtests of the K-ABC, the two groups of children
differed significantly on all the visual recognition tasks in the
simultaneous processing domain as well as on the sequential
processing (immediate recall) tasks of number recall and hand
movements. Finally, the groups differed significantly on spatial
memory, which is a simultaneous processing subtest.
Multifactor covariate analysis for the Kaufman Assessment
Battery for Children. An additional analysis was completed
for the K-ABC raw score values rather than the standardized
values based on a normative sample of American children.
This was a one-factor blocked analysis of covariance with the
Zairian children blocked into four subgroups on the basis of
gender and age (boys 3 years of age and younger, boys older
than 3 years, girls 3 years and younger, and girls older than 3
years). HIV status of the child was the main effect, and weight
standardized according to height (WHO, 1983) served as the
covariate. Significant between-group differences remained for
all of the K-ABC global measures and the ECSP motor
measure (Table 5). However, the subsequent pairwise compari¬
sons for the covariate ANOVA was particularly instructive in
attempting to statistically separate the direct and indirect
developmental effects of HIV infection in children and their
mothers. For this analysis, the control group born to nonin-
fected mothers performed significantly better than the HIV
groups born to infected mothers on the ECSP motor develop¬
ment total and all of the global K-ABC scales.
For the children born to infected mothers, the HIV-negative
group performed significantly better than the HIV-positive
group, specifically on the sequential processing global score
and mental processing composite (p < .001). These prelimi¬
nary findings indicate that the infected children demonstrated
global cognitive impairment that apparently extended beyond
the indirect developmental effects of the mother's being ill
with HIV disease and remained even when nutritional and
developmental well-being was statistically controlled for by
using weight standardized according to height as a covariate.
Discussion
In the initial study, motor and social development were
implicated as the major domains in which significant differ¬
ences began to emerge between HIV-negative and HIV-
positive perinatally infected children during the first 2 years of
life. The developmental screening measures that these conclu¬
sions were based on, however, are most useful in the context of
the general screening and identification of developmentally
at-risk children for further intervention. They were not in-
Table 4
Between-Groups Comparisons ofthe Standardized Scores from the Kaufman Assessment Battery
for Children (K-ABC) in Study 2
HIV-positive HIV-negative Control
Measure M SD M SD M SD F(2, 38)
Simultaneous Processing-Visual
Recognition
Magic Window 3.1 1.2 4.0 1.6 8.1 2.4 20.77***
Face Recognition 8.0 2.4 9.4 2.1 11.1 2.7 4.00*
Gestalt Closure 5.6 3.1 7.1 2.1 9.7 3.7 6.06**
Simultaneous Processing-Visual-
Spatial Organization
Triangles 6.0 2.8 8.7 3.1 8.0 2.7 1.34
Spatial Memory 5.7 2.9 8.0 1.2 11.4 3.4 5.75*
Matrix Analogies 6.0 2.5 6.5 0.7 7.4 1.4 0.94
Sequential Processing (Immediate
Recall Memory)
Number Recall 7.8 2.2 9.1 2.9 13.2 1.9 18.70***
Hand Movements 8.3 2.4 11.9 2.9 14.3 4.6 9.46***
Word Order 6.1 2.1 7.7 2.5 8.1 1.2 2.12
Global performance
Sequential Processing 86.9 12.3 105.2 14.3 122.7 21.9 14.03***
Simultaneous Processing 71.1 10.4 81.0 6.6 96.5 17.5 13.76***
Mental Processing 75.1 10.9 89.6 9.6 109.0 21.2 16.32***
Nonverbal total 70.4 9.3 86.0 7.1 91.6 12.9 4.93*
*p < .05. **p < .01. ***p < .001.
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Figure 3. Group means and standard errors on the Early Childhood
Screening Profiles (ESCP) and on the Kaufman Assessment Battery
for Children (K-ABC) for HIV-positive, HIV-negative, and control
children in Study 2. The plotted values represent the raw score totals
adjusted for age and the Quaker Arm Circumference (Arm Circumfer¬
ence -f- Height) for physical development.
tended to monitor very specific developmental effects of
subacute infections, such as in the very initial stages of HIV
infection (Goldman, Stein, & Guerry, 1983). The assessment
protocol in the second study, however, was intended to provide
for a more comprehensive and detailed measurement of both
cognitive and motor processes that might be affected by
pediatric HIV infection in children who were still asymptom¬
atic.
In comparing the HIV-positive with HIV-negative children,
consistent deficits were noted for the HIV-infected children
with respect to the sequential and simultaneous processing
abilities assessed with the K-ABC. Based on the use of the
K-ABC with Zairian children in other health intervention
settings and on reports by Diamond et al. (1987) and Belman
et al. (1988), who used the K-ABCwith HIV-infected children,
spatial memory seems to be the subtest most sensitive to the
direct impact of the virus on the neurological integrity of the
developing child. Significant differences in motor development
also emerged in the second study, which confirms some of the
major findings in the first study even though entirely different
tests and samples were used. However, these findings cannot
be considered definitive because of the small size of the sample
ofHIV-positive children. Also, our sample was selective in that
these were African children who were asymptomatic with
respect to the immunodeficiency associated with the initial
stages of AIDS and who were socially responsive enough to
complete the assessment. Such a sample may represent only
those children with a static subacute course of pediatric HIV
infection, rather than those with an acute progressive encepha-
lopathic course for the disease (Belman et al., 1988).
The control group of HIV-negative children born to nega¬
tive mothers differed from the HIV-negative Kimpese group
born to infected mothers on K-ABC global cognitive perfor¬
mance measures. This finding suggests that at least a portion of
the deficits seen in the HIV-positive children was due to the
effects of HIV infection on the health of the mother and the
subsequent developmental integrity of the home environment.
On the other hand, the fact that the control group did not
differ from the Kimpese group with respect to motor develop¬
ment and performance suggests that the motor deficits that
have been consistently observed in other studies (Belman et
al., 1988; Diamond et al., 1987) are probably the direct result
ofHIV infection in children's early development.
In cases of pediatric AIDS, basal ganglia calcification has
been documented (Price et al., 1988). Even in cases where
calcification is barely detectable, T2-weighted magnetic reso¬
nance imaging showed increased signal in this region, which
indicates that even in the pre-AIDS stage, the virus is attacking
important motor regions of the brain directly (Belman et al.,
1988; Epstein, Sharer, & Goudsmit, 1988). Thus, central
nervous system motor centers are being affected in the early
stages of the disease and perhaps contributing to the neurode-
velopmental delays consistently seen in HIV-infected children
even in the absence of substantial immunodeficiency. This
dynamic of the disease process is likely a contributing factor in
the motor developmental deficits witnessed for the HIV-
positive children in our studies.
Language and global cognitive deficits on the part of the
HIV-positive children in this study were possibly due to both
the direct effects of the virus on neuropsychological develop¬
ment and the impact of maternal infection on the favorability
of the home environment for the child. However, Pizzo et al.
(1988) achieved significant improvement in global cognitive
ability and social development level for children with AIDS in
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Table 5
Between-Groups Comparisons for the Raw Scores for the GlobalMeasures from the Kaufman Assessment Battery for Children
(K-ABC) andMotor Development from the Early Childhood Screening Profiles (ECSP) forHIV-Positive (n = 11), HTV-Negative
(n = 15), and Control (n = 15) Children in Study 2
HIV-positive HIV-negative Control Pairwise
Measure M SD M SD M SD HIV group8 Age x Sexb Covariatec comparisons
K-ABC
Sequential Processing 12.11*** 1.35 3.50 ab*, ac***, be***
Raw score 18.6 3.5 22.4 3.2 30.3 4.8
Covariate-adjusted
score 18.5 5.3 21.1 6.1 32.0 4.9
Simultaneous Processing 20.54*** 2.58 2.09 ac***, be***
Raw score 19.7 4.9 22.3 2.8 31.0 5.8
Covariate-adjusted
score 22.0 5.5 22.4 6.2 30.6 5.0
Mental Processing Com¬
prehension 20.36** 2.22 3.24 ab*, ac***, be***
Raw score 38.4 6.7 44.9 4.9 61.3 9.4
Covariate-adjusted
score 40.3 9.5 43.9 10.8 62.7 8.7
Nonverbal total 7.31** 1.06 6.24* ac***, be**
Raw score 20.3 5.6 23.4 3.1 29.2 6.2
Covariate-adjusted
score 22.6 7.2 24.6 8.2 30.4 6.6
ECSP Motor Development 6.90** 2.50 2.35 ac**, be**
Raw score 28.9 9.4 27.9 7.2 35.5 4.6
Covariate-adjusted score 27.8 8.0 28.5 9.1 36.1 7.4
Note. For pairwise comparisons, a = HIV-positive group, b = HIV-negative group, and c = control group.
aMain effect (dfs = 2, 23). bBlocking variables (boys more than 3 years of age, boys 3 or fewer years, girls more than 3 years, and girls 3 or fewer
years; dfs — 3, 23). cWeight standardized to height (dfs = 1, 23).
*p < .05. "p < .01. ***p < .001.
response to continuous intravenous infusion of AZT. Because
the home environment for these children was unlikely to have
dramatically changed during the treatment, the effects of the
drug on the virus as well as on the improved immunological
and health status of the children may have been largely
responsible for the improvements in global cognitive ability
that were documented. These findings also emphasize the
importance of evaluative pediatric HIV research with children
who are not being treated with antiretroviral drugs if one is to
understand the natural course of the infection on neuropsycho¬
logical development.
For families that struggle to maintain their standard of living
in rural subsistence agricultural settings, AIDS can have a
devastating socioeconomic impact. HIV infection and illness
on the part of the mother of an HIV-infected child can
seriously undermine the social and nutritional favorability of
that home environment, given that so much of it depends on
the mother in sub-Sahara Africa. The fact that verbal ability
and development for a child depends largely on the interac¬
tions that the mother provides and that a verbal deficit is a
major feature of pediatric HIV infection (e.g., Condini et al.,
1991) is consistent with our findings. Subsequently, such
second-order effects may ultimately be as much at fault for the
verbal, social, and global intellectual deficiencies of the HIV-
infected child as the direct effects of the virus itself. To
summarize, within the context of the overwhelming human and
economic need associated with life for African children in the
interior of Zaire, the additional burden of AIDS on family
members can have devastating effects on the development of
those children irrespective of their infection status.
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Stable seroprevalence of HIV-1 in antenatal women in rural Bas-Zai're, 1988-1993
For many countries the HIV-1 seroprevalence rate in
pregnant women is the most representative picture
available of HIV infection in the general population.
It is a valuable measure because it relates to the in¬
fection risk in both mother and baby and because
it is an index of heterosexual transmission in the
most sexually active age-group, without focusing on
special risk groups.
In a longitudinal study of vertical transmission,
plasma samples from 8733 pregnant women attend¬
ing two maternity units in Kimpese, rural Zaire, were
tested for HIV antibody (Ab) during a 5-year period
between September 1988 and July 1993- The study
protocol was approved by both the regional pae-
diatric ethical committee in Edinburgh and the Na¬
tional AIDS Committee in Zaire. Kimpese is a town
of about 30000 people situated on the main road
between Kinshasa (225 km) and the port of Matadi
(140 km). The economy of this savannah region is
based on agriculture with some commerce and two
cement factories. Approximately 70% of all deliver¬
ies in the area were performed in the two mater¬
nity departments. A number of women from larger
cities returned to Kimpese (their family home) for
delivery but most were living in the town and and
surrounding rural area. At their first visit, all women
had a venesection for haemoglobin which was to
be measured as part of the antenatal service. Sam¬
ples were tested for HIV Ab using either the Ab¬
bott recombinant enzyme-linked immunosorbent as¬
say (ELISA) HIV-1 + 2 or the Wellcome competitive
ELISA (latterly Murex, Dartford, England, UK), and
positive results were confirmed by the alternative ®
ELISA test andWestern blot (Organon Teknika, Cam¬
bridge, England, UK).
The overall prevalence of HIV Ab was 3-8% [95%
confidence limits (CL), 3-4-4.2], Ab-positive speci¬
mens were tested for HIV-2 during the first 3 years,
but in no case was antibody to HIV-2 found. Dur¬
ing the 5-year period the seroprevalence varied lit¬
tle, with a maximum of 4.2% in the first year and
a minimum of 3-4% in the third year (Table 1). The
difference between years was not significant (%2, 2.5;
P= 0.5).
Table 1. HIV-antibody prevalence in women attending two antenatal
clinics in Kimpese, Bas-Zai're.
Date of first attendance Number % HIV-positive (95% CL)
1 Aug 88-31 Jul 89 2364 4.2 (3.4-5.0)
1 Aug 89-31 Jul 90 2530 3.9 (3.1-4.7)
1 Aug 90-31 Jul 91 2591 3.4 (2.7-4.1)
1 Feb 93-31 Jul 93 1248 4.0 (2.9-5.1)
CL, confidence limits.
Since 1985, seroprevalence studies of pregnant
women have been conducted in a number of African
countries. Direct comparisons between this study
and others are difficult because of the different ways
in which data have been collected. In general, sur¬
veys ofHIV infection in antenatal women in Uganda,
Zambia and Malawi have shown a rise to levels of
20-30%. In Kenya (Nairobi) and the Central African
Republic (Bangui) the rise has been slower [1]. In
a few countries with high levels there has been a
tendency for rates to plateau. In antenatal women in
the capital of Zaire, Kinshasa, a more stable level at
5-6% has been reported [1]. Kaseka et al. [2] reported
that 4611 spouses of factory workers in Kinshasa had
rates of 2.7% in 1988, 3-7% in 1989 and 2.8% in 1990.
Magazani et al. [3] have recently reported a marked
contrast in seroprevalence rates between the Shaba
region of Zaire and the adjacent province of Zam¬
bia. In Shaba, 13 studies on 4285 antenatal women
between December 1989 and April 1991 indicated
a steady seroprevalence of 3% (range, 2.8-3-4%). In
contrast in Zambia, a rate of 12% in Lusaka in 1987
[4] had risen to 21% by 1990 [5], and rural rates in¬
creased to 14% [6]. The stable rate in our study in
Zaire is, like that of Magazani et al. [3], in clear con¬
trast to the results of most surveys in sub-Saharan
Africa.
Our results, obtained by the same team in the same
maternity units and covering the same population
during a 5-year period, show that the rate was rel¬
atively low as well as being stable. Although an
HIV seroprevalence of 3-8% still constitutes a major
health problem, it is significantly less than that in
several other African countries. The causes of this
stability, whether biological or behavioural in origin,
need to be investigated.
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